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ABSTRACT 
 
CHARACTERIZATION OF G-PROTEIN COUPLED RECEPTORS IN PAIN, 
DEPRESSION AND ANXIETY  
 
 
 
By 
Neil Christopher Lax 
December 2018 
 
Dissertation supervised by Dr. Benedict J. Kolber 
 Chronic pain and major depressive disorder are widespread conditions in the 
world. Interestingly, these conditions often occur comorbidly, with each individual 
disease amplifying the symptoms of the other.  A significant amount of preclinical 
research in pain and depression focuses on G-protein coupled receptors (GPCRs), 
implying that GPCRs may be useful in treating this comorbidity.  Our efforts have sought 
to characterize several poorly understood GPCRs, including the serotonin receptor 
subtypes 2C and 7 (5-HT2CR and 5-HT7R) and metabotropic glutamate receptor 5 
(mGluR5), along with more well-known GPCRs such as the mu opioid receptor (MOR), 
and the role that they play in comorbid pain and depression.  Our approach for targeting 
these receptors uses (1) 5-HTR targeting compounds isolated from marine cyanobacteria, 
(2) a repurposed mGluR5 existing drug and (3) a novel formulation of a MOR existing 
drug.  (1) From our cyanobacterial collections, compounds that were screened and tested 
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showed strong in vitro affinity for both the 5-HT2CR and 5-HT7Rs.  Cyanobacterial 
extracts were screened for in vivo activity using a series of pain and depression 
behavioral assays.  Extracts were delivered into male and female mice via intra-
cerebroventricular (ICV) cannulas for initial characterization.  Knockout animals and 
delivery into specific areas of the brain known to express serotonin receptors was also 
completed.  Extracts were also tested in naïve mice or in mice subjected to a model of 
comorbid pain and depression, the Spared Nerve Injury (SNI). We found cyanobacterial 
compounds that induce antidepressant and anxiolytic-like effects in male mice. These 
antidepressant and anxiolytic-like effects for 5-HT7R were found to be specific to males, 
as no behavioral effects were found in female mice and were also found to induce no 
effects in knockout animals.  (2) For targeting mGluR5, a drug originally made for 
treating anxiety, fenobam, was evaluated.  Fenobam was used to determine the role of 
mGluR5 in the conditioned place preference assay, an assay that tests for the reduction of 
spontaneous chronic pain.  Mice with the chronic pain model of SNI were tested for the 
development of preference for the drug compared to sham animals. Fenobam was found 
to block the development of preference in animals with SNI surgery without affecting 
sham animals. (3) Lastly, for targeting MOR, the novel polymer drug called 
PolyMorphine was utilized. PolyMorphine was characterized in several different pain 
models and paradigms, including experimenter-induced and spontaneous models of pain. 
PolyMorphine was found to be analgesic in both mechanical and cognitive pain assays, 
and last significantly longer than traditional morphine. Overall, our results suggest that 
cyanobacteria produce compounds with neuroactive properties and that these compounds, 
along with repurposed and novel drugs, may be useful in understanding as well as 
treating spontaneous pain and comorbid pain and depression. 
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INTRODUCTION 
Today, much of what we know about the neurochemistry and the function of the central 
nervous system (CNS) has been aided by the use of natural products (Prisinzano, 2009).  In fact, 
many of the receptors within the CNS were discovered by studying their interactions with 
products from the environment.  For example, research on opium alkaloids from Papaver 
somniferum (Papaveraceae) has guided researchers to the discovery of the opioid receptors and 
has helped to elucidate the mechanism of antinociception mediated by these receptors (Calixto et 
al., 2001; Waldhoer et al., 2004; Prisinzano, 2009).  In this case, ethnopharmacological 
knowledge has aided in the identification and study of a terrestrial natural product.  
Ethnopharmacological knowledge is that which derives from cultural groups and how they use 
certain plants to treat different conditions.  In contrast, relatively little ethnopharmacological data 
is available for marine natural products (Proksch et al., 2002; Gerwick and Fenner, 2013).  Due 
to the high biological diversity of marine ecosystems, marine natural products are an obvious 
source of novel compounds that can modulate CNS activity.  Marine organisms have evolved the 
ability to biosynthesize CNS-active molecules as a means of chemical defense (Haefner, 2003).  
There are a wide variety of compounds that have been discovered from marine sources with 
activity against these key targets within the CNS (Martins et al., 2014).  More than 22,000 
natural products have been discovered from the marine environment to date, with the majority 
coming from microbial sources (Gerwick and Fenner, 2013). The marine environment therefore 
has an immense potential for drug discovery with approved drugs on the market and others in 
clinical trials for neuropathic pain (Bagal et al., 2014), cancer (Gerwick and Fenner, 2013), 
Alzheimer’s disease (Martins et al., 2014), and schizophrenia (Olincy and Stevens, 2007), all 
with origins in marine compounds. 
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Another area of active drug discovery research includes looking at ways in which old 
drugs are being used beyond their original or intended indication (Oprea and Mestres, 2012).  
This is especially important today because of the cost and time it takes to test new drugs.  It is 
estimated that around two billion dollars and an average of thirteen years is involved to bring a 
brand new drug to market (Paul et al., 2010).  Finding ways of using drugs that have already 
been approved or have gone through some of the regulatory steps of development, radically 
reduces costs and the overall time it takes to get to market. It is estimated that repurposed drugs 
already account for approximately 25% of pharmaceutical industry revenues (Barratt and Frail, 
2012). 
Finally, drug discovery efforts are also investigating novel ways of administering already 
known and effective drugs so as to make them last longer in vivo.  In this realm, some efforts are 
looking at ways to chemically alter functional groups of effective drugs.  Recent developments 
herein have been attempts to more slowly administer (e.g. time-released) doses of drug.  
Methods using this technology have included synthesizing capsule forms of drugs (King and 
Khabazian, 2003; Hagen et al., 2005; Ross and Hahn, 2008), polymer coated pellets (Nicholson, 
2008), nanogels (Hassanzadeh et al., 2016) liposomes (Smith et al., 2003) and polymer forms of 
drugs (Anastasiou and Uhrich, 2003; Schmeltzer and Uhrich, 2006; Gonçalves et al.; Schmeltzer 
et al., 2013; Miyazaki et al., 2017).  
Regardless of their source or administration route, molecules with the ability to modulate 
ion channels or GPCRs can be used to understand the pharmacology of and treatment of CNS 
disorders. They regulate a number of physiological functions that are linked to human disorders 
such as sleep, anxiety, seizures, pain, mood, appetite, cognition and memory (Lim, 2007; 
Kaczorowski et al., 2008; Waszkielewicz et al., 2013). Ion channels and GPCRs are two of the 
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most important drug targets of the human body (Alexander et al., 2011).  An analysis of all drugs 
approved by the FDA over the last three decades has shown that GPCRs, ligand-gated ion 
channels and voltage-gated ion channels are the top three drug target areas, respectively (Rask-
Andersen et al., 2011).  All of these targets are known to control important functions of the CNS 
and alteration of their functions are associated with various disease states like Parkinson’s (Judge 
et al., 2007), Alzheimer’s (Judge et al., 2007), schizophrenia (Judge et al., 2007), depression 
(Pytliak et al., 2011), anxiety (Waszkielewicz et al., 2013), memory loss (Pytliak et al., 2011), 
addiction (Pytliak et al., 2011), neuropathy (Livett et al., 2006; Yu et al., 2013b), epilepsy (Judge 
et al., 2007; Waszkielewicz et al., 2013), brain/spinal cord ischemia (Judge et al., 2007), 
migraine (Judge et al., 2007), pain (Waszkielewicz et al., 2013), and sleep disorders (Pytliak et 
al., 2011; Waszkielewicz et al., 2013).  This prologue will discuss the historical context and 
current drug discovery efforts in marine natural products for CNS GPCR modulators.  In 
addition, examples of drugs that have been repurposed and novel ways of administering 
compounds related to CNS GPCR modulators will also be discussed. 
 
G-PROTEIN COUPLED RECEPTORS 
GPCRs are a class of proteins found on the membranes of cells throughout the body, 
including the CNS. On an evolutionary timescale, GPCRs originated very early and can be found 
in organisms as diverse as plants, fungi, and protozoans (Schoneberg et al., 2004).  Due to their 
long history, CNS GPCRs have diversified into a variety of different subtypes and are involved 
in physiological processes ranging from vision and smell, to behavior and mood.  While different 
classifications exist, human GPCRs can be classified into five main structural families: 
glutamate, rhodopsin, adhesion, frizzled/taste2 and secretin (Schiöth and Fredriksson, 2005).  Of 
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these groups, by far the largest is the rhodopsin family, which includes many receptors that are 
common drug targets in the central nervous system such as the opioid, serotonin and dopamine 
receptors (Lagerstrom and Schioth, 2008).  Though GPCRs are extremely diverse, they share 
many common structural and functional components.  GPCRs consist of seven transmembrane 
helices and have an extracellular N-terminal domain and an intracellular C-terminal domain.  
The extracellular domain is where ligand binding occurs, while the intracellular domain is where 
the receptor interacts with the G-protein.  The G-protein is a heterotrimeric protein consisting of 
Gα, Gβ and Gγ subunits.  In its inactive state, the three subunits of the G-protein remain bound to 
the intracellular domain of the GPCR and guanosine diphosphate (GDP).  Upon ligand binding, 
GDP is exchanged for guanosine triphosphate (GTP), and this leads to a conformational change 
in which the G-protein splits into two parts: the Gα/GTP subunit and the Gβ/Gγ subunit.  These 
two subunits are released from the intracellular domain of the GPCR and act as secondary 
messengers inside of the cell.  The distinct Gα, Gβ and Gγ subunits with which a GPCR interacts 
are what determine that receptor’s specific function (Wettschureck and Offermanns, 2005). 
 
MARINE-DERIVED GPCR MODULATORS 
 Due to their ubiquitous nature, malfunctioning GPCRs are the cause of many different 
disease conditions and it is estimated that 34% of drugs on the market today target 108 unique 
GPCRs (Hauser et al., 2017).  Some of these drugs and knowledge of the receptors that they 
target were originally developed using ethnopharmacological information.  As described in the 
introduction, the discovery of morphine from poppy plants and its targeting of the μ-opioid 
receptor is a classic example of this process.  It is presumed that compounds that act as 
exogenous ligands to GPCRs evolved for their anti-feedant activity against potential herbivores 
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(de Nys et al., 1998).  Recently, researchers have moved beyond the diversity of terrestrial 
natural products and have started to uncover the biological diversity that exists in marine 
ecosystems for GPCR drug discovery.  Several important modulators of GPCRs in the CNS are 
known to have been isolated from organisms in marine environments.  Here, we will review 
several GPCRs in the CNS for which marine-derived ligands have been found.  These include 
the adenosine, cannabinoid, serotonin, and opioid receptors. 
 
Adenosine Receptor Modulators From Marine Sources 
Adenosine receptors are found throughout the body, including the CNS, and are involved 
in cardiac rhythm, circulation, immunity, sleep regulation, angiogenesis, ischemia-reperfusion 
and neurodegenerative disorders (Chen et al., 2013).  There are four types, A1, A2A, A2B and A3, 
with the main endogenous ligand for each of these receptors being the nucleic-acid and ATP 
intermediate, adenosine.  Several exogenous ligands of the A1 receptor, in particular, have been 
found in species of marine invertebrates.  
The A1 receptor exists throughout the body, but the highest amounts are located in the 
CNS, especially in the brain at excitatory nerve endings (Chen et al., 2013).  An example of a 
marine compound found to contain a ligand for the A1 receptor is psammaplin A 11’-sulfate, 
isolated from the marine sponge Aplysinella rhax (Pham et al., 2000a).  This compound is a 
nearly symmetrical bromotyrosine disulfide, that is able to block the binding of the highly 
selective A1 receptor antagonist DPCPX (8-Cyclopentyl-1, 3-dipropylxanthine) with an IC50 = 
90 μM.  Similar A1 receptor binding is seen with the compounds anthoptilides B and C, isolated 
from the Australian sea pen Anthoptilum Cf. kukanthali (Pham et al., 2000b).  These two 
compounds are diterpenes that block DPCPX binding to A1 with high potency, IC50 = 45, 3.1 
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μM, respectively.  A final example of compounds able to block the binding of DPCPX are 
cembranes 1 and 2, isolated from a Sarcophyton coral (Pham et al., 2002).  These compounds are 
also diterpenes, which were previously identified synthetically but were not known to occur 
naturally.  Cembranes 1 and 2 inhibit the binding of DPCPX with IC50 = 300 μM for both.  
While all of these marine invertebrate-derived compounds have been shown to block the binding 
of the selective A1 antagonist DPCPX (Coates et al., 1994), further testing is needed to determine 
their exact affinities and whether they act as agonists or antagonists to this receptor. 
Other marine-derived adenosine receptor binding compounds have been found to interact 
with multiple receptor subtypes, and more information is known about these.  One example, 5′-
deoxy-5′-methylthioadenosine-2′,3′-diester was isolated from the sea squirt Atrolium robustum 
(Kehraus et al., 2004).  This compound is a nucleoside that contains a rare methylthioadenosine 
moiety (a methylthio group at the 5’ position on the ribose in place of a hydroxyl group).  The 
ribose moiety is also esterified with 3-(4-hydroxyphenyl)-2-meth-oxyacrylic acid at the 2′ 
position and with urocanic acid at the 3′ position.  The compound shows micromolar affinity for 
the A1, A2A, and A3 receptors (Ki = 3.26, 17.1, and 6.94 μM, respectively). Additional assays 
have shown that this compound acts as a partial agonist of both the A1 and A3 receptors. Partial 
agonists of the A1 receptor can be analgesic, sedative, and/or act as cardiac depressants, implying 
that this compound could have a variety of potential therapeutic uses.  Partial agonists of the A1 
receptor, because of their limited side effects, often have better therapeutic profiles compared 
with traditional full agonists. The addition of the two esterified groups make this molecule more 
lipophilic, allowing it to be absorbed and cross the blood brain barrier easier. This implies that it 
could enter the CNS to exert its effects.  Testing of this compound would first need to be done in 
animal models to see if any of these predicted effects exist but to date this has not been done. 
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The β-carboline alkaloid, eudistomin D, originally isolated from the marine tunicate 
Eudistoma olivaceum (Ohshita et al., 2007) provides an especially interesting story.  Originally, 
this compound was found to be a potent inducer of calcium release from the sarcoplasmic 
reticulum (SR). While this is seemingly unrelated to effects on any receptors in the CNS, it is 
known that caffeine, a competitive antagonist to both the A1 and A2A receptors, is also an inducer 
of SR calcium release. Therefore, a series of analogues of caffeine and eudistomin D were made 
to examine the mechanism of action on these receptors.  Indeed, a hybrid compound made of 
both eudistomin and caffeine shows high affinity for the A1 and A2A receptors, with Ki = 0.38 
and 0.89 μM, respectively. These values are much better than that of caffeine for these same 
receptors (Ki = 49 and 18.1 μM, respectively), showing once again how modification of marine-
derived product, as well as repurposing known drugs like caffeine, can lead to the synthesis of 
potent ligands for GPCRs (Ohshita et al., 2007). 
 
Cannabinoid Receptor Modulators From Marine Sources 
Cannabinoid receptors are activated by the endocannabinoids (endogenous 
cannabinoids), and are involved in processes including pain, anxiety, metabolic regulation, 
feeding behavior and immune function.  There are two main groups of these receptors, CB1 and 
CB2.  CB1 receptors are of main interest to this discussion, because they are primarily found in 
the CNS; CB2 receptors, on the other hand, are found primarily in immune cells (Mackie, 2006). 
The most well-known exogenous agonist for CB receptors is the compound Δ9-
tetrahydrocannabinol (THC), the psychoactive compound found in marijuana.  Some ligands for 
the CB1 cannabinoid receptor have been obtained in marine environments, with the most notable 
originating from cyanobacteria.  Many of the natural products derived from cyanobacteria have 
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originated from one particular genera, Lyngbya, but from recent papers, this is likely an artifact 
of misidentification of samples by researchers (Engene et al., 2013).  Two compounds that both 
interact with cannabinoid receptors, grenadamide (Sitachitta and Gerwick, 1998) and 
serinolamide A (Gutierrez et al., 2011) were reported from collections of cyanobacteria obtained 
in different parts of the world. Grenadamide, obtained off of the island of Grenada in the 
Caribbean, is a cyclo-propyl containing a fatty acid derivative with a -phenylethylamine 
substructure.  Since this substructure is common in many sympathomimetic drugs, it may be able 
to work in a similar fashion.  Grenadamide shows some affinity for the CB1 receptor (Ki = 4.7 
μM), providing additional evidence that this may be the case.  Serinolamide A, also isolated from 
Lyngbya majuscula, shows agonist activity at the CB1 receptor (Ki = 1.3 μM).  Serinolamide A is 
also a fatty acid derivative, but lacks the cyclopropyl-containing component of grenadamide. 
Serinolamide instead has a serinol unit, most likely derived from the incorporation of the amino 
acid serine.  The sample of Lyngbya majuscula that was found to produce serinolamide was 
isolated from a sample collected from the coast of Papua New Guinea, displaying how similar, 
yet not identical compounds can be produced by related species depending on the environment in 
which they live. Varying ecological signals or factors could activate/express different 
biochemical pathways in the same species, leading to the production of different compounds.  
Understanding the circumstances in which these biosynthetic pathways are activated, or finding 
alternative ways to synthesize compounds produced in the natural environment is an important 
aspect of marine natural products research. 
Other species of cyanobacteria have been found to produce CB ligands as well. Lyngbya 
semiplena, collected in Papua New Guinea, produces three CB1 receptor binding agonists, 
semiplenamides A, B and G (Han et al., 2003).  These compounds are fatty acid amides that 
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resemble the structure of the endogenous cannabinoid anandamide (N-
arachidonoylethanolamine). Their Ki values are 19.5, 18.7 and 17.9 μM, respectively, while 
anandamide has a Ki value of 0.4 μM at the CB1 receptor.  The interactions of the three 
semiplenamides are hypothesized to have a weaker interaction with CB1 because of the structure 
of their aliphatic carbon chains.  All three compounds have linear aliphatic carbon chains, 
semiplenamide B and G’s chains are saturated, whereas B’s has one trans-double bond in the 
chain.  SAR for fatty acid ligands at the CB1 receptor have shown that one or more cis double 
bonds in the fatty acid chain are required to cause a “U” shape and allow tight binding with the 
receptor.  Moreover, three conjugated double bonds are required for optimal interaction with the 
CB1 receptor, something that all three semiplenamides lack. 
One final example of a cyanobacteria that produces cannabinoid receptor ligands comes 
from a species of a different genera, Moorea bouillonii (Mevers et al., 2014).  This species, also 
collected from Papua New Guinea, produces a compound called mooreamide A, which has a 
structure very similar to that of anandamide and another endocannabinoid, 2-
arachidonoylglycerol.  Mooreamide A is a marine natural product that has shown the strongest 
CB1 receptor affinity to date, with a Ki = 0.47 μM.  This high affinity is likely due to the fact that 
mooreamide A has five double bonds in its fatty acid chain (one trans, four cis).  It has also been 
suggested that the higher affinity may be due to the fact that both of the oxygen functional 
groups in the amine head group are free alcohols, unlike those in serinolamide. Regardless, 
mooreamide A offers a contrast to serinolamide and shows how molecular structure directly 
relates to the affinity of the molecules for the cannabinoid receptors.  A comparison of these 
differences can be used in the synthesis of new compounds or generation of natural product 
derivatives with better pharmacological properties. 
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Opioid Receptor Modulators From Marine Sources 
Opioid receptors are involved in a broad range of processes that include pain, addiction 
and mood-related behavior (Waldhoer et al., 2004).  These receptors fall into three families, the 
mu, delta, and kappa opioid receptors (MOR, DOR, and KOR, respectively).  Unlike the 
serotonin receptors found in mammals that have only one primary ligand (i.e. serotonin), the 
opioid receptors each interact with different endogenous opioid peptides including endorphins 
(mu), enkephalins (delta) and dynorphins (kappa) and have different affinities for each.  Due to 
the diversity of ligands able to bind with these receptors, many natural products from marine 
environments have been found to act as highly selective agonists and antagonists to all three of 
these receptor subtypes.  Extracts obtained from vertebrates to invertebrates and algae have been 
found to produce these types of compounds. 
 One notable example of a marine natural product derived from a vertebrate comes from 
an extract of the skin of the plane head filefish, Stephanolepis hispidus, originating in the marine 
waters of Brazil (Carvalho et al., 2013).  Fishermen in this part of the world are known to make 
water infusions of dried and powdered skins of this fish for treatment of mild inflammatory 
conditions of the respiratory system.  Upon closer examination, it was discovered that these skin 
extracts have antinociceptive activity that is associated with activation of opioid receptors.  The 
extracts, when administered intraperitoneally to mice, act as an analgesic in several behavioral 
models of pain, including the acetic acid writhing model, thermal plantar test (i.e. “Hargreaves” 
test) and tail-flick assay (Carvalho et al., 2013).  Furthermore, when the skin extracts are co-
administered with the known opioid receptor antagonist naloxone, some of these analgesic 
effects are blocked.  This suggests that one or more compounds found in this skin extract induce 
analgesia through the activation of opioid receptors (Carvalho et al., 2013).  However, further 
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studies are needed to determine which compounds are bioactive, their structures, and their 
selectivity. 
 Opioid ligands from invertebrates, such as the phidianidines A and B from the sea slug 
Phidiana militaris (Carbone et al., 2011) have been much better studied as to structure and 
pharmacological profile. Phidianidines A and B, contain an unusual 1, 2, 4-oxadiazole ring 
linked to an indolamine structure.  It was later found that the phidianidines could be synthesized 
from known indole acetic acids in relatively high yields (Brogan et al., 2012) making the 
problem of supply of these interesting compounds a non-issue. Further tests with the 
phidianidines have shown that they are selective MOR agonists (Ki = 310, 680 nM, respectively) 
as well as inhibitors of the dopamine receptor (Ki = 230, 340 nM, respectively).  Selective 
ligands for opioid receptors have also been found in other marine invertebrates, including the 
Australian marine sponge, Ianthella flabelliformis (Carroll et al., 2010).  The most potent ligand 
derived from this organism, bastadin-26, has a high selectivity for the DOR (Ki = 100 nM).  This 
compound is unusual in that it is a macrocyclic molecule in which two tyramino tyrosine groups 
are oxidatively coupled to yield a macrocyclic ether.  Insufficient yields of extracts and the 
inability to synthesize this compound mean that it is still unknown whether bastadin-26 behaves 
as an agonist or antagonist at the DOR, and further studies need to be conducted (Carroll et al., 
2010) 
Ligands for the opioid receptors have also been found in species of red algae, including 
Lophocladia sp., a genus of algae found throughout the tropics and subtropics (Gross et al., 
2006).  In one particular sample of this genera collected off of the coast of the Fiji islands, a 
compound known as lophocladine A was been found to have DOR antagonist activity.  
Lophocladine A is an alkaloid with a 2,7-naphthrydine ring system.  Until its discovery, the only 
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naturally occurring example of a compound with this type of structure, dipyridylmethyl ketone, 
was found in the roots of the valerian plant, Valeriana officinalis (Gross et al., 2006).  Despite 
the vastly different sources, plant root versus red marine algae, these sources produce two similar 
chemical structures demonstrating the relatedness of biosynthetic pathways across species.  
 
Serotonin Receptor Modulators From Marine Sources 
Serotonin (5-HT) is one of the principle monoamine neurotransmitters of the CNS.  This 
neurotransmitter, along with the seven families of serotonin receptors (5-HT1-7R) with which it 
binds, has been found to play a role in many physiological processes and disease states, 
including mood, sleep, learning and memory, appetite, depression, anxiety and disorders like 
schizophrenia (Pytliak et al., 2011).  Naturally occurring ligands with high affinity for the 
serotonin receptors have been derived from marine organisms, with several notable compounds 
originating from sponges. Compounds derived from sponges and their symbionts have been 
found to have a variety of bioactivities, many of which act on serotonin receptors.  
Marilone B, isolated from a marine sponge and its symbiont, is a selective ligand for the 5-
HT2BR. This ligand was obtained from a fungus (Stachylidium sp.), which lives on the sponge 
Callyspongia sp. Cf. C. flammea.  Marilone B is a phthalide [2-benzofuran-1(3H)-one] derivative 
(Almeida et al., 2011).  Phthalide containing compounds have been shown to have a variety of 
activities, including modulation in the CNS.  Marilone B has the strongest affinity for 5-HT2BR 
(Ki = 7.7 μM) and acts as an antagonist (Almeida et al., 2011).  In the CNS, the 5-HT2BR plays a 
role in anxiety, appetite and sleep (Pytliak et al., 2011).  Antagonists of this receptor have 
anxiolytic properties (Kennett et al., 1994) and are involved in the development of mechanical 
hyperalgesia in animal models (Lin et al., 2011).  It has also been shown that antagonizing 5-
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HT2BR in the periphery and spinal cord prevent formalin-induced flinching behavior in rodents, 
implying that antagonists of this receptor could be used to develop analgesic drugs (Cervantes-
Duran et al., 2012).  Another ligand selective for the 5-HT2BR and found in the marine 
environment comes from an actinomycete, Streptomyces sp. CP32, found living on a species of 
cone snail, Conus pulicarius (Lin et al., 2010). Five novel compounds, known as the pulicatins A 
– E, have been isolated from these bacteria. These symbiotic bacteria have also yielded several 
known compounds, including pulicatins F and G (two compounds now classified as pulicatins 
based on their structural similarity to the novel compounds described), watasemycin A and B and 
aerugine (Lin et al., 2010).  All of these compounds are a part of the larger family of 
benzothiazole and thiazoline containing natural products.  These all bind very strongly to the 5-
HT2BR, with Ki values ranging from 505 to 4965 nM.  The thiazoline compounds, such as 
pulicatin A, have the highest affinity for the receptor, while the bisthiazolines, have weaker 
affinities in comparison.  Searching for new ligands of the 5-HT2BR is a challenge due to the 
known selective cardiac effects produced by manipulating this receptor (Brea et al., 2010).  
Therefore, finding new compounds in the marine environment that are unlike any known ligands 
may allow for the discovery of compounds that lack these undesired effects via biased agonism. 
 In addition to compounds that bind to the 5-HT2BR, marine sponges have also yielded 
compounds that bind to other serotonin receptor subtypes. For example, the Jamaican sponge 
Smenospongia aurea, has been found to produce compounds that interact with the 5-HT2AR as 
well as the 5-HT2CR (Hu et al., 2002).  Both of these receptor subtypes are involved with 
anxiety, appetite, sleep, mood, thermoregulation and sexual behavior (Pytliak et al., 2011). Three 
compounds isolated from this Jamaican sponge, 6-bromo-2’-de-N-methylplysinopsin, 6-
bromoaplysinopsin and N-3’-ethylaplysinopsin, all contain an indolamine pharmacophore 
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identical to that found in the endogenous ligand serotonin. They also show affinity for the 5-
HT2AR and 5-HT2CR subtypes with 6-bromoaplysinopsin in particular showing the highest 
affinity.  Because these three indolamine compounds are structurally similar to serotonin, they 
may have been evolutionarily selected for because of these similarities. By contrast, the 
compounds isolated from Stachylidium sp. and Streptomyces sp., have no structural similarities 
to serotonin.  They represent novel chemotypes to be further explored.  These non-indolamine 
compounds could imply that a basis for future drug development, different from that of the 
traditional ligands approach, exists to develop compounds that interact with serotonin receptors. 
  After screening and identifying structures of marine natural products that resemble 
serotonin, medicinal chemists have modified some of them to synthesize ligands with higher 
selectivity and affinity.  An example of this is barretin, originally isolated from the marine 
sponge Geodia barretti, and the analogs synthesized from barretin (Sjogren et al., 2006).  
Originally, barretin was found to be an anti-fouling agent that inhibited the deposition of settling 
stage larvae of the barnacle Balanus improvises.  Barretin was later found to bind with specificity 
to serotonin receptors.  This is most likely due to the homology between mammalian serotonin 
receptors and the 5-HT1R present in many species of barnacle.  Testing the ability of several 
barretin derivatives to inhibit larval growth has shown that minor modification of its chemical 
structure can significantly change the ability of the compound to bind serotonin receptors and 
ultimately inhibit barnacle growth.  In particular, with barretin and its analogues, much has been 
learned about the importance of the location of the bromine atom in giving this family of 
compounds activity.  When bromine is replaced with Cl, NO2, CH3 or MeO at the fifth or sixth 
position of the indole ring, no significant bioactivity is displayed. Barretin and its derivative 8, 9-
dihydrobarretin were shown to have selective serotonin binding activity.  Barretin shows affinity 
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for three serotonin receptor subtypes, 5-HT2AR, 5-HT2CR and 5-HT4R (Ki = 1.93, 0.34 and 1.91 
μM respectively), while the dihydro analog shows exclusive affinity for the 5-HT2CR (Ki = 4.63 
μM).  These compounds differ in that, 8, 9-dihydrobarretin contains a double bond between the 
tryptophan and arginine residues, whereas barretin contains a single bond in the same location.  
The double bond therefore plays an important role in determining selectivity among serotonin 
receptor subtypes. This research, involving barretin derived from sponges provides evidence that 
marine products can be used to develop new pharmacological tools (Hedner et al., 2006).  In this 
thesis, several compounds and extracts from marine cyanobacteria that were found to target 
serotonin receptors are characterized. 
 
REPURPOSING OF DRUGS IN NEW CONTEXTS 
 One way in which pharmacologists investigate methods to treat diseases is by looking at 
compounds that have already been described and used in other contexts.  Most of the successes 
in this area of drug discovery have come from unexpected beneficial side effects in patients 
being treated.  By rerouting efforts after observing these side effects, many years and billions of 
dollars have been saved in finding effective ways for treating disease.  There are many notable 
examples of drug repurposing efforts.  One of the most famous examples is the drug sildenafil 
(Viagra), which was originally developed to treat angina pectoris (chest pain associated with 
heart disease) (Ghofrani et al., 2006).  During clinical studies, its effects on erectile disfunction 
were discovered and now the drug is principally used to treat that condition. Another well-known 
example of this is the drug Celebrex.  This drug has been widely used for the treatment of 
osteoarthritis through its mechanism of inhibiting COX-2 receptors (Lane, 1997).  In patients 
taking Celebrex that also had colon cancer, it was found to reduce the risk of additional polyp 
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formation (Montrose et al., 2016).  Finally, an additional example of how repurposing efforts 
have worked comes from the acne medicine tretinoin.  This topical compound, when combined 
with traditional chemotherapy has been shown to cause remission of acute promyelocytic 
leukemia in 90% of patients (Fenaux et al., 2001).  These are a sampling of some of the most 
famous examples of repurposed drugs, dozens of others, including acetylsalicylic acid, 
armantadine, atomoxetine, doxepin, finasteride, hydroxychloroquine, raloxifene, and thalidomide 
exist (Aronson, 2007).  One note-worthy takeaway about the compounds and drugs is that in 
many cases, the disease the drug was originally working to target had nothing to do with the 
other conditions that drug was found to be more effective in treating.  In this thesis, a drug called 
fenobam, originally developed in the 1970s as a treatment for anxiety (Porter et al., 2005), is 
characterized in its newly discovered role in targeting the GPCR mGluR5 and chronic pain.   
 
NOVEL ADMINISTRATION TECHNIQUES FOR DRUGS 
Finally, a significant amount of effort is being placed on investigating new ways to 
extend the effects of drugs with short half lives in vivo.  In so doing this, drugs that already work 
well could be vastly improved, thereby reducing the need for re-dosing and helping with 
problems of adherence.  Many different methods are currently being utilized to look for novel 
administration routes to accomplish this goal.   One of the most common ways this is being done 
is by creating capsule forms of drugs (King and Khabazian, 2003; Hagen et al., 2005; Ross and 
Hahn, 2008).  These tablets work by allowing the drug to slowly dissolve over time, leading to a 
constant administration over time.  This has been particularly useful with opioid drugs, but often 
leads to abuse because they can be crushed into a powder leading to bolus release of the drug.  
Other methods have looked into sequestering drugs into polymer coatings, such as nanogels 
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(Hassanzadeh et al., 2016) and liposomes (Smith et al., 2003) in order to increase the duration of 
their effects.  More recently, drug discovery efforts have looked into ways of creating covalent 
polymers of drug.  In these formulations, monomeric drug units of already known to be effective 
compounds are chemically modified so that they form long chains.  These long chains can then 
be administered, and if they work effectively, monomeric drug units are hydrolyzed from the 
polymers, delivering an effective dose over time.  To date, polymers of NSAIDs (Schmeltzer et 
al., 2013), antiseptics (Schmeltzer and Uhrich, 2006) and antioxidants (Anastasiou and Uhrich, 
2003) have been produced with effectiveness, however, these are yet to be FDA approved.  
Certain polymer backbones have been shown to be more effective than others.  For example, 
polyurethane polymer backbones have been found to not work well due to their inability to 
degrade in vivo (Mahkam and Sharifi-Sanjani, 2003).  Finding methods to extend the length of 
time drugs act is proving to be a greatly expanding area of drug discovery research.  In this 
thesis, a newer polymer form of morphine, a drug that targets the mu opioid receptor (MOR), 
called PolyMorphine, and utilizes a poly(anhydride-ester) backbone is characterized. 
 
CONCLUSIONS  
A vast number of compounds derived from marine organisms and compounds that have 
been transformed from their original purpose have been found to have bioactivity on mammalian 
ion channels and receptors. Novel ways of administering drugs through time-released 
mechanisms have also opened up new potentials in delivering drugs to patients suffering from 
chronic illnesses.  Researchers have only scratched the surface on what these novel compounds 
and administration routes have to offer. As technology, collection and screening methods 
improve, more and more compounds will be discovered from the oceans, rediscovered from 
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known compounds that were not effective for their original purpose, and modified to make more 
potent and selective ligands. Some of the newly discovered compounds from the marine 
environment are already being used as therapeutic agents. In fact, several known pharmaceuticals 
on the market today were originally derived as marine natural products. These include 
trabectedin (originally found in the sea squirt, Ecteinascidia turbinata) for the treatment of 
cancer (Newman and Cragg, 2014), vidarabine (originally synthesized from a compound from 
the sponge, Tethya crypta) for the treatment of viral infection (Sagar et al., 2010) and ziconotide 
(originally found in the sea snail, Conus magus) for the treatment of moderate to severe pain 
(Williams et al., 2008).  None of these compounds target GPCRs despite the fact that that nearly 
36% of all prescription drugs on the market today target a GPCR of some type (Rask-Andersen 
et al., 2011).  Ion channels are found to be more frequently targeted by these compounds. But 
this trend does not negate the potential of GPCRs since discovery of ion channel modulatory 
activities results from more emphasis of ion channel research with marine natural products. 
Therefore, in addition to simply screening compounds for receptor binding activity, the next 
major step of drug discovery research will be to test GPCR-modulatory compounds from the 
ocean and pharmacological databases in biological assays that look for potential therapeutic 
effects. With the vast array of physiological processes that GPCRs regulate, some of these 
ligands, whether newly discovered, repurposed compounds, or given via a new administration 
method could be developed into analgesics, anxiolytics, antidepressants and more.  
In this dissertation, I investigated the role of several GPCRs in depression, anxiety and 
pain using (section 1, chapters 1 and 2) novel compounds extracted from marine cyanobacteria, 
(section 2, chapter 1) a repurposed drug, and (section 2, chapter 2) a polymer form method of 
administration of a common analgesic drug.  In section 1, several extracts from samples of 
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cyanobacteria with activity at serotonergic receptors were characterized.  Detailed studies were 
carried out using one extract with activity at the 5-HT2CR and another with activity at the 5-
HT7R.  I explored the way that these extracts from marine sources could alter, pain, depression 
and anxiety-like behaviors and showed how they could be used as therapeutic leads for learning 
more about the serotonergic system.  In section 2, I explored the role of two non-serotonergic 
GPCRs in various models of chronic pain.  A repurposed drug, fenobam, which was originally 
made to treat anxiety, and is now to be a known potent and selective negative allosteric 
modulator of metabotropic glutamate receptor 5 (mGluR5), was used to study the role of 
mGluR5 in a model of spontaneous chronic pain.  Finally, a novel polymer form of the well-
known analgesic drug morphine (a MOR agonist), called PolyMorphine, was characterized by 
investigating its effects in several models of experimenter-induced and spontaneous assays of 
pain, its side effects and its potential mechanism of action.  Collectively, this work revealed 
previously undescribed neuroactive effects of compounds derived from marine cyanobacteria, 
characterized repurposed and novel analgesic compounds and also deepened our understanding 
of the role of GPCRs in depression, pain and anxiety.  
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SECTION 1 
Characterization of cyanobacterial-derived 
serotonergic receptor ligands in pain and depression 
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Section 1 
Chapter 1 
Screening of ligands with serotonin receptor subtype 2C (5-HT2CR) 
activity 
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The majority of the text contained within this chapter is adapted from the following publication: 
Lax NC, Ahmed KT, Ignatz CM, Spadafora C, Kolber BJ, Tidgewell KT. 2016. Marine 
cyanobacteria-derived serotonin receptor 2C active fraction induces psychoactive behavioral 
effects in mice. Pharmaceutical Biology. DOI:10.1080/13880209.2016.1181659. 
 
Photographs of sample 2064 in Figure 1 were taken by Kevin Tidgewell.  Kh Tanvir Ahmed 
prepared the HPLC spectrum and Ki graphs in Figure 2, 6 and 7E.   In vitro tropical disease 
bioassays were performed by Carmen Spadafora.  Primary and secondary binding in vitro 
screening of extracts was performed by the NIMH Psychoactive Drug Screening Program 
(PDSP), directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill 
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ABSTRACT  
Marine cyanobacteria offer a robust resource for natural products drug discovery due to 
the secondary metabolites they produce. Cyanobacteria were collected from Las Perlas 
Archipelago, Panama and subjected to dichloromethane/methanol extraction and fractionation by 
column chromatography before being screened for affinity against a panel of CNS targets. 
Fractions of three cyanobacterial extracts (2064H, DUQ0008C and DUQ0008G) was subjected 
to HPLC, and the major peak from 2064H was isolated (2064H3).  At a dose of 20 g per 
animal, 2064H, 2064H3, DUQ0008C and DUQ0008G (and several purified fractions) were 
tested in mice using behavioral assays that included the forced swim, open field, tail suspension 
and formalin tests.  2064H, DUQ0008C and DUQ0008G were shown to bind to the 5-HT2CR, a 
known target for depression and pain treatment.  Both 2064H and 2064H3 decreased immobility 
time in the first minute of the tail suspension test. 2064H increased time, distance and number of 
entries in the center region in the first half of the open field test. 2064H increased overall 
nocifensive behaviors in the formalin test.  2064H was found to degrade after the first screening 
tests.  In contrast, DUQ0008C and DUQ0008G had no effects in either the open field or tail 
suspension tests.  Overall, manipulating the 5-HT2CR with these receptor-specific ligands derived 
from cyanobacteria can alter pain, depression and anxiety-like behaviors, illustrating the 
importance of this receptor in affective behaviors. However, not all fractions with 5-HT2CR 
activity will necessarily have behavioral effects.  These results demonstrate the potential of 
cyanobacteria as a source for CNS-active compounds. 
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INTRODUCTION 
 
Cyanobacteria are a diverse group of organisms that are ubiquitous in aquatic and 
terrestrial environments around the world.  These organisms are photosynthetic prokaryotes that 
often form multicellular, filamentous colonies. Cyanobacteria are known to produce a wide 
variety of chemically complex secondary metabolites, some of which are thought to act as a 
means of protection by exuding antiherbivory effects on other organisms (Nagle and Paul, 1999).  
For many years, marine pharmacognosy researchers have explored the pharmacological potential 
of some of these marine cyanobacterial metabolites (Dixit and Suseela, 2013).  These 
compounds have been shown to have diverse bioactivities, including anticancer (Tripathi et al., 
2011; Tripathi et al., 2012; Costa et al., 2014) and antiparasitic (Gutierrez et al., 2010) activity. 
Interestingly, many of the metabolites produced by marine cyanobacteria are cyclic peptides, 
short linear peptides, and mixed polyketide/peptide sections that resemble endogenous 
mammalian ligands for GPCRs (Tan, 2007).  Several species from the genus Moorea (formerly 
known as Lyngbya), for example, produce compounds that were serendipitously shown to have 
activity on the GPCR subfamily of cannabinoid receptors (Sitachitta and Gerwick, 1998; Han et 
al., 2003; Gutierrez et al., 2011; Montaser et al., 2012).  The goal of our work is to screen marine 
cyanobacteria extracts against a large panel of CNS-active targets in order to find novel ligands 
with a focused approach on the CNS.  Cyanobacterial extracts were screened for activity for 
affinity against a panel of 48 known CNS GPCRs, ion channels, and transporters involved in 
depression, anxiety, and/or pain.   
Serotonin, one of the main monoamine neurotransmitters in the nervous system, acts as a 
ligand for the fourteen total serotonin receptors that fall into seven families (5-HT1-7R) and plays 
a role in many physiological processes including learning, memory, mood, behavior, pain, sleep, 
  27
and appetite (Pytliak et al., 2011).  Many mood disorders are associated with dysfunction 
involving the 5-HT Rs. Of particular interest, 5-HT2CR has been implicated as a target for 
depression and anxiety treatment (Artigas, 2013). Pharmacological manipulation of this receptor 
can modulate depression and anxiety-like behaviors in animal models.  In both mice and rats, 
antagonists for 5-HT2CR tend to decrease depression-like behaviors (Dekeyne et al., 2008; 
Nahata et al., 2013).  Changes in anxiety-like behaviors tend to occur with activation of 5-
HT2CRs in the basolateral amygdala (BLA), dorsal periaqueductal gray (PAG) or ventral 
hippocampus (Campbell and Merchant, 2003; Alves et al., 2004; Overstreet et al., 2006; Gomes 
and Nunes-De-Souza, 2009; Yamashita et al., 2011; Pockros-Burgess et al., 2014; Vicente and 
Zangrossi, 2014).  Similarly, ligands for 5-HT2CR can also alter pain-like behavior. Spinal or 
peripheral activation of 5-HT2CR decreases pain-like behavior while brain activation of 5-HT2CR 
increases pain-like behavior in animals (Jeong et al., 2004; Obata et al., 2004; Nakajima et al., 
2009; Nakai et al., 2010; Baptista et al., 2012; Gregoire and Neugebauer, 2013). 
In the clinical setting, the 5-HT2CR antagonist agomelatine was approved for the 
treatment of major depressive disorder (MDD) by the European Medicines Agency in 2009 
(Gahr, 2014) and was found to be significantly more effective than placebo in reversing 
depression symptoms as measured by the Hamilton Rating Scale for Depression (Taylor et al., 
2014).  In humans, this drug was also found to work as effectively as other antidepressant agents 
such as the selective serotonin reuptake inhibitors (SSRIs) fluoxetine, paroxetine, sertraline, and 
escitalopram as well as the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine 
(Guaiana et al., 2013). Agomelatine works to inhibit both anxiety- and depression-like behaviors, 
as seen in coat state degradation and home cage activity, in mice with chronic corticosterone 
treatment as well as responses in the open field test, novelty suppressed feeding, splash test, and 
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the forced swim test (Rainer et al., 2012).  Given the similarity of cyanobacterial secondary 
metabolites to endogenous ligands of GPCRs and the integral role of the GPCR 5HT2C in pain, 
depression, and anxiety, we sought to find novel 5-HT2CR binding ligands derived from marine 
cyanobacteria that could induce similar in vivo effects in a mouse model. The goal was to 
identify novel scaffolds for the design of more effective compounds for treating psychiatric 
disturbances with pain in humans. 
In our study, extracts of cyanobacteria collected in the Las Perlas Archipelago, Panama 
(2064 and DUQ0008) were used for screening.  Crude extracts from the cyanobacteria were 
fractionated using silica gel chromatography and screened by the PDSP at the University of 
North Carolina Chapel Hill (Besnard et al., 2012).  The PDSP screens researcher-supplied 
fractions for affinity to an array of GPCRs, ion channels, and transporters, including the 5-
HT2CR. Fractions are screened through competitive inhibition assays to determine binding 
affinity at specific targets. Fractions with selective affinity for the 5-HT2CR were injected into 
the lateral ventricle of mice via intracerebroventricular (ICV) injections. Following compound 
administration, mice were tested in a series of depression, anxiety and pain behavioral 
paradigms, including the tail suspension, open field, and formalin tests. We hypothesized that 
fractions demonstrating selective affinity to the 5-HT2CR would induce pain-like behavior in 
animals when applied through ICV injection. We further hypothesized that these fractions would 
similarly impact anxiety-like and depression-like behavior in these animals. 
 
RESULTS 
Cyanobacteria Sample 2064 – Screening and Pharmacology Reveals a 5-HT2CR Compound 
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 A green cyanobacterial mat was collected by hand using SCUBA from a sandy bottom in 
~10 feet of water off of Mogo Mogo, an island in the Las Perlas Archipelago, Panama (Figure 
1A).  The cyanobacterium was excreting a reddish pigment upon being removed from the sandy 
substrate, so both seawater and the cyanobacterial mass were saved and used for extraction.  
Based on morphology, the collection was given the field identification of Oscillatoria sp. but 
could also be from the Moorea or Okeania genera (Figure 1A and B).  Phylogenetic 
determination was not possible since no viable genetic material was saved.  A total of 4 L of 
cyanobacterial biomass and pigmented water were brought back to the laboratory in Panama City 
for extraction.  
 
Figure 1. Picture of cyanobacteria 2064 and apparent Ki curve for fraction 2064H (A) 
Photo of the cyanobacterium in the field; (B) microscope image of the cyanobacterium shown at 
40X (left) and 10X magnification; (C) Apparent Ki curve for fraction 2064H showing the 
standard 5-HT2CR ligand ritanserin for comparison. KT – pictures and microscopy. PDSP – Ki 
curve. KT – designed experiment. 
 
Following extraction and fractionation, fractions of extract 2064 were screened in 
antiparasitic (L. donovanii, P. falciparum, T. cruzi) and cytotoxicity assays, as well as screened 
by the PDSP for CNS activity.  For the PDSP screening, the fractions were screened against a 
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panel of 48 targets (receptors, transporters and ion channels) with importance in the CNS, 
ranging from serotonergic and opioid receptors to dopaminergic among others.  The PDSP first 
screens compounds with a competitive radioligand-binding assay.  Anything showing greater 
than 50% inhibition of binding is further screened to determine a Ki.  Typically, a Ki value would 
be reported as a molar concentration but because our extracts are mixtures of compounds rather 
than a pure compound of known molecular weight, we refer to these secondary values from 
PDSP as “apparent Ki” or IC50 and report them in units of ng/mL.  The apparent Ki is very 
important for our prioritization of “hits” in that it allows us to determine if inhibition of binding 
appears to be because of a truly potent compound (i.e. low apparent Ki) or simply a large 
concentration of a weakly binding compound (i.e. high apparent Ki).   
No fractions showed any activity in the antiparasitic or cytotoxicity assays, but there were 
a number of hits from the primary PDSP screen (Table 1).  Fractions that showed greater than 
50% inhibition of binding in the primary screening then underwent secondary screening to 
determine apparent Ki values for the fraction.  Fractions that showed greater than 50% inhibition 
of binding in the primary screening, but an apparent Ki > 10 μM in the secondary screening, 
were considered non-specific hits.  Fractions 2064H and 2064I showed greater than 50% 
inhibition of binding (Table 1) and also a low apparent Ki (ng/mL) (Table 2) for the 5-HT2CR, 
meaning that these fractions possessed true affinity for the receptor.  Figure 1C shows the 
apparent Ki curve for 2064H and also gives a comparison curve for ritanserin, a potent serotonin 
receptor antagonist (Boess and Martin, 1994).  The curve shows a clear affinity dose response 
profile for 2064H and gives an apparent Ki value in the ng/mL range.  2064H was chosen for 
further HPLC purification due to the fact that it showed higher affinity than 2064I (179 ng/mL 
versus 512 ng/mL, respectively). 2064H also showed higher specificity given that 2064I also 
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showed some non-specific binding to 5-HT3R, delta opioid and kappa opioid receptors (Tables 1 
and 2).  
 
 
Table 1: Selected bioassay results of 2064H. Hits are defined as fractions with greater than 
50% inhibition of binding/growth in the initial screen (highlighted in yellow). a Assays 
performed by the Spadafora lab as described in Experimental Section. Data represent percent 
inhibition of growth (N = 2). b Primary binding assays performed by PDSP as described in 
Experimental Section. Data represent average percent inhibition of binding of a standard 
radiolabeled ligand (N = 4). No fractions showed any affinity for other receptors screened 
against so they have been omitted. DOR = delta opioid receptor, KOR = kappa opioid receptor, 
MOR = mu opioid receptor. PDSP – conducted experiment. KT – designed experiment. 
 
Table 2: Secondary Binding Assays for 2064H with Apparent Ki for primary hits. Data are 
presented as apparent Ki in ng/mL. Ki values are calculated from best-fit IC50 values using the 
Cheng-Prusoff equation. Open boxes with (-) indicate that fractions failed primary binding 
criterion of > 50% inhibition at 10 μM. PDSP – conducted experiment. KT – designed 
experiment. 
 
Chromatography of 2064H 
 
2064 
 
Chagasa 
 
Malariaa 
 
Cancera 
 
Leisha 
 
5-HT2ARb 
 
5-HT2BRb 
 
5-HT2CRb 
 
5-HT3Rb 
 
DORb 
 
KORb 
 
MORb 
A 0.46 7.1 5.32 4.0 -16.6 91.2 12.3 -14.7 9.8 26.3 -1.4 
B 0.67 19.4 5.48 8.3 1.2 96.2 13.4 8.8 9.8 20.4 15.9 
C 2.12 10.1 4.26 9.2 -2.5 96.4 25 3.5 11.2 42.1 18.9 
D 3.57 8.2 8.71 9.6 18.4 95 13.3 -5.1 14.4 18.3 19.6 
E 1.57 4.4 8.65 13.2 7 94.4 12.4 -4.8 19.5 26.8 18.3 
F 4.29 17.1 4.97 4.1 7.8 10.9 4.9 -5.1 23.4 15.2 55.8 
G 2.60 0.0 3.99 0.0 9.7 3.2 15.8 2.1 26 31.1 51.5 
H 1.30 10.9 3.40 0.0 -1.9 7.9 59.6 20.1 40 36.1 43.5 
I 0.72 3.5 0.0 0.0 -0.8 33.5 50 56.3 66.8 50 39.6 
2064 5-HT2BR  5-HT2C R 5-HT3 R DOR         KOR MOR 
A > 10,000 - - - > 10000 - 
B > 10,000 - - - - - 
C > 10,000 - - - - - 
D 8,270 - - - - - 
E 6,868 - - - - - 
F - - - - - > 10000 
G - - - - - > 10000 
H - 179 - - - - 
I - 512  > 10000  > 10000  > 10000 - 
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The initial HPLC showed a single major peak with a number of smaller peaks (Figure 2).  
HPLC conditions were determined to separate the major peak with a short run time.  Final HPLC 
conditions used were the following: a gradient from 50% acetonitrile(ACN):water to 84% 
ACN:water over 20 minutes followed by increasing to 100% ACN and holding for 10 minutes 
before re-equilibration. The major peak had a retention time of 16.440 min, with some small 
satellite peaks nearby. The major peak (2064H3) was isolated for additional analysis.  
    
Figure 2. Original HPLC chromatogram of 2064H. Reverse Phase HPLC (100 μL injection; 
10 mg/mL); Major peak at 16.440 min and 2573 mAU was isolated as pure compound 2064H 
(taken July 2011). KA – chromatography.  KA, KT – designed experiment. 
 
Alteration of Depression, Anxiety and Pain-like Behaviors in vivo with 2064H  
After determining that 2064H showed affinity for the 5-HT2CR, we sought to test its 
potential effects using an in vivo mouse model.  Since the structure and exact nature of the active 
compound in this fraction were unknown, ICV administration was used to directly administer the 
compounds into the cerebrospinal fluid of the lateral ventricle of the brain (Glascock et al., 
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2011), circumventing the need for a compound structure capable of crossing the blood-brain 
barrier. Through this administration route, compounds disperse throughout the CNS. This is 
important because it is unknown where the active component of 2064H acts in the brain or if it 
has the ability to cross the blood-brain barrier.  
We first sought to test if there might be any effects induced by the vehicle used to 
dissolve both 2064H and 2064H3 (50% artificial cerebrospinal fluid (aCSF)/ 50% DMSO).  We 
found no statistically significant differences between the 100% aCSF, 50% DMSO/50% aCSF 
and 100% DMSO vehicles (administered ICV 0.5 μL) in the open field test (n=6 per group; 
mean time in center of open field (sec)  SEM – 100% aCSF: 44.28  7.75, 50% DMSO/50% 
aCSF: 38.30  2.63, 100% DMSO: 47.72  7.94, one-way ANOVA p=0.602, Bonferroni tests 
n.s.; mean distance traveled in open field (m) +/- SEM – 100% aCSF: 34.14  2.91, 50% 
DMSO/50% aCSF: 38.06  3.72, 100% DMSO: 32.43  3.79, one-way ANOVA p=0.521, 
Bonferroni tests n.s.).  We also did not find any significant differences between the 100% aCSF, 
50% DMSO/50% aCSF and 100% DMSO vehicles (administered ICV 0.5 μL) in the tail 
suspension test (n=6 per group; mean time immobile (sec)  SEM – 100% aCSF: 154.25  14.2, 
50% DMSO/50% aCSF: 111.34  8.101, 100% DMSO: 135.09  10.30, one-way ANOVA 
p=0.0492, Bonferroni tests n.s.).  Finally, we did not find any significant differences between the 
vehicles in the formalin test (n=6 per group; mean time exhibiting pain-like behaviors (sec)  
SEM – 100% aCSF: 1536  215.1, 50% DMSO/50% aCSF: 1624  195.8, 100% DMSO: 1330  
114.0, one-way ANOVA p=0.5133, Bonferroni tests n.s.).  These data confirm that vehicle 
administration alone did not influence basal measures of rodent activity indicating that it was a 
suitable vehicle to proceed with further behavioral assays. 
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The first set of behavioral experiments were conducted to test both the fraction 2064H 
and the purified HPLC peak 2064H3 via the tail suspension test.  This assay measures the 
amount of time an animal spends immobile when it is suspended upside down by the distal end 
of its tail. A longer duration of immobility is a proxy for greater depression-like behavior and a 
shorter duration of immobility indicates a compound demonstrates antidepressant-like effects.  
We verified the efficacy of ICV antidepressant delivery with a pilot study using the well-
characterized SSRI, fluoxetine. Following ICV pretreatment with fluoxetine or vehicle (aCSF), 
fluoxetine-treated mice spent statistically significantly lower amount of time immobile compared 
to control mice (fluoxetine n = 4 128.8 ± 14.8 sec; control n = 4 177.8 ± 4.9 sec; t-test p=0.02).  
Following a 5 minute pretreatment with 2064H3 or vehicle via ICV injection, mice spent a 
statistically significantly lower amount of time immobile in the first minute of the test compared 
to vehicle-treated mice (Figure 3A, unpaired t-test, *p = 0.048).  Similarly, mice pretreated with 
2064H showed a trend towards lower immobility compared to vehicle-injected mice also in the 
first minute of the test (Figure 3A, unpaired t-test, p = 0.067).  This effect was not seen in the 
latter half of the test during the one-to-six minute time period (Figure 3B, unpaired t-test, p = 
0.893 (2064H), p = 0.439 (2064H3)). These decreases in immobility time suggest a modest 
antidepressant-like effect of the active compound contained in 2064H and 2064H3 vs vehicle. 
In addition to effects in depression assays, anxiety and locomotor behaviors were 
measured using the open field test.  Due to the limited amount of pure compound available, only 
fraction 2064H, which includes the 2064H3 compound, was tested in this assay.  Here, 5 minute 
pretreatment of 2064H significantly increased the amount of time that animals spent in the center 
region of the open field apparatus compared to vehicle-injected animals during the first half of 
the test (Figure 3C, unpaired t-test, *p = 0.047) suggesting anxiolytic-like effects of the 
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compound.  Similarly, 2064H-treated animals spent less time in the outside region of the open 
field box compared to vehicle-treated animals during this same portion of the test (Figure 3D, 
unpaired t-test, *p = 0.047).  Together, these measurements indicate an antianxiety-like effect of 
2064H.  The open field test also allows for the measurement of locomotion by tracking how far 
an animal travels in the open field apparatus.  Mice treated with 2064H traveled more in the 
center of the open field box during the first half of the test (Figure 3E, unpaired t-test, p = 
**0.006) further indicating an anxiolytic-like effect.  Moreover, 2064H caused mice to trend 
towards entering the dead center of the open field apparatus a greater number of times as 
compared to vehicle-treated mice in the first half of the test (Figure 3G, unpaired t-test, p = 
0.075).  Importantly, 2064H did not alter overall locomotive behavior.  Mice treated with 2064H 
did not travel overall farther in the full apparatus compared to vehicle-treated mice (Figure 3H, 
unpaired t-test, p = 0.1408).  This suggests that the effects of 2064H are likely truly anxiolytic 
and not confounded by general locomotor side-effects.  To account for any individual changes in 
locomotion, the percent distance traveled in the center zone was calculated for each mouse 
(center distance/total distance × 100). Animals treated with 2064H had a small, and nearly 
statistically significant increase in percent distance traveled in the center of the open field box 
compared to vehicle-injected animals in the first part of the test (Figure 3F, unpaired t-test, p = 
0.051).  These data also suggest an antianxiety effect of 2064H that was not likely confounded 
by hyper or hypolocomotion.  No differences in any of these parameters of the open field test 
were seen in the latter half of the test (Time in center vehicle-treated mice = 16.94 ± 4.69 sec, 
2064H-treated animals = 19.44 ± 4.86 sec, un-paired t-test, p =0.7169; Percent distance in center 
vehicle-treated mice = 10.86 ± 1.73 sec, 2064H-treated animals = 9.41 ± 1.40 sec, un-paired t-
test, p =0.5257).  Finally, 2064H was tested in an inflammatory pain model, the formalin test.  In 
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this assay, 2064H had an overall effect of increasing pain-like behaviors compared to vehicle-
injected mice (Figure 3I, 2-way ANOVA, overall effect of treatment, *p = 0.0011).  When 
looking at each individual phase of the formalin test, animals treated with 2064H showed a trend 
if increasing pain-like behaviors in both the first phase (Mean time exhibiting pain-like behaviors 
vehicle-treated animals = 160.2 ± 35.49 sec, mean time exhibiting pain-like behaviors 2064H-
treated animals = 251.2 ± 25.83 sec, unpaired t-test, p=0.0547) and second phase (Mean time 
exhibiting pain-like behaviors vehicle-treated animals = 718.6 ± 121.2 sec, mean time exhibiting 
pain-like behaviors 2064H-treated animals = 1000 ± 120.1 sec, unpaired t-test, p=0.1213) of the 
assay. 
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Figure 3. Behavioral effects of fraction 2064H and pure compound 2064H3 in vivo. (A) 
Mice treated with 2064H3 (n = 6) significantly decrease time immobile compared to vehicle (n = 
6) in the first minute of the tail suspension test; mice treated with 2064H (n = 6) show a similar 
trend. (B) These same animals show no difference in immobility time in the latter half of the test. 
(C) Mice treated with 2064H (n = 8) spend more time in the center of the open field box 
compared to vehicle treated mice (n = 8). (D) 2064H-treated mice also show a decrease in the 
time spent in the outside of the open field apparatus. (E) Mice treated with 2064H travel more in 
the center of the open field box compared to vehicle. (F) Mice treated with 2064H show a trend 
of having a greater percent distance traveled in the center of the open field box compared to 
vehicle (p = 0.051). (G) 2064H-treated mice also show a trend in entering the dead center of the 
open field box more than vehicle-treated mice (p = 0.075). (H) 2064H-treated mice show no 
difference in total distance traveled compared to vehicle-treated mice. (I) Mice treated with 
2064H (n = 8) show an overall main effect of treatment (2-way ANOVA) of increasing pain-like 
behaviors compared to vehicle-treated mice (n = 8) in the formalin test. A,C,D,F - * p<0.05, 
**p<0.01, unpaired t-test; I - * p<0.01, 2-Way ANOVA main effect of treatment. Data shown as 
mean ± SEM.  NL – conducted experiment. NL, BK – designed experiment. 
 
 
Attempted Blockade of 2064H Effects with a Known Agonist of 5-HT2CR, CP809101 
 Subsequent to these behavioral findings, we wanted to test if we could stop the 
behavioral effects of 2064H with co-administration of a drug that would block the active 
compound in 2064H.  Based on the literature, the most likely type of compound in 2064H is an 
antagonist of the 5-HT2CR, since those compounds typically induce antidepression and 
anxiolytic-like effects (Overstreet et al., 2006; Dekeyne et al., 2008; Nahata et al., 2013).  
Therefore, we chose the selective 5-HT2CR agonist CP809101 and conducted the tail suspension 
and open field tests at various doses with ICV administration to determine if this compound has 
any behavioral effects of its own.  Prior to co-administration with 2064H, we first tested 
CP809101 in both the open field and tail suspension tests at both 10 μg and 20 μg doses.  Mice 
treated with either 10 μg or 20 μg of CP809101 via ICV injection did not show any differences 
in time spent in center of the open field box (Figure 4A, One-Way ANOVA, p = 0.9301) or 
percent distance traveled in the center of the open field box (Figure 4B One-Way ANOVA, p = 
0.4482).  Similarly, animals treated with either 10 μg or 20 μg of CP809101 via ICV injection 
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did not show any differences in time immobile in the tail suspension test (Figure 4C One-Way 
ANOVA, p = 0.5258).  
 
Figure 4. Behavioral effects of known 5-HT2CR agonist CP809101. (A) Mice treated with 10 
μg (n = 6) or 20 μg (n = 7) of CP809101 do not spend more time in the center of the open field 
box compared to vehicle (n = 8). (B) Mice treated with 10 μg (n = 6) or 20 μg (n = 7) CP809101 
do not travel a greater percent of overall distance traveled in the center of the open field box 
compared to vehicle (n = 8). (C) Mice treated with 10 μg (n = 6) or 20 μg (n = 6) CP809101 do 
not travel show any differences in overall time immobile in the tail suspension test compared to 
vehicle (n = 5). One-Way ANOVA. Data shown as mean ± SEM.  NL – conducted experiment. 
NL, BK – designed experiment. 
 
Replication of 2064H Effects and Re-evaluation of Parent Fraction by HPLC 
Based on these results that showed CP809101 had no behavioral effects of its own in 
these assays, a dose of 10 μg was chosen in order to attempt to block the effects of 2064H.  Here, 
20 μg of 2064H was co-administered with 10 μg of CP809101 in both the open field and tail 
suspension tests.  Interestingly, when the fraction was tested with the agonist, in the positive 
control group with 2064H alone, the anxiolytic effects that were seen after the first tests via ICV 
injection were no longer present.  Animals treated with 20 μg of 2064H alone did not spend more 
time in the center of the open field box compared to vehicle-only control (Figure 5A, One-Way 
ANOVA, p = 0.1159) and they also did not travel a greater percent distance in the center of the 
open field box (Figure 5B, One-Way ANOVA, **p = 0.0028, Bonferroni post-test n.s.).  No 
difference was seen between the vehicle control and 2064H with agonist group in time in center 
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(Figure 5A, One-Way ANOVA, **p = 0.0028, Bonferroni post-test n.s.), but animals treated 
with 2064H and the agonist traveled a significantly smaller percent distance in the center 
compared to the vehicle-control (Figure 5B, One-Way ANOVA, **p = 0.0028, Bonferroni post-
test **p<0.01). This significant finding was anxiogenic (i.e. increased anxiety-like behavior), 
compared to the earlier data with 2064H alone (Figure 3).  Similar to the open field test, the 
antidepression-like effects that were found with 2064H the first round of testing in the tail 
suspension were also no longer present in this group of animals.  Animals treated with 2064H 
alone showed no difference in overall time immobile compared to the control animals (Figure 
5C, One-Way ANOVA, p = 0.2418).  Animals treated with 2064H and the agonist also showed 
no difference overall time immobile compared to control animals (Figure 5C, One-Way 
ANOVA, p = 0.2418).  No differences were seen in the first minute of the tail suspension test 
either (Figure 5D, One-Way ANOVA, p = 0.3298).  The lack of repeatability with 2064H in this 
set of data compared to the first tests make the results with 2064H and co-administration of the 
agonist difficult to interpret. 
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Figure 5. Behavioral effects of 2064H with 5-HT2CR agonist CP809101 coadministration. 
(A) Mice treated with 20 μg of 2064H (n = 5) or 20 μg of 2064H and 10 μg CP809101 (n = 6) do 
not spend more time in the center of the open field box compared to vehicle (n = 6). (B) Mice 
treated with 20 μg of 2064H (n = 5) do not travel a greater percent of overall distance traveled in 
the center of the open field box compared to vehicle (n = 6), but those treated with 20 μg of 
2064H and 10 μg CP809101 (n = 6) travel a lesser percent of overall distance traveled in the 
center compared to vehicle treated animals. (C) Mice treated with 20 μg of 2064H (n = 5) or 20 
μg of 2064H and 10 μg CP809101 (n = 6) do not show any differences in overall time immobile 
in the tail suspension test compared to vehicle (n = 5). One-Way ANOVA. Data shown as mean 
± SEM.  NL – conducted experiments. NL, BK – designed experiments. 
 
 We reasoned that there were at least two possible reasons for the lack of behavioral 
effects of the parent fraction 2064H alone upon retesting.  First, it is possible that the effects that 
were seen in the first round of behavioral screening were an anomaly and were not a real effect.  
Second, the compounds causing the behavioral effects had degraded and were no longer present. 
We decided to test the original parent fraction with an HPLC spectrum to see if there were any 
changes in the compounds in the fraction. An HPLC spectrum of the original parent fraction was 
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taken once again, allowing us to determine if there was any change in the compounds that were 
found to have the initial behavioral effects.  Interestingly, this spectrum showed that nearly all of 
the active compound that was originally present in the major peak with the retention time of 
16.440 min was nearly gone (Figure 6).  The area under the curve at that peak had decreased 
from 2573 mAU (see Figure 2) to 135 mAU, meaning that approximately 95% of the amount of 
compound from the original sample was no longer present. 
 
Figure 6. Second HPLC chromatogram of 2064H. Reverse Phase HPLC (20 μL injection; 1 
mg/mL); Major peak at 16.440 min and 135.1 mAU (highlighted green, taken April 2014). KA – 
chromatography.  KA, KT – designed experiment. 
 
 Due to these findings of the reduced peak size, we decided to test the original parent 
fraction alone versus vehicle control in another round of open field and tail suspension tests to 
determine if the lack of effect seen with the coadministration of the agonist could be explained 
by this reduced amount of active compound.   In this final round of testing, a lack of anxiolytic 
and antidepression-like effects were found once again.  In the open field test, animals treated 
with 20 μg of 2064H did not spend more time in the center of the open field box (Figure 7A, un-
paired t-test, p = 0.5554) or travel a greater percent distance in the center (Figure 7B, un-paired 
t-test, p = 0.9174).  Similarly, in the tail suspension test, animals treated with 20 μg of 2064H did 
not show any difference in overall time immobile compared to control animals (Figure 7C, un-
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paired t-test, p = 0.2859) or in the first minute of the test (Figure 7D, un-paired t-test, p = 
0.6404).  Finally, a final HPLC of the parent fraction was taken after the fraction failed to induce 
the same antidepression effects in this round of testing.  It was found that the peak at 16.440 min 
was now completely gone (Figure 7E).  This suggested that the compound had continued to 
degrade from the last HPLC (see Figure 6) and provides an explanation as to why the anxiolytic 
and antidepression-like effects were lost over time. 
 
Figure 7. Behavioral effects of 2064H are lost after degradation of the active compound. (A) 
Mice treated with 20 μg of 2064H (n = 9) do not spend more time in the center of the open field 
box compared to vehicle (n = 9). (B) Mice treated with 20 μg of 2064H (n = 9) do not travel a 
greater percent of overall distance traveled in the center of the open field box compared to 
vehicle (n = 9). (C) Mice treated with 20 μg of 2064H (n = 9) do not show any differences in 
overall time immobile in the tail suspension test compared to vehicle (n = 9). (D) Mice treated 
with 20 μg of 2064H (n = 9) do not show any differences in time immobile in the first minute of 
the tail suspension test compared to vehicle (n = 9). (E) Third HPLC chromatogram of 2064H – 
Reverse Phase HPLC (20 μL injection; 1.5 mg/mL); Major peak at 16.440 min no longer present 
(taken March, 2015). Un-paired t-tests. Data shown as mean ± SEM.  NL – conducted behavior 
experiment.  KA – chromatography.  KA, NL, BK, KT – designed experiment. 
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 Once it was discovered that the active compound/peak in 2064H had completely 
degraded (from a peak of 2573 mAU in July 2011, to 135.1 mU in April 2014 to 0 mAU in 
March 2015), despite the promising results this compound was originally showing, subsequent 
testing was not possible and other fractions with 5-HT2CR activity were pursued for potential 
leads.  
 
Cyanobacteria Sample DUQ0008 – Screening and Pharmacology Reveals a 5-HT2CR Compound 
Also from Las Perlas Archipelago, Panama, another gray/green filamentous 
cyanobacterial mat was collected from near Isla Mina by hand using SCUBA from a sandy 
bottom (Figure 8A – C). Similar to 2064H, this collection was given the field identification of 
Oscillatoria or Moorea genera based off of cell morphology.  16S rRNA sequencing from this 
organism showed that it grouped closely with the genus Okeania (Figure 8D).   
 
Figure 8. Photos of cyanobacteria DUQ0008 and phylogeny. (A) Macroscopic picture of 
sample DUQ0008 before collection. (B) Confocal microscopy image of DUQ0008 at 10X 
magnification with FITC (487 nm), TRITC (560nm) and Cy5 (637 nm) channels. Scale bar = 
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200 μm.  (C) Transmitted light image of DUQ0008. Scale bar = 200 μm.  (D) Phylogenetic tree 
showing the closest related species to DUQ0008 based off of 16S rRNA sequencing with 
comparison to natural product producing cyanobacteria from the Okeania genus. Compounds 
produced by species are indicated if available; accession numbers are in brackets; numbers next 
to tree show percent of trees showing alignment in 600 replicates.  NL – tree building.  AZ – 16S 
sequencing.  KT – photographs.  NK – microscopy.  NL, BK, KT – designed experiment. 
 
Following extraction and fractionation, fractions of this cyanobacteria were screened 
using the PDSP.  There were a number of hits from the PDSP screen (Table 3).  Fractions that 
showed greater than 50% inhibition of binding, but an apparent Ki > 10 uM, were considered 
non-specific hits.  Fractions DUQ0008C and DUQ0008G showed greater than 50% inhibition of 
binding (Table 3) and also a low apparent Ki (ng/mL) (Table 4) for the 5-HT2CR, meaning that 
these fractions possessed true affinity for the receptor.   Fraction DUQ0008G was also further 
purified into two purer subfractions: DUQ0008GF1 and DUQ0008GF1H7 that likely contained 
the active compounds of DUQ0008G.   
 
 
 
Table 3: Selected bioassay results of DUQ0008. Hits are defined as fractions with greater than  
50% inhibition of binding/growth in the initial screen (highlighted in yellow). Primary affinity 
assays were performed by PDSP as described in Experimental Section. Data represent average 
percent inhibition of binding of a standard radiolabeled ligand (N = 4). DOR = delta opioid 
receptor, KOR = kappa opioid receptor, MOR = mu opioid receptor. SERT – serotonin 
transporter; NET – norepinephrine transporter. PDSP – conducted experiment. KT – designed 
experiment. 
 
 
DUQ0008
 
5-HT1AR 
 
5-HT1BR 
 
5-HT1DR 
 
5-HT1ER 
 
5-HT2AR 
 
5-HT2BR
 
5-HT2CR
 
5-HT3R
 
5-HT5AR
 
5-HT6R
 
5-HT7R
 
DOR 
 
KOR 
 
MOR 
 
SERT 
 
NET 
A -0.8 -5 -8.6 -2.8 7.4 0.2 18.1 -1.3 -13.6 -7.6 -3.8 -14.6 -4.5 -6.5 29 -7.1 
B -2.4 -2.7 -4.9 11.2 34 13.2 21.6 -6.9 -15.9 -9.7 -18.5 10.1 22.8 22.6 18.2 -2.7 
C 39.5 26.7 12.7 39.8 40.5 24.3 51.1 22.7 20.8 13.5 7.1 25.1 18.9 39.1 20.4 1.7 
D 33.7 17.3 4.1 34 51.7 20.8 37.9 1.7 1.8 15.3 -4.5 62.3 20 47.9 9.7 1.4 
E 25.2 -7.3 -1.5 1.7 38.2 1.9 34.8 -12.4 -4.5 -4 -11.6 38.8 22 36.5 1.7 -15.9 
F 21.2 -9.8 -7 1.2 5.2 3 11.5 -11.7 -0.8 13.9 -5.5 2 36.9 2.1 5.6 -19.2 
G 27.6 -3 2.5 6.1 53.5 15.8 58.8 -7.3 4.8 6.3 -7 50 49.9 35.4 19.5 -13.1 
H 31.3 -2.8 3.8 13.5 26.6 11.4 29.4 -6.2 5.2 14.8 17.2 30.2 23.2 34.7 25.7 -6.7 
I 63.6 10.8 6.1 26.7 32.8 27.6 41.5 -10.7 6.1 23.4 72.7 13.6 20.5 21.2 24.4 9.3 
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Table 4: Secondary Binding Assay Apparent Ki for PDSP hits for DUQ0008. Data are 
presented as apparent Ki in ng/mL. Ki values are calculated from best-fit IC50 values using the 
Cheng-Prusoff equation. Open boxes with (-) indicate that fractions failed primary binding 
criterion of > 50% inhibition at 10 μM. PDSP – conducted experiment. KT – designed 
experiment. 
 
Testing for Potential Alteration of Depression and Anxiety-like Behaviors in vivo with 
DUQ0008C and DUQ0008G  
 
 Since we had previous success with testing another 5-HT2CR active fraction (2064H) in 
the open field test, we decided to initially test both of these fractions and purified subfractions 
using this same assay.  Starting with DUQ0008C, using male animals with ICV injections, we 
found that mice treated with 20 μg of DUQ0008C showed a trend of spending more time in the 
center of the open field box compared to vehicle-treated control animals (Figure 9A, un-paired t-
test, p = 0.1045).  These same animals, however, did not show any difference in terms of overall 
percent distance traveled in the center of the open field box (Figure 9B, un-paired t-test, p = 
0.9787).  While not pursued any further here, the possible anxiolytic-like effects with the time 
data indicate that this fraction may be worth investigating further. 
                
DUQ0008 5-HT1AR  5-HT2AR  5-HT2CR  5-HT7 R DOR   
A - - - - - 
B - - - - - 
C - -  191 - - 
D - > 10000 - - 1776.0 
E - - - - - 
F - - - - - 
G - 1854.0 98 - - 
H - - - - - 
I  2441.0  - - 1223.0 - 
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Figure 9. Anxiolytic-like trend of DUQ0008C in the open field test. (A) Mice treated with 20 
μg of DUQ0008C (n = 16) show a trend of spending more time in the center of the open field 
box compared to vehicle (n = 15). (B) Mice treated with 20 μg of DUQ0008C (n = 16) do not 
travel a greater percent of overall distance traveled in the center of the open field box compared 
to vehicle (n = 15).  Un-paired t-tests. Data shown as mean ± SEM.  NL – conducted experiment.  
NL, BK – designed experiment. 
 
Moving onto the other 5-HT2CR active fraction from this collection (DUQ0008G), this 
fraction, along with the two purer subfractions (DUQ0008GF1 and DUQ0008GF1H7) were also 
tested using the open field test.  Here, the same dosage of each fraction/subfraction was used (20 
μg).  We predicted that if the active compound within these samples had any behavioral effects, 
the purest subfraction (DUQ0008GF1H7) would have the greatest behavioral effect since the 
active compound would be administered at the highest dose (this purest subfraction contains the 
highest amount of potentially active compound).  Using male animals and ICV administration, 
we found that neither 20 μg of DUQ0008G, DUQ0008GF1 or DUQ0008GF1H7 changed the 
amount of time that animals spent in the center of the open field box compared to the control 
group (Figure 10A, One-Way ANOVA, p = 0.8840).  This same dose of each fraction and 
subfraction also did not change the overall percent distance that the animals traveled in the center 
of the open field box (Figure 10B, One-Way ANOVA, p = 0.9097).  This indicated that there 
was a complete lack of anxiolytic-like effects from the 5-HT2CR active compound within this 
fraction.          
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Figure 10. DUQ0008G, DUQ0008GF1, DUQ0008GF1H7 do not induce any effects in the 
open field test (A) Mice treated with 20 μg of DUQ0008G (n = 4), 20 μg of DUQ0008GF1 (n = 
4) or 20 μg of DUQ0008GF1H7 (n = 4) spend equal time in the center of the open field box 
compared to vehicle treated animals (n = 4). (B) Mice treated with 20 μg of DUQ0008G (n = 4), 
20 μg of DUQ0008GF1 (n = 4) or 20 μg of DUQ0008GF1H7 (n = 4) do not travel a greater 
percent of overall distance traveled in the center of the open field box compared to vehicle 
treated animals (n = 4).  One-Way ANOVA. Data shown as mean ± SEM. NL – conducted 
experiment.  NL, BK – designed experiment. 
 
Due to the lack of behavioral effects in the open field test, we decided to also test 
DUQ0008G and the next purest subfraction DUQ0008GF1 in the tail suspension test.  Similar to 
what was found with open field, neither 20 μg of DUQ0008G nor 20 μg of DUQ0008GF1 
administered ICV altered overall time immobile compared to the control animals in the tail 
suspension test (Figure 11, One-Way ANOVA, p = 0.3830).  This showed that despite the 
positive hit at the 5-HT2CR in the PDSP screening and our previous positive results with 2064H, 
the compound lacked a behavioral effect in vivo. 
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Figure 11. DUQ0008G and DUQ0008GF1 do not induce any effects in the tail suspension 
test. Mice treated with 20 μg of DUQ0008G (n = 6) or 20 μg of DUQ0008GF1 (n = 5) spend 
equal time in the center of the open field box compared to vehicle treated animals (n = 5). One-
Way ANOVA. Data shown as mean ± SEM.  NL – conducted experiment.  NL, BK – designed 
experiment. 
 
DISCUSSION 
Overall, our results show that compounds with affinity in the PDSP screening do not 
necessarily have effects in animal models and that each compound along with its stability must 
carefully be considered and evaluated. While 2064H, DUQ0008C and DUQ0008G all had 
positive hits at the 5-HT2CR, only fraction 2064H (and the pure compound 2064H3) induced 
changes in the open field, tail suspension and formalin tests.  2064H and 2064H3 caused 
antidepressant, anxiolytic, and nocifensive behavioral effects in an in vivo mouse model prior to 
the discovery that the likely active compound in the fraction degraded.  
The tests used in this chapter have a long history in the field of drug-discovery testing.  
The oldest of these tests, the open field test was first described by C.S. Hall in the 1930’s (Hall 
and L. Ballachey, 1931).  In this first iteration of the test, Hall observed how a rat behaved when 
placed in a novel environment that was split up into 49 squares with and without food present in 
the center of the box.  He noted that the rats tended to stay towards the edges of the box, away 
from the center in the absence of food.  They seemed to enter the center area more frequently 
only when there was food present.  From these initial observations made by Hall, this assay was 
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mainly used in the field of experimental psychology to observe “emotionality states” of the rats 
placed in these types of boxes, where time exploring food objects, amount of 
urination/defecation were recorded.  Then in the 1960’s, with the discovery of benzodiazepines 
and their enormous success in treating anxiety in humans, models like the open field test became 
validated as a measure of anxiety-like behavior in rodents (Bourin, 2015).  Rodents that received 
injections of this class of drugs would spend significantly more time in the center of open field 
boxes, consuming more food placed in the center of the box and have a greater mean amount of 
food consumed per visit to the center with food (Britton and Britton, 1981).  While not all drugs 
that successfully treat anxiety in humans show these effects in the open field assay, it still offers 
a sold starting point for the screening process.  For example, while many serotonergic agents 
treat anxiety, many do not show effects in this type of anxiety assay (Bourin, 2015).  In fact, it is 
estimated that only about 25% of the drugs that work to treat anxiety in humans show efficacy in 
animal models of anxiety (Haller and Alicki, 2012).  Despite this drawback, the fact that fraction 
2064H has efficacy in this model suggests that if the active compound were to be identified, it 
has the potential to work in humans to treat anxiety.   
The depression assay utilized in this chapter, the tail suspension test is a much newer 
assay compared to the open field anxiety test.  It was developed as a modification of the Porsolt 
swim test (forced swim test, described in more detail in Chapter 2).  This assay, based on the 
principle of learned-helplessness was first described by Steru in 1985 (Steru et al., 1985).  In this 
first publication, he found that known antidepressant drugs that work in humans, 
psychostimulants and atropine all decreased the overall immobile time of the mice that were 
suspended by their tails.  He also noted that when the test is coupled with measurements of 
locomotor activity, the hyperactive effects can be separated from the antidepressant effects.  
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These early validation experiments conducted by Steru have made the tail suspension test a 
commonly used assay to screen compounds for antidepression-like effects.  Moreover, the tail 
suspension test is an attractive model for depression due to the similarities between the way an 
animal responds in an unavoidable stressful scenario and uncontrollable stressful events that can 
lead to depression in humans (Wang et al., 2017).  However, one of the major drawbacks of this 
test is the fact that acute treatments of antidepressants induce the changes in immobility in mice, 
but in humans, it takes weeks of chronic treatment to see a recovery from depression (Cryan et 
al., 2005).  Despite this, the tail suspension test has excellent predictive validity as a screening 
assay, especially with tricyclic antidepressants (SSRIs, SNRIs and NRIs) (Cryan et al., 2005).  
The excellent predictive ability of this assay indicates a particularly promising active compound 
from fraction 2064H. 
In the last test that was utilized for screening the 5-HT2CR active fraction, the formalin 
test, was first described by Debuisson and Dennis in 1977 (Dubuisson and Dennis, 1977).  In this 
first iteration of the test, dilute formaldehyde solution was injected into the forepaws of both cats 
and mice.  The researchers observed the various pain-like responses that were induced by the 
formalin, which included biting, licking, flinching, raising and guarding the afflicted paw as well 
as vocalizations.  A biphasic response in these pain-like behaviors is observed with this test, 
where the first phase (0 – 10 minutes) results from the activation of primary nociceptors and the 
second phase (10 – 60 minutes) results from inflammation-induced central sensitization of the 
spinal cord.  The original researchers validated this as a model of measuring analgesic-like 
behaviors with two effective opioid drugs, morphine and meperidine, and observed a significant 
decrease in all of these behaviors in the formalin-injected animals that received these drugs.  
Since then, these assays has been used to show the efficacy of a variety of opioids, 
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oxyphenylbutazone, acetylsalicylic acid, corticosteroids, diflunisal, diacerhein, carbamazepine, 
topiramate, gabapentin and antagonists of both TRPA1 and NMDA receptors (Muley et al., 
2016).  One of the major drawbacks of this assay is that it has little translational relevance, due to 
the fact that formalin activates TRPA1 receptors, a receptor not often associated with pain in 
humans.  Despite this drawback, the formalin test is still a valuable screening tool for analgesic-
like effects of drugs due to its ease of use and high reproducibility.  In our screening of 2064H, 
the fact that this fraction increased pain-like responses indicates how this compound may not be 
a desired drug for ever treating pain in humans, but provides a valuable tool in showing the 
relationship and common underlying mechanism between pain and depression. 
The behaviors that were observed with 2064H using these depression, anxiety and pain 
assays correspond to those obtained when manipulating the 5-HT2CR with previously described 
ligands.  In tests of depression, antidepression-like behaviors were seen with broad 
administration of 5-HT2CR antagonists (Dekeyne et al., 2008; Nahata et al., 2013), data 
suggesting that blocking the 5-HT2CR induces these antidepression-like behaviors.  In terms of 
anxiety-like behaviors, more anatomical specific data is known. Activation of 5-HT2CR in the 
lateral/basolateral amygdala (BLA) (Campbell and Merchant, 2003; Pockros-Burgess et al., 
2014; Vicente and Zangrossi, 2014) or ventral hippocampus induced anxiety-like effects (Alves 
et al., 2004).  Administration of a 5-HT2CR inverse agonist reversed anxiety-like behavior in rats 
(Overstreet et al., 2006).  In dorsal PAG administration, agonists of the 5-HT2CR induced 
anxiolytic-like effects (Gomes and Nunes-De-Souza, 2009), while others have found activation 
of 5-HT2CRs increased anxiety-like behaviors (Yamashita et al., 2011). Taken together, these 
known effects on depression and anxiety-like behaviors suggest that the active compound in 
2064H may be an antagonist of the 5-HT2CR.  While further testing to block the effects of 2064H 
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with the known agonist CP809101 would have provided strong evidence that the active 
compound in 2064H is indeed an antagonist, this was impossible due to the degradation of the 
compound.  Since activation of 5-HT2CR in the amygdala and hippocampus increases anxiety-
like behavior (Campbell and Merchant, 2003; Alves et al., 2004; Gomes and Nunes-De-Souza, 
2009; Pockros-Burgess et al., 2014; Vicente and Zangrossi, 2014), it is possible that the 
antagonist in 2064H/2064H3 is acting in these regions to cause the anxiolytic-like and 
antidepressant-like effects demonstrated in this study.  The amygdala and hippocampus are also 
located close to the site of ICV injection, making this a distinct possibility. Future studies will be 
necessary to address the anatomical specificity of 2064H behavioral effects. 
Ligands of the 5-HT2CR have also been shown to alter pain-like behaviors, with 
anatomical-dependent effects. Local paw administration of 5-HT2CR antagonists reduced the 
total number of flinches in phase 2 of the formalin test (Nakajima et al., 2009).  Activation of 5-
HT2CR in the spinal cord reduced pain in the formalin test (Jeong et al., 2004) and prevented the 
development of allodynia in rats with infraorbital nerve ligation (Nakai et al., 2010) or spinal 
nerve ligation (Obata et al., 2004). While there are limited data on the effects of the 5-HT2CR in 
specific brain regions, it is possible that the compound in 2064H could be acting to increase 
pain-like behavior by binding with these receptors in the PAG.  Activation of 5-HT2CRs in this 
region is analgesic (Baptista et al., 2012), so it is possible that antagonism causes an increase in 
nociceptive responses.  The PAG also surrounds the cerebral aqueduct, which contains the 
cerebrospinal fluid where 2064H is dispersed in ICV injections, further supporting this 
hypothesis. 
The behavioral results seen in this study and their effects seen in depression, anxiety, and 
pain assays were expected based on the known comorbidity that exists between depression, 
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anxiety, and pain.  Patients that suffer from a chronic pain condition often report accompanying 
feelings of depression – 15 to 100% of patients that suffer from depression are described as also 
having some type of chronic pain, with percentages varying with the type of pain studied (Bair et 
al., 2003).  Correspondingly, rates of depression among chronic pain patients are also high, 
ranging from 13 to 82% (Bair et al., 2003).  Comorbidity of chronic pain and depression in turn 
appears to amplify each individual condition, with patients often reporting more intense 
symptoms when the diseases occur together (Von Korff et al., 1992).  There is also a 
synchronicity between anxiety and pain over time, with patients who have anxiety reporting 
more severe pain and higher levels of pain even after remission compared to healthy controls 
(Gerrits et al., 2015).  This overlap implies that a common mechanism may link psychiatric 
conditions and pain and that a single treatment used for one disorder may prevent the 
development of the other.  Most early drug screenings look only at affective assays (i.e. 
depression and anxiety) or pain assays, not both.  Novel compounds that have activity at 
receptors such as the 5-HT2CR should be screened for effects in affective and pain conditions.  
Finding one compound that could help alleviate the effects of both conditions would lead to a 
better understanding of how these comorbid conditions arise.  In the present study, our 5-HT2CR 
compound had opposing therapeutic effects on depression and anxiety compared to pain.  
However, it should be appreciated that the lack of anatomical targeting in the present study may 
contribute to an incomplete picture of the potential for 5HT2CR in treating comorbid pain and 
depression. Direct administration of the 5-HT2CR antagonist SB242084 to the BLA along with 
intraperitoneal administration of the SSRI fluvoxamine inhibited pain-like vocalizations and 
anxiety-like behaviors in rats using an arthritis pain model (Gregoire and Neugebauer, 2013), 
suggesting that specific antagonism of 5-HT2CRs in this brain region may be a key to 
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understanding comorbid pain and depression.  Furthermore, only the formalin test was used in 
my studies and it is not known to produce consequential effects on anxiety or depression like 
behavior. A full analysis of 2C in comorbidity would require a chronic pain model with 
comorbidity.  
Our results also highlight that differences exist between the screening of a fraction of raw 
compounds (2064H) and an isolated HPLC peak obtained from that fraction (2064H3).  These 
differences are illustrated in the tail suspension data (Figure 3A and 3B), the only assay in which 
we were able to test both 2064H and 2064H3 (we were not able to test 2064H3 in any other 
behavioral assays due to the low amount obtained following purification). During the first minute 
of the tail suspension test, the pure compound 2064H3 induced a significantly lower immobility 
time in these mice compared to vehicle-treated mice.  In contrast, when the fraction 2064H was 
administered, a similar, but not statistically significant trend was seen.  These data imply that the 
behavioral trends seen with 2064H were due to the presence of 2064H3 in that fraction.  In both 
cases, 20 μg of 2064H or 2064H3 was injected.  When the pure compound is administered in 
isolation at a full 20 μg dose, the effect becomes significant.  The presence of other inactive 
compounds in fraction 2064H (such as chlorophylls and other inactive metabolites) means that 
less than 20 μg of the active 2064H3 in this mixture is being administered.  Our results also show 
that not all raw fractions or purified HPLC peaks that contain PDSP active compounds have 
effects in vivo. DUQ0008C may provide a lead for testing purer subfraction due to the 
anxiolytic-like trends seen with the open field test (Figure 9).  However, further testing will be 
needed to show this. Conversely, DUQ0008G and the purer subfractions DUQ0008GF1 and 
DUQ0008GF1H7 had no hint of an effect on animals in the open field (Figure 10) or tail 
  55
suspension tests (Figure 11), suggesting that they are most likely behavioral dead ends with ICV 
injections. 
Finally, the results from the tests with 2064H show the potential instability of the active 
compounds that cyanobacteria produce.  While impossible to know definitively, the fact that the 
cyanobacteria mass 2064 was excreting a red pigment upon extraction could signal that this 
species only produces these psychoactive compounds upon a potential threat targeting the 
organism.  The active compound could have been in this excretion and may be chemically 
unstable. This observation correlates with the decrease in amount of active peak that was seen 
over time with 2064H.  The HPLC showed that from July 2011 (see Figure 2) to April 2013 (see 
Figure 6), the relative area under the curve of that peak decreased ~95%.  Then, by March 2015, 
the peak was completely gone (see Figure 7).  The initial characterization experiments that were 
done were completed in the summer of 2013, and this was when the antidepression-like and 
increase in pain-like behaviors were observed (see Figure 3).  All subsequent tests with 2064H, 
completed in the fall and winter of 2014, showed none of these same effects, indicating that this 
may be the time when the compound had degraded to a level that was too low to induce any 
behavioral effects.  Since it is unknown what the exact structure of these compounds are upon 
initial testing, these compounds are stored at 4oC in the dark (in case the compounds are light 
sensitive).  Notably, natural products, especially those from plants, have been found to have 
many different issues including poor solubility, complex structures and instability (Yao et al., 
2017).  Often, medicinal chemists seek to chemically modify identified compounds to prevent 
their rapid breakdown (Rao et al., 2017).  In our sample, the breakdown was possibly slowed for 
the initial two years after collection due to the storage conditions of the parent fraction between 
testing, but still indicates how storage conditions may need to be changed in the future to prevent 
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degradation from happening.  Additionally, structural identification should be completed 
immediately after collection so that even if degradation occurs, a structure is known and 
synthesis could be undertaken.  This provides a possible explanation as to why the compound 
was unable to stay present under optimal storage conditions. 
 
METHODS 
Field Collection  
For 2064, a green cyanobacterial mat was collected in September 2011 (collection code 
PAL-22Sep11-4) by hand using SCUBA in 8-10 ft of water off of sandy bottom substrate near 
Mogo Mogo in the Las Perlas Archipelago, Panama (GPS coordinates: N8 34.837 W79 01.177; 
Figure 1). The cyanobacterial mat had large green filaments and grew in dispersed clumps in the 
sand.  A voucher sample was taken for storage at the Smithsonian Tropical Research Institute in 
Panama.  Upon collection, the cyanobacteria were excreting a reddish pigment into the water, 
which was saved in seawater and combined with cyanobacterial biomass for extraction purposes.  
The total volume collected was 4 L. 
For DUQ0008, green/gray cyanobacterial filaments were collected in January 2013 
(collection code PLP-29Jan13-3) by hand using SCUBA in 8-10 ft of water off of sandy bottom 
substrate near Isla Mina in the Las Perlas Archipelago, Panama.  The cyanobacterial mat had 
large green filaments and grew in dispersed clumps in the sand.  A voucher specimen (PLP-
29Jan13-3) is deposited in the Department of Medicinal Chemistry, Graduate School of 
Pharmacy, Duquesne University. 
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Microscopy 
Samples of DUQ0008 used for microscopy were prepared using a piece of the sample 
stored in RNAlater solution.  Filaments were spread out onto a slide with distilled H2O and 
imaged at 20X on a (Nikon 1AR-HD) using the FITC (487 nm), TRITC (560nm) and Cy5 (637 
nm) channels. 
 
16S rRNA Gene Sequencing and Phylogenetic Analysis 
 Genomic DNA was extracted from DUQ0008 (GenBank Number: MH345835.1) that 
was preserved in RNAlater® solution (Thermo Fisher) after collection.  Lysis buffer (10 mM 
Tris, 0.1 M EDTA, 0.5% (w/v) SDS, 20 μg/mL RNase, pH 8.0) was added to the cyanobacteria 
mass at 10X the biomass of the cells (i.e. 100 mg cells = 1000 μL lysis buffer).  This was 
followed by 100 μL of lysozyme solution (10 mg/mL, Sigma) for 30 minute with an incubation 
at 37°C.  0.01X the volume of Proteinase K (10 mg/mL, Gene Link) was then added and 
incubated for 1 hr at 50°C.  Following this, the mixture was centrifuged at 13,000 rpm for 3 
minutes and the remaining pellet was used with the Wizard Genomic DNA Purification Kit 
(Promega).  Extracted genomic DNA then underwent PCR to amplify the 16S rRNA gene with 
primers (CYA106F and CYA1509R) previously utilized (Nubel et al., 1997; Engene et al., 
2010).  Successful PCR amplifications (~1370 bp) underwent PCR purification using the Min 
Elute PCR Purification Kit (Qiagen) and purified PCR products were used for TOPO cloning.  
One Shot E. coli cells along with the pCR® 4-TOPO vector with kanamycin resistance from the 
TOPO TA Cloning ® Kit (Invitrogen) were used and cells were plated overnight at 37°C on LB 
KAN plates.  Successful transformants were selected and used in colony PCR with the M13F and 
M13R primers to confirm the presence of the 16S rRNA sequence now in the TOPO vector 
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(~1535 bp).  Purified PCR product for correct samples was sent to Beckman Coulter (now 
GENEWIZ) to undergo forward and reverse Sanger sequencing with the M13F and M13R 
primers.  Our sequence for DUQ0008, along with 16S rRNA gene sequences that were obtained 
with sequence data available at the National Center for Biotechnology (NCBI) webpage 
(http://www.ncbi.nlm.nih.gov) were then used for phylogenetic analysis.  Gene sequences were 
aligned using the Muscle algorithm and phylogeny reconstruction was done using maximum 
likelihood method with 500 bootstrap replicates using the MEGA (version 5.1) program (Hall, 
2013). 
 
 Compound Extraction 
Collected cyanobacterial biomass for both 2064 and DUQ0008 was transported in sea-
water and stored at -20°C until extraction. A small sample was preserved in an RNA preserving 
solution (RNALater, Qiagen), but no viable genetic material could be obtained for 2064, making 
phylogenetic determination impossible. Cyanobacterial biomass and water were extracted 
repeatedly with a 2:1 mixture of dichloromethane:methanol (5 x 500 mL for each extraction) and 
filtered through cheese cloth. Organic layers obtained from each extraction were combined and 
concentrated by rotary evaporation at 25°C to obtain 4.2 g of the crude extract.  This crude 
extract was then subjected to flash silica gel column chromatography and eluted with 
hexane:ethyl acetate (100:0, 80:20, 60:40, 40:60, 20:80 and 0:100) and ethyl acetate:methanol 
(75:25, 50:50 and 0:100) to obtain nine fractions (2064A to 2064I).  Fractions and crude extracts 
were then subjected to bioassays.  Fractions were stored at 4OC in the dark between testing. 
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Leishmania Bioassay 
Axenically grown (cell free) amastigotes of Leishmania donovani (LD-
1S/MHOM/SD/00-strain 1S), the species responsible for the visceral and lethal forms of 
leishmaniasis, were used to assess parasite growth and survival.  Samples were tested in 
duplicate at 10 μg/mL.  The results were expressed as a percentage of growth inhibition (IG) 
compared to controls. Samples that showed above 70% IG were considered active and were then 
assayed at four different concentrations (0.08, 0.4, 2, and 10 μg/mL) to determine IC50 values. 
Amphotericin B was used as a positive control with the typical IC50 response of 0.08-0.13 μM 
(Williams et al., 2003). 
 
Chagas’ Disease Bioassays 
Trypanosoma cruzi bioassays were performed using a colorimetric method, and the 
inhibition of parasite growth was assessed by the expression of the reporter gene for β-
galactosidase (β-Gal) in the recombinant Tulahuen clone C4 of T. cruzi.  Assays were performed 
in duplicate on the amastigote, the intracellular form of the parasite infecting African green 
monkey kidney (Vero) cells, exposed during 120 h to different concentrations (10, 2 and 0.4 
μg/mL) of the test compounds at 37°C under an atmosphere of 5% CO2/95% air.  The resulting 
color from the cleavage of chlorophenol red-β-D-galactoside (CPRG) by β-Gal expressed by the 
parasite was measured at 570 nm.  The concentration that inhibited 50% expression of β-Gal 
(IC50) was calculated by log regression of the obtained optical density values, and compared with 
the untreated controls.  Nifurtimox was used as a positive control (IC50 10-16 μM) (Buckner et 
al., 1996). 
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Malaria Bioassays 
Antiplasmodial activity was evaluated using a fluorometric method based on the 
detection of parasite DNA with the fluorochrome PicoGreen using a chloroquine-resistant strain 
(Indochina W2) of Plasmodium falciparum.  The sample was considered active if it inhibited 
>70% of the growth of the parasites as compared to their untreated controls at 10 μg/mL.  The 
IC50 was calculated by normal regression of the resulting inhibition percentages at 0.08, 0.4, 2, 
and 10 μg/mL.  The parasites were maintained in vitro by a modification of the method of Trager 
and Jensen (Trager and Jensen, 1976).  Chloroquine was used as a positive control (IC50 80-100 
nM) (Corbett et al., 2004). 
 
Cytotoxicity Assay 
H-460 cells were added to 96-well plates at 3.33x104 cells/mL of Roswell Park Memorial 
Institute (RPMI) 1640 medium with fetal bovine serum (FBS) and 1% penicillin/streptomycin. 
The cells, in a volume of 180 μL per well, were incubated overnight (37°C, 5% CO2) to allow 
recovery before treatment with test compounds.  Compounds were dissolved in DMSO to a stock 
concentration of 10 mg/mL. Working solutions of the compounds were made in RPMI 1640 
medium without FBS, with a volume of 20 μL added to each well to give a final compound 
concentration of either 30 or 3 μg/mL. An equal volume of RPMI 1640 medium with FBS was 
added to wells designated as negative controls for each plate. Plates were incubated for 
approximately 48 h before staining with dimethylthiazolyl-diphenyltetrazolium bromide MTT.  
Using a ThermoElectron Multiskan Ascent plate reader, plates were read at 570 and 630 nm 
(Mevers et al., 2011). 
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Psychoactive Drug Screening Program (PDSP) CNS-activity screening 
All binding assays for 2064 (including crude fraction and fractions 2064A to 2064I) and 
DUQ0008 (including crude fraction and fractions DUQ0008A to DUQ0008I) were generously 
provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program 
(NIMH PDSP) using a radioligand competition-binding assay.  Experimental details are 
available online at http://pdsp.med.unc.edu/.  Binding assays performed by the NIMH PDSP 
employ stably or transiently transfected cell lines expressing human recombinant receptors, 
monoamine transporters, or ion channels for targets of interest.  Targets screened for our 
cyanobacterial fractions from 2064H and DUQ0008 included 5-HT1AR, 5-HT1BR, 5-HT1DR, 5-
HT1ER, 5-HT2AR, 5-HT2BR, 5-HT2CR, 5-HT3R, 5-HT4R, 5-HT5AR, 5-HT6R, 5-HT7R, Alpha1A, 
Alpha1B, Alpha1D, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2, Beta3, CB1, CB2, D1, D2, D3, 
D4, D5, DAT, DOR, GABAA, H1, H2, H3, KOR, M1, M2, M3, M4, M5, MOR, NET, PBR, 
SERT, Sigma 1, Sigma 2.  For primary binding experiments, fractions were tested at a single 
concentration (10 μM) and in quadruplicate in 96-well plates.  For primary binding results, non-
specific binding in the presence of 10 μM of a reference compound is set as 100% inhibition; 
total binding in the absence of fraction or reference compound is set as 0% inhibition. Plates are 
incubated with compounds and fractions at room temperature and in the dark for 90 minutes.  
Reactions are stopped by vacuum filtration onto 0.3% polyethyleneimine (PEI) soaked 96-well 
filter mats using a 96-well Filtermate harvester, followed by three washes with cold wash 
buffers. Scintillation cocktail is then melted onto the microwave-dried filters on a hot plate and 
radioactivity is counted in a Microbeta counter.  Compounds showing a minimum of 50% 
inhibition at 10 μM are tagged for secondary radioligand binding assays to determine equilibrium 
binding affinity at specific targets.  In secondary binding assays, fractions are tested at 11 
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concentrations (0.1, 0.3, 1, 3, 10, 30, 100, 300 nM, 1, 3, 10 μM) and in triplicate (3 sets of 96-
well plates).  Radioactivity is counted in the same way as the primary assay.  The following 
radio-labeled and reference compounds were used for the receptors that underwent secondary 
screening: 5-HT1AR, [3H]-Way100635 and OH-DPAT; 5-HT2AR, [3H]-Ketanserine and 
clozapine; 5-HT2BR, [3H]-LSD and SB206553; 5-HT2CR, [3H]-mesulergine and ritanserion; 5-
HT3R, [3H]-GR65630 and zacopride; 5-HT7R, [3H]-LSD and clozapine; DOR, [3H]-DADLE 
and naltrindole; MOR, [3H]-DAMGO and DAMGO; KOR, [3H]-nociceptin and JDTiC.  Total 
binding and nonspecific binding are determined in the absence and presence of 10 μM of each 
reference compound and IC50 is the concentration at which 50% observed binding was inhibited. 
Ki values are calculated from best-fit IC50 values using the Cheng-Prusoff equation.  
 
HPLC 
HPLC separation was carried out on a Dionex UltiMate 3000 equipped with a diode array 
detector.  A Synergi 4u Fusion-RP-80A (150 x 10 mm, 4 micron) column was used for the 
separation.  The reverse phase separation started at a constant flow rate of 2 mL/min with a linear 
gradient from 50% acetonitrile (ACN) in water to 84% ACN over 20 minutes followed by an 
increase to 100% ACN and holding at 100% ACN for 10 minutes.  For each run, 100 µL of each 
sample was injected at a concentration of 10 mg/mL.  Fractions were collected based on UV 
absorption at 235 nm and 2064H3 was collected at a retention time of 16.4 min.  
 
Animals  
 All animal procedures were reviewed and carried out in accordance with the National 
Institutes of Health Guide for the Care and Use of Animals and the Institutional Animal Care and 
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Use Committee at Duquesne University. All experiments were carried out on male C57Bl/6J 
mice that were 8-10 weeks old.  Animals were individually housed and maintained on a 12 h 
light/dark cycle (lights on between 7:00 AM and 7:00 PM) with ad libitum access to food and 
water. All procedures were carried out during the light cycle. All behaviors performed were 
recorded and analyzed by a male experimenter blinded to experimental treatment.  
 
Surgical Procedures 
 Animals were anesthetized with 3% isoflurane/0.6% O2 during all surgical procedures. 
Intracerebroventricular (ICV) cannulation surgeries were performed as described previously 
(Glascock et al., 2011).  Briefly, mice were placed in a stereotaxic frame and an 8.00 mm steel 
cannula was placed into the right lateral ventricle at the following anatomical coordinates: 0.5 
mm anterior to bregma, 1.0 mm lateral to midline and 2.0 mm ventral to the skull. A dental 
cement skullcap secured with two bone screws was used to hold the cannula in place.  Mice 
recovered on heating pads and were given one week of recovery prior to the beginning of 
behavioral testing. Following all behavioral tests, cannula placement was verified with necropsy. 
 
Compound Preparation and Administration  
 Cyanobacterial extracts from collection 2064, fraction H (2064H) and HPLC peak 3 
(2064H3) and collection DUQ0008, fraction C (DUQ0008C), fraction G (DUQ0008G), 
subfraction F1 (DUQ0008GF1) and subfraction H7 (DUQ0008GF1H7) were dissolved in a 
mixture of 50% DMSO and 50% artificial cerebrospinal fluid (aCSF) containing the following 
(in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 2.0 CaCl2, 1.0 MgCl2 and 25 D-
glucose, bubbled with 95% O2/5% CO2 for 20 minutes prior to use.  Microinjections were 
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performed using a 32-gauge injector that extended 0.5 mm beyond the tip of the ICV cannula.  
The injector was attached to flexible tubing and a 1.0 μL syringe (Hamilton) that was used to 
deliver a total volume of 0.5 μL over a 2 minute period.  The injector was kept in place for an 
additional 1 minute to allow complete compound infusion.  For all injections, fraction 2064H, 
2064H3, DUQ0008C, DUQ0008G, DUQ0008GF1 and DUQ0008GF1H7 were administered at a 
20 μg dose.  50%/50% aCSF/DMSO (0.5 μL) was used as a vehicle control. 
 Behavioral Testing 
 Mice were habituated for 1 h with 60 dB of white noise to block ambient noise.  All 
animals received fraction/compound (2064H / 2064H3 / DUQ0008C / DUQ0008G / 
DUQ0008GF1 / DUQ0008GF1H7) or vehicle 5 minutes prior to the beginning of testing.  All 
behavioral testing took place in room 103G in the Duquesne University Animal Care Facility 
Tail Suspension Test: The tail suspension test was performed to measure depression-like 
behaviors (Steru et al., 1985; Kolber et al., 2010b). After compound administration via ICV 
cannula, mice were returned to their home cages for 5 minutes.  After this 5 minute pretreatment, 
mice suspended by the distal ends of their tail with lab tape in a Plexiglas enclosure (35 × 25 × 
25 cm) with white sides.  Tubes were placed over the animals’ tails to prevent them from 
climbing up their tails.  Two animals could be tested at once with a Plexiglas divider down the 
middle of the enclosure.  The animals’ movements were recorded with webcam (Logitech) for 
scoring offline in one minute bins for a total of 6 minutes.  Immobility was defined as time when 
the mouse did not exhibit any outward movement of its limbs or body.   
Open Field Testing: Anxiety-like behaviors were measured with the open field (Hall and 
L. Ballachey, 1931; Montana et al., 2011).  The test was performed in a dimly lit room (no 
overhead lights on, two desk lamps facing the corners of the room, one above the open field box 
  65
to brightly illuminate).  After compound administration via ICV cannula, mice were returned to 
their home cages for 5 minutes.  After this 5-minute pretreatment, mice were placed in the 
bottom corner, facing the fall of a brightly lit Plexiglas box with high walls (25 × 25 × 35 cm) 
and tracked with an over-head camera and ANY-maze software (Stoelting Co., version 4.98).  
Time spent and distance traveled in the center and outside regions of the box were recorded for 
the 10 minute test.  The enclosure was cleaned with Quatricide spray in between each animal. 
Formalin Testing: Spontaneous pain-like behaviors were measured using the formalin 
test (Dubuisson and Dennis, 1977; Kolber et al., 2010a).	 	 Mice were habituated in clear, 
ventilated Plexiglas boxes (12 × 12 × 20 cm), with dividers between them, for 2 hours.  The 
enclosures were raised above two video cameras (Logtech) placed underneath. 12 animals could 
be tested at the same time.  After compound administration via ICV cannula, mice were returned 
to their Plexiglas enclosures for 5 minutes.  After this 5-minute pretreatment, the animal received 
a 10 μL intradermal injection of 4% formalin (Sigma; diluted with saline to 4% formalin) into 
the right hindpaw and was videotaped for 1 h followed by offline scoring.  The mice were 
analyzed for nocifensive behaviors (lifting, biting, lifting and flinching of the injected paw) in 5 
minute bins. 
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The majority of the text contained within this chapter is adapted from the following publication: 
Lax NC, Parker SA, Hilton EJ, Seliman Y, Tidgewell KT, Kolber BJ. 2018. Cyanobacterial 
extract with serotonin receptor subtype 7 (5-HT7R) affinity modulates depression and anxiety-
like behavior in mice. Synapse. DOI:10.1002/syn.22059. 
  
 
Photographs of sample DUQ0002 in Figure 12 were taken by Kevin Tidgewell.  Screening of 
extracts for affinity was performed by the NIMH PDSP, directed by Bryan L. Roth MD, PhD at 
the University of North Carolina at Chapel Hill.  Sarah Leep and Vianie Henri (Kolber Lab) 
assisted with formalin testing and scoring in Figure 21. 
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ABSTRACT 
Marine cyanobacteria represent a unique source in the field of drug discovery due to the 
secondary metabolites they produce and the structural similarity these compounds have to 
endogenous mammalian receptor ligands.  One sample, a cyanobacterium identified by 16S 
rRNA sequencing as Leptolyngbya from Las Perlas archipelago in Panama, contained a fraction 
with noted affinity for the 5-HT7 receptor (5-HT7R).  This fraction (DUQ0002I) was screened 
via intracerebroventricular (ICV) injections in mice using depression anxiety and pain assays 
including the forced swim, tail suspension, elevated zero maze, light-dark preference, formalin, 
von Frey, Hargreaves and OPTA tests.  5-HT7R knockout male animals were also characterized 
in these same assays and compared to wild-type animals. DUQ0002I decreased depression and 
anxiety-like behaviors in males and did not have effects in 5-HT7R knockout or female mice, 
while not having any effects in pain assays.  Similarly, 5-HT7R knockout male animals showed 
an antidepression-like phenotype compared to 5-HT7R knockout female animals (preliminary).  
Administration of DUQ0002I to the CA1 of the hippocampus induced antidepression-like, but 
not anxiolytic-like behaviors.  Testing of further purified materials showed no behavioral effects, 
leading us to hypothesize that the behavioral effects are likely caused by a synergistic effect 
between multiple compounds in the fraction.  Finally, DUQ0002I was used in a model of 
neuropathic pain with comorbid depression (spared nerve injury – SNI).  DUQ0002I had a 
similar antidepressant effect in animals with SNI, suggesting a role for the 5-HT7R in the 
development of comorbid pain and depression.  These results demonstrate the potential that 
cyanobacterial metabolites have in the field of neuropharmacognosy. 
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INTRODUCTION 
 Filamentous cyanobacteria are small, photosynthetic prokaryotes found in diverse 
environments around the globe. They are known to produce secondary metabolites that were first 
studied in freshwater environments due to the poisoning of domestic cattle drinking from water 
with cyanobacterial blooms (Stewart et al., 2008) and in marine environments for their 
involvement in “swimmer’s itch” (Osborne and Shaw, 2008).  These metabolites are thought to 
have originally evolved as a type of chemical protection against predation (Nagle and Paul, 
1999).  In marine environments, these intracellular metabolites are released when cells are lysed 
(Organization, 1999), as when an herbivore grazes on the organism, or can be released into the 
water as intercellular signaling molecules in the complex communities created by filamentous 
species.  Regardless of their purpose, the fact that these compounds can have direct effects on 
animals has led to the investigation of cyanobacterial metabolites on cytotoxicity including for 
cancer and infection (viral, microbial, malaria) and antifeedant effects, among others (Dixit and 
Suseela, 2013). 
What remains relatively unexplored beyond cytotoxic effects of cyanobacterial 
compounds is if these metabolites can modify signaling cascades in mammals, especially in the 
nervous system. A large number of compounds produced by cyanobacteria and other 
microorganisms are small linear and cyclic peptides (Tan, 2007; Ahmed et al., 2015; Yano et al., 
2015), which structurally resemble endogenous ligands to G-protein coupled receptors (GPCRs) 
found in mammalian cells.  To date, only a handful compounds extracted from cyanobacteria 
have been investigated for activity at GPCRs.  These include extracts from the genus Moorea 
(formerly Lyngbya (Engene et al., 2012)) acting on the cannabinoid (Sitachitta and Gerwick, 
1998; Han et al., 2003; Gutierrez et al., 2011; Montaser et al., 2012) receptors and an extract 
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from the genus Oscillatoria acting on the serotonin system identified in our previous publication 
(see Section 1 Chapter 1) (Lax et al., 2016).  The goal of the present research was to further 
probe metabolites extracted from cyanobacteria against GPCRs found in the CNS. We sought to 
determine potential psychoactive effects of metabolites in affective disorders such as depression 
and anxiety.  By doing so we hope to find compounds that could be used as therapeutic agents 
and as tools that lead to a better understanding of biological systems within the CNS, with a 
primary focus on the serotonin receptor subtype 7 (5-HT7R). 
 Serotonin (5-HT) is one of the main monoamine neurotransmitters in the nervous system 
and plays a role in many physiological processes including behavior, mood, pain, learning, 
memory, sleep, and appetite (Pytliak et al., 2011; Gellynck et al., 2013a; Monti and Jantos, 
2014).  Serotonin binds to serotonin receptors, which are broadly classed into seven families (5-
HT1-7R) (Pytliak et al., 2011).  These receptors are mainly found peripherally in the GI tract 
(Tuladhar et al., 2003) and smooth muscle of blood vessels (Bard et al., 1993) and in the CNS 
(Bonaventure et al., 2004).  Many common affective disorders, including depression and anxiety, 
are known to be associated with 5-HT signaling.  Most of the common anti-depressants (e.g. 
selective serotonin reuptake inhibitors (SSRIs)) target 5-HT re-uptake, causing an increase in 
synaptic levels of 5-HT following normal release (Ferguson, 2001).  This increase in serotonin 
can then bind to serotonin receptors (e.g. 5-HT1AR, 5-HT2AR, 5-HT2CR, 5-HT4R, 5-HT6R, 5-
HT7R) (Pytliak et al., 2011) that are known to have effects in depression.  Of these, 5-HT7R is a 
relatively under-studied receptor with strong potential to enhance the antidepressant effects of 
SSRIs when pharmacologically inhibited (Guseva et al., 2014; Tokarski et al., 2014) and many 
animal studies have shown that targeting the 5-HT7R receptor can modulate affective behaviors.  
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  The 5-HT7R was first discovered independently by several laboratories in 1993 and was 
one of the last of the serotonin receptors to be described (Bard et al., 1993; Lovenberg et al., 
1993; Ruat et al., 1993).  5-HT7R is a postsynaptic receptor expressed in many regions of the 
nervous system, including the cortex, hippocampus, amygdala, hypothalamus and thalamus, and 
it is also expressed in the periphery in the gastro-intestinal tract and blood vessels (Bonaventure 
et al., 2004; Gellynck et al., 2013b).  The receptor belongs to the Gs family of GPCRs.  When 
activated by its endogenous ligand, serotonin, the receptor increases the amount of cyclic 
adenosine monophosphate (cAMP) through its coupling to adenlyate cyclase (Nikiforuk, 2015).  
This receptor plays a role in a variety of physiological processes, including depression and 
anxiety. 
In rodents, administration of selective 5-HT7R antagonists generally decreases 
depression-like behaviors (Hedlund et al., 2005; Wesolowska et al., 2006; Sarkisyan et al., 2010; 
Kim et al., 2014).  Another study showed that inhibiting the 5-HT7R may have faster therapeutic 
action in rats than the commonly prescribed SSRI fluoxetine (Mnie-Filali et al., 2011).  Similar 
to the antagonist data, male mice lacking the 5-HT7R show decreased depression-like behaviors 
(Guscott et al., 2005).  In terms of anxiety-like behavior, the role of 5-HT7R is not as clear.  In 
mice, some studies have shown that blockade of the 5-HT7R reduces anxiety-like behavior in the 
open field test (Wesolowska et al., 2006; Hedlund and Sutcliffe, 2007; Guilloux et al., 2013), 
however, another study found that 5-HT7R agonists reduce anxiety-like behavior (Adriani et al., 
2012).   Knockout studies showed no differences between 5-HT7R knockout animals and wild 
type animals in the elevated plus maze and light-dark preference tests (Roberts et al., 2004; 
Guscott et al., 2005).  Overall, these data demonstrate that targeting the 5-HT7R can alter both 
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affective behavior in animals, but the role of this receptor in anxiety-like behavior is still being 
explored.  
 In human studies, the multimodal antidepressant vortioxetine (Brintellix), which acts as a 
5-HT7R antagonist, while also increasing serotonin concentrations through reuptake inhibition, 
has been shown to reduce major depressive disorder (MDD) in both short and long-term clinical 
trials (Pearce and Murphy, 2014).  Additionally, the clinically established effects of some 
antipsychotic drugs, including amisulpride, aripiprazole and lurasidone most likely function 
through the 5-HT7R (Bonaventure et al., 2007; Abbas et al., 2009; Cates et al., 2013).  Given the 
possible presence of CNS active compounds in cyanobacterial metabolites and the well-
established role that the 5-HT7R plays in depression and anxiety, we sought to discover ligands 
for the 5-HT7R from cyanobacterial extracts that could induce antidepressant and anxiolytic-like 
effects. 
In this study, an extract from a cyanobacterium collected in the Las Perlas Archipelago, 
Panama, was screened for effects in depression and anxiety-like behaviors in animal models.  
Crude extracts from the cyanobacterium were fractionated using silica gel chromatography and 
screened in vitro for GPCR binding affinity by the Psychoactive Drug Screening Program 
(PDSP) (Besnard et al., 2012).  One particular fraction with significant binding (>50% in 
primary assay) and relative selective affinity for the 5-HT7R, DUQ0002I (IC50 = 749 ng/mL), 
was injected into the lateral ventricle of mice via intracerebroventricular (ICV) injections for 
initial screening in a series of depression, anxiety and pain behavioral assays, including the 
forced swim, tail suspension, elevated zero maze, light dark preference, formalin, tail flick, von 
Frey, Hargreaves tests and operant plantar thermal assay (OPTA).  We hypothesized that this 
fraction would alter anxiety-like, depression-like and pain-like behaviors in these animals.  After 
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the initial characterization via ICV, we next explored the specificity of the in vivo results using 
5-HT7R knockout (5-HT7R -/-) mice and investigated possible sex differences in the observed 
behavior.  We also characterized the 5-HT7R knockout male animals compared to wild-type 
animals in a series of depression, anxiety and pain assays.  Next, we explored the anatomical 
specificity of the behavioral effects by utilizing brain region specific targeting of DUQ0002I to 
the CA1 region of the hippocampus.  Additionally, purified subfractions of the parent fraction 
DUQ0002I were tested.  Finally, we utilized DUQ0002I as a therapeutic lead to determine if this 
fraction could alleviate the depression-like effects induced by the neuropathic pain model, spared 
nerve injury (SNI). 
 
RESULTS  
Cyanobacterial Collection, Phylogeny and Screening  
A dark green/black cyanobacterial mat was collected in ~0.6 m of water off Mogo-Mogo 
in the Las Perlas Archipelago, Panama (8°34’50.2”N, 79°01’10.6”W) and was given the 
extraction ID of DUQ0002 (Figure 12A).  Confocal (Figure 12B) and transmitted light (Figure 
12C) microscopy was performed in order to see the microscopic structure of the organism.  
Based on the morphology of the specimen, this sample was field identified as belonging to the 
genera of Oscillatoria or Moorea.  In order to definitively determine the species of 
cyanobacteria, sequencing of the 16S rRNA gene was performed.  Using a collection of 
sequences from Engene (2013) that highlights the relatedness of natural product producing 
marine cyanobacterial strains (Engene et al., 2013), we found that DUQ0002 groups within the 
Leptolyngbya clade (Figure 12D, GenBank Number: MH357345).   
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Figure 12. Pictures of cyanobacteria DUQ0002 and phylogeny. (A) Macroscopic picture of 
sample DUQ0002 before collection. (B) Confocal microscopy image of DUQ0002 at 20X 
magnification with FITC (487 nm), TRITC (560nm) and Cy5 (637 nm) channels. Scale bar = 
100 μm.  (C) Transmitted light image of DUQ0002. Scale bar = 100 μm.  (D) Phylogenetic tree 
showing the closest related species to DUQ0002 based off of 16S rRNA sequencing. KT – 
photography.  NL, BK – microscopy.  NL – tree building.  EH – 16S sequencing.  NL, BK – 
designed experiments. 
 
 
Screening Marine Cyanobacterial Fractions DUQ0002A-I 
To evaluate the potential of marine cyanobacteria for lead compounds to treat pain and 
depression, fractions (named DUQ0002A – I) were screened using the PDSP radioligand 
competition-binding assay.  Fractions were screened for their ability to bind to a panel of CNS 
targets including GPCRs, monoamine transporters (MATs), and ion channels. The results 
obtained from the NIMH PDSP for the nine fractions screened are summarized in Tables 5 and 
6. “Hits” for the primary assay (defined as >50% inhibition in the primary screen) highlighted in 
yellow in Table 5, were observed for fractions A-I at one or more receptors and/or transporters.    
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Table 5. PDSP primary binding assay of DUQ0002 fractions. PDSP “hits” are highlighted in 
yellow and represent fractions showing >50% inhibition of binding.  Data represented as mean % 
inhibition (N = 4 separate determinations). Negative inhibition represents stimulation of binding.  
Abbreviations: mGluR5 – metabotropic glutamate receptor 5; DOR – delta opioid receptor, KOR 
– kappa opioid receptor; MOR- mu opioid receptor; SERT – serotonin transporter; NET – 
norepinephrine transporter; ND – not determined. PDSP – conducted experiment. KT – designed 
experiment. 
 
Fractions showing greater than 50% inhibition of binding of radioligand in the primary 
binding screen were subjected to secondary binding assay for IC50 determination, which is then 
used to determine the IC50 (Table 6). Interestingly, of the fractions screened, only DUQ0002I 
displayed affinity for 5-HTRs.  Fraction DUQ0002I displayed two-fold selectivity for 5-HT7R 
(Ki = 749 ng/mL) over 5-HT1AR (Ki = 1746 ng/mL) and five-fold selectivity over mGluR5 (Ki = 
3676 ng/mL). Selectivity for the 5-HT7R was encouraging as there are little to no truly selective 
ligands for 5-HT7R (Rague and Tidgewell, 2017) and none reported from a natural source.  
Generally, the lack of selective agonists and antagonists have been attributed to the high 
sequence homology amongst 5-HTR subtypes (Hoyer et al., 1994). Both 5-HT1AR and 5-HT7R 
target adenylyl cyclase (AC) with opposing effects; 5-HT7R activates AC increasing the 
concentration of cyclic adenosine monophosphate (cAMP) whereas 5-HT1AR inhibits AC, 
decreasing cAMP concentrations (Hannon and Hoyer, 2008).  
 
 
DUQ0
002 
 
5-HT1AR 
 
5-HT1BR 
 
5-HT1DR 
 
5-HT1ER 
 
5-HT2AR 
 
5-HT2BR
 
5-HT2CR
 
5-HT3R
 
5-HT5AR
 
5-HT6R
 
5-HT7R
 
mGluR5
 
DOR 
 
KOR 
 
MOR 
 
SERT 
 
NET 
A -6.4 -1.5 -3.6 -1.3 -6.9 -4.2 -12.4 7.5 -0.9 -8.7 -9.6 ND -16 -8.6 7.7 91.7 9.2 
B 3.7 9.8 12.1 -7.2 -9.2 -7.9 -12.7 15.1 -4.8 -10.9 -13.4 ND -4.7 -6.7 -2.7 86.4 2.5 
C 14.6 6.4 15.4 -1.4 -8.5 8.2 -1.2 5.9 9.6 8.2 5.5 75.5 1.9 -2.3 9.0 80.3 9.9 
D 53.0 28.6 12.1 0.6 3.7 16.6 10.2 15.2 16.2 22.2 20.5 75.4 9.3 4.8 16.7 50.0 4.7 
E 7.9 17.7 15.8 -1.8 -12.4 5.6 -7.1 6.5 1.3 1.4 -3.2 58.1 3.5 0.6 8.8 57.7 22.9 
F -3.4 13.9 13.7 11.6 -12.5 8.9 -17.9 4.3 -8.2 -4.7 -18.1 76.5 0.2 10.2 12.6 22.2 50.0 
G 3.2 12.5 22.4 24.6 -5.2 3.6 -15.9 13.5 -5.0 -2.0 -8.2 76.4 7.6 25.0 10.2 14.6 50.0 
H 0.5 -3.8 1.8 29.0 7.4 0.5 -10.2 14.0 3.8 0.6 -2.0 73.4 17.5 19.5 21.0 -19.0 50.0 
I 58.3 23.8 16.5 32.3 5.5 19.9 38.6 15.5 20.1 5.1 71.2 65.2 9.7 13.8 20.6 24.0 50.0 
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Table 6. Secondary Binding Assay Apparent Ki for PDSP hits for DUQ0002. Data are 
presented as apparent Ki in ng/mL. Ki values are calculated from best-fit IC50 values using the 
Cheng-Prusoff equation. Open boxes with (-) indicate that fractions failed primary binding 
criterion of > 50% inhibition at 10 μM. PDSP – conducted experiment. KT – designed 
experiment. 
 
Initial Characterization of DUQ0002I in Males via Intracerebroventricular (ICV) Injections 
After determining DUQ0002I affinity for the 5-HT7R, 5-HT1AR, and mGluR5, we began 
to initially characterize its potential effects using in vivo assays in male mice.  Since the specific 
nature and sites of action in the nervous system of the active compound in DUQ0002I were 
unknown, we began our characterization of this fraction using ICV injections.  This method of 
administration allows for the delivery of compounds to the lateral ventricle of the brain and 
disperses the compound throughout the cerebrospinal fluid of the CNS (Glascock et al., 2011).  
This administration route was also utilized due to the fact that it was unknown whether the active 
compound(s) had the ability to cross the blood-brain barrier and eliminated any possible 
interference of first pass metabolism of any active components. 
In this initial screening, we tested whether the fraction DUQ0002I could alter depression-
like and anxiety-like behaviors in a group of male mice.  Each animal was randomly assigned to 
a testing group, and all animals underwent the forced swim test, tail suspension test, elevated 
zero maze, and light-dark preference test.  For all behavioral tests, a dose of 40 μg of DUQ0002I 
was used.  This is twice the dose that was used for 5-HT2CR active fractions tested in the 
previous chapter and was used to give animals more of the potentially active compound than was 
DUQ0002 5-HT1AR  5-HT7 R mGluR5  SERT  NET  
A - - - > 10000 - 
B - - - > 10000 - 
C - -  4662 > 10000 - 
D > 10000 -  37 > 10000 - 
E - - > 10000 > 10000 - 
F - - > 10000 - > 10000 
G - - > 10000 -  6945 
H - - > 10000 - > 10000 
I  1746  749  3676 - > 10000 
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done in the initial screening with 2064H, DUQ0008C and DUQ0008G.  This dose was based 
upon the dose that was used for the initial in vitro PDSP screening, which was done at 4 mg/mL, 
and then adjusted for ICV injections and intra-amygdala injections in mice that we have done 
previously (Kolber et al., 2010a; Lax et al., 2016).  Starting with the depression assays, the 
forced swim test was used.  This standard test of depression measures the amount of time an 
animal spends immobile after it is placed in a beaker of water, from which it cannot escape.  
Longer time spent immobile in the water is correlated with greater depression-like behavior 
while less time spent immobile is correlated with greater antidepression-like behavior (Porsolt et 
al., 1977). 
 Following a five-minute pretreatment with 40 μg of DUQ0002I or vehicle, animals 
treated ICV with DUQ0002I spent a statistically significantly lower time immobile compared to 
control animals (Figure 13A, unpaired t-test, **p=0.0019).  The tail suspension test was next 
used to further measure changes in depression-like behavior.  Similar to the forced swim test, 
this assay measures the amount of time an animal spends immobile after being suspended upside 
down by the distal end of its tail.  As with the forced swim test, longer time spent immobile is 
indicative of depression-like behavior while less time spent immobile is associated with 
antidepression-like behavior (Steru et al., 1985).  Mice pretreated with DUQ0002I did not show 
any changes in total time spent immobile compared to vehicle-treated animals (Figure 13B, 
unpaired t-test, p=0.5520).  
In addition to studying depression-like behaviors, we also looked for changes in 
locomotor and anxiety-like behavior using several different assays.  First, we used the elevated 
zero maze (EOM) which measures the amount of time and distance traveled in a circular maze 
with high-walled and low-walled regions.  Increased time and percent overall distance traveled in 
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the open arms is correlated with anti-anxiety-like (anxiolytic) effects, while decreases are 
correlated with anxiogenic behavior (Shepherd et al., 1994).  Since this assay also measures total 
distance traveled, it can also be used to measure locomotor effects.  Animals pretreated with 
DUQ0002I showed no difference in the overall distance traveled in the EOM compared to 
control animals (Figure 13C, unpaired t-test, p=0.1807), suggesting that the fraction does not 
cause hyperactivity.  However, these same animals pretreated with DUQ0002I showed an overall 
statistically significantly greater amount of time spent in the open arms of the EOM (Figure 
13D, unpaired t-test, *p=0.0188) and significantly greater overall percent distance (distance 
traveled in open/total distance traveled × 100) traveled in the open arms (Figure 13E, unpaired t-
test, *p=0.0166).  
Second, we used the light-dark preference (LDP) test, where animals are placed in a two-
chamber box with a brightly illuminated side and a completely dark side, separated by a small 
door.  Increases in total time spent in the light are correlated with decreased anxiety-like effects, 
while decreases are correlated with increases in anxiety-like effects (Crawley and Goodwin, 
1980).  Pretreatment with DUQ0002I caused animals to trend towards spending more time in the 
light side compared to control animals in the latter half of the test (Figure 13F, unpaired t-test, 
p=0.1203).  DUQ0002I also caused animals to have a greater mean visit to the light side 
compared to animals pretreated with vehicle in the latter half of the test (Figure 13G, unpaired t-
test, **p=0.0025).  Together, these data from both the EOM and LDP indicate an anxiolytic 
effect of DUQ0002I.   
  79
        Figure 13.  Initial characterization of the antidepression-like and anxiolytic-like effects of 
cyanobacterial fraction DUQ0002I in male animals via ICV administration.  (A) Mice 
treated with DUQ0002I (n=18) decrease time immobile compared to vehicle (n=18) in the forced 
swim test.  (B) Mice treated with DUQ0002I (n=9) show no change in time immobile compared 
to vehicle (n=9) in the tail suspension test.  (C) Mice treated with DUQ0002I (n=18) show no 
changes in total distance traveled compared to vehicle (n=17) in the elevated zero maze.  (D) 
Mice treated with DUQ0002I (n=18) show increased time spent in the open arms of the elevated 
zero maze (EOM) assay compared to vehicle (n=17).  (E) Mice treated with DUQ0002I (n=18) 
also travel a greater percent of total distance traveled in the open arms of the EOM compared to 
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vehicle (n=17).  (F) Mice treated with DUQ0002I (n=19) show a trend (p=0.1203) of spending 
more time in the light side of the Light-Dark Preference (LDP) test during the latter half of the 
test compared to vehicle (n=15).  (G) Mice treated with DUQ0002I (n=19) also show a higher 
average mean visit to the light side of the LDP test during the latter half compared to vehicle 
(n=15). Un-paired t-tests, *p<0.05, **p<0.01. Data shown as mean ± SEM.  NL – conducted 
experiment.  NL, BK – designed experiment. 
 
 Following the characterization of DUQ0002I in the depression and anxiety assays, we 
also tested the raw fraction in a wide series of pain assays.  We began the pain testing by seeing 
if DUQ0002I would alter the pain-like behaviors seen in the formalin test, an inflammatory 
model of pain.  In this assay, animals are injected with a dilute formalin solution into the plantar 
surface of their right hind paw.  This causes an inflammatory response, and animals will bite, 
flinch and flick the injected paw (Dubuisson and Dennis, 1977).  Decreases in these pain-like 
behaviors are correlated with an analgesic effect. Animals pretreated with DUQ0002I showed no 
difference in the overall time exhibiting pain-like behaviors compared to control animals (Figure 
14A, 2-way ANOVA, overall effect of time p < 0.0001, overall effect of treatment p = 0.9013, 
Bonferroni tests n.s.).  Since no effects were found in this inflammatory model, we also tested 
DUQ0002I in two different thermal pain assays to see if the fraction had any effects in altering 
behaviors in this type of pain.  We first utilized the tail-flick assay, where the distal end of an 
animal’s tail is placed in a beaker of hot water (Dewey et al., 1970).  The time it takes the animal 
to flick its tail out of the water is recorded, with higher times indicative of an analgesic-like 
effect.  Using ICV administration of DUQ0002I, we found that this fraction did not change 
average time-to-flick compared to control animals (Figure 14B, unpaired t-test, p = 0.4391).  In 
another thermal pain assay, the thermal plantar test (aka Hargreaves’ test), a radiant beam of 
light is used to heat the plantar surface of an animal’s foot (Hargreaves et al., 1988).  Latency to 
withdrawal is measured, with increases in withdrawal times correlated with an analgesic-like 
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effect.  Similar to the tail-flick results, animals that received a 5-minute pretreatment with 
DUQ0002I showed similar paw withdrawal latencies to control treated animals (Figure 14C, 
unpaired t-test, p=0.6376).  Withdrawal latencies at 15 and 30 minutes post administration also 
showed no differences between DUQ0002I treated animals and control animals (15 minutes: 
DUQ0002I-treated withdrawal time = 6.17 ± 1.23 sec, control-treated withdrawal time = 6.46 ± 
1.25 sec, unpaired t-test, p = 0.8684; 30 minutes: DUQ0002I-treated withdrawal time = 5.82 ± 
0.88 sec, control-treated withdrawal time = 6.45 ± 0.68 sec unpaired t-test, p = 0.5797).  
Subsequent to the lack of findings in both inflammatory and thermal assays, we next tested to see 
whether or not DUQ0002I had any effects in a mechanical assay, the von Frey test.  Here, naïve 
male animals received an ICV pretreatment of DUQ0002I and withdrawal thresholds were 
measured.  As with all of the other pain-tests utilized so far, we found that DUQ0002I had no 
effect in changing the frequency of withdrawals compared to control animals (Figure 14D, 
unpaired t-test, p=0.7663). Withdrawal latencies at 30 minutes post administration also showed 
no differences between DUQ0002I treated animals and those that received control (DUQ0002I-
treated average number of withdrawals out of 10 trials = 3.89 ± 0.59, control-treated average 
number of withdrawals out of ten = 3.67 ± 0.58, unpaired t-test, p = 0.7909). 
 Since there were no effects found with any of these experimenter-induced pain assays, we 
wanted to test if DUQ0002I could have any effects in an operant pain assay.  Here, we decided to 
test DUQ0002I in a new, yet to be published assay, called the operant plantar thermal assay 
(OPTA), developed by our colleague Steve Davidson and presented at the 2017 American Pain 
Society meeting in Pittsburgh, PA (Sammohi et al., 2017).  In this assay, animals are trained to 
learn the location of a sucrose-containing water bottle on a heated platform that is split into two 
sides.  There is also an empty water bottle in the apparatus.  For the first two days of training, 
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both sides of the platform are heated to 30oC, a neutral temperature that causes no aversion.  
However, on day 3, the testing day, the side of the heated platform with the sucrose bottle is 
raised to 45oC (the side with the empty water bottle remains at 30oC).  45oC is a noxious 
temperature for mice, which typically induces some aversion. Time that the animal spends 
licking the sucrose bottle/empty bottle or on the sucrose side/empty side of the apparatus is 
measured as a metric for pain tolerance.  Animals that are willing to spend more time on the 
heated side are said to have a higher pain tolerance to get the sucrose reward, and therefore can 
be interpreted as an analgesic-like effect.  Before testing DUQ0002I, we needed to conduct a 
pilot experiment to determine if we could get the assay to work with a well-characterized pain 
model (in this case, the complete Freund’s adjuvant (CFA)).  Based on data presented at the 2017 
American Pain Society meeting (Sammohi et al., 2017), we predicted that mice with the pain 
model would spend significantly less time around the sucrose bottle with the raised temperature.  
A naïve group of male animals was trained for two days to learn the side of the thermal plate 
with the sucrose solution.  Then, in the evening of Day 2 following training, animals were either 
injected with control or CFA solution into their hind-right paw.  Finally, on Day 3, with the 
empty water bottle-side remaining at 30oC and the sucrose bottle-side now set to 45oC, time 
spent in the area around the sucrose bottle was measured.  Here, there was no significant 
different between the groups injected with CFA and control injection (Control animals (n = 3) 
time spent around sucrose bottle = 83.78 ± 27.41 (sec); CFA animals (n = 3) time spent around 
sucrose bottle = 42.18 ± 14.75 (sec); unpaired t-test, p = 0.3261).  Even though there were no 
significant effects with this pilot, when we looked at the data, the overall trend was consistent 
with Davidson’s work.  Thus, we proceeded to use the assay for characterization of DUQ0002I 
Here, animals underwent the same two days of pretraining.  On day 3, animals were pretreated 
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with either formalin or no injection (i.e. naïve) into the hind paw 1 hour before compound 
administration.  Then, animals received a 5-minute pretreatment via ICV injection with 
DUQ0002I or control and time measured by sucrose water bottle was measured.  Similar to all of 
the other pain assays tested, DUQ0002I had no effect on changing the time spent on the sucrose 
side of the apparatus in either the naïve group or the formalin pre-treated group (Figure 14E, 2-
Way ANOVA, overall effect of drug injection, p = 0.8726, overall effect of paw treatment, p = 
0.8155).  Collectively, all of the pain data collected show that, at least through ICV 
administration, DUQ0002I has no effect on altering pain-like behaviors. 
 
Figure 14.  Initial characterization of DUQ0002I in pain tests using male animals via ICV 
administration.  (A) Mice treated with DUQ0002I (n=9) do not have a difference in total time 
exhibiting pain-like behaviors compared to control animals (n=8) in the formalin test.  (B) Mice 
treated with DUQ0002I (n=7) show no difference in latency to flick compared to vehicle treated 
animals (n=7) in the tail flick test.  (C) Mice treated with DUQ0002I (n=9) show no changes in 
withdrawal latency compared to vehicle (n=9) in the Hargreaves test.  (D) Mice treated with 
DUQ0002I (n=9) show no difference in the average number of withdrawals out of ten compared 
to vehicle (n=9).  (E) Naïve mice and formalin-treated mice injected with DUQ0002I show no 
difference in average time spent in the sucrose bottle zone when heated to 45C compared to 
vehicle injected animals (n=4) in OPTA.  2-way ANOVA (A, E), Un-paired t-tests (B-D). Data 
shown as mean ± SEM.  NL – conducted experiment.  NL, BK – designed experiment. 
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 Since we found no effects with our compound, we wanted to see if systemic 
administration of a known 5-HT7R antagonist could have any effects with altering pain-like 
behaviors.  In order to do this, we decided to test the known antagonist SB269970.  With this 
compound, we tested both an experimenter-induced (von Frey) and operant pain assay 
(conditioned place preference) using animals with spared nerve injury, a model of chronic pain 
(Decosterd and Woolf, 2000).  Starting with the von Frey test, we measured if SB269970 could 
block the hypersensitivity induced by the spared nerve injury 12 weeks after surgery in a group 
of male mice.  We showed that 10 mg/kg of SB269970 blocked SNI-induced hypersensitivity up 
to four hours post administration, while control treated animals remained hypersensitive (Figure 
15A, 2-way ANOVA, overall effect of time *p = 0.0199, overall effect of treatment **p = 
0.0057, Bonferroni tests *p <0.05, ***p<0.001).  Sham animals treated with both SB269970 or 
vehicle did not show any changes in hypersensitivity (Figure 15B, 2-way ANOVA, overall 
effect of time p = 0.4300, overall effect of treatment p = 0.4374, Bonferroni tests n.s.).  We next 
tested if the same dose of SB269970 (10 mg/kg) would cause SNI animals to develop a 
preference for this compound in the conditioned place preference test.  In this assay, animals 
learn to associate a physical visual cue with the effects of a particular drug.  Conditioned place 
preference has been widely used to test the rewarding and addictive potentials of numerous drugs 
(Tzschentke, 1998).  In this 5-day assay, on day 1, animals are freely allowed to explore a two-
chamber box that differ in patterns on the wall.  On days 2 – 4, animals are restricted to one 
chamber where they receive a drug (in this case SB269970) in the morning and several hours 
later in the afternoon, they are restricted to the opposite chamber where they receive vehicle.  
Finally on day 5, animals are again allowed to explore the entire apparatus and time preferences 
for the drug-paired chamber are measured by comparing day 5 times to day 1 times.  In our 
  85
testing with SB269970, both SNI and sham animals were used.  We found that neither SNI 
(Figure 15C, unpaired t-test, p=0.9610) nor sham animals (Figure 15D, unpaired t-test, 
p=0.8577) developed preference for the chamber paired with SB269970. 
 Figure 15.  The 5-HT7R antagonist SB269970 reverses SNI-induced hypersensitivity 12 
weeks post surgery, while not affecting sham animals or causing preference for the 
compound to develop.  (A) SNI mice treated with SB269970 (n=6) do not show 
hypersensitivity for up to four hours post injection compared to control treated animals (n=5) in 
the von Frey test.  (B) Sham mice treated with SB269970 (n=5) do not show do not show any 
differences in withdrawal thresholds compared to control treated animals (n=5) in the von Frey 
test. (C) SNI mice treated with SB269970 (n=8) show no preference for the chamber paired with 
SB269970 (n=8) in the CPP test.  (D) Sham mice treated with SB269970 (n=8) show no 
preference for the chamber paired with SB269970 (n=8) in the CPP test.  2-way ANOVA (A,B); 
Un-paired t-tests (C,D), *p<0.05, ***p<0.001. Data shown as mean ± SEM.  NL – conducted 
experiment.  NL, BK – designed experiment. 
 
Characterization of the Specificity of DUQ0002I Effects 
DUQ0002I showed secondary binding affinity for 5-HT1AR, 5-HT7R, and mGluR5. 
Given the two-fold selectivity of 5-HT7R over 5-HT1AR and five-fold selectivity over mGluR5 
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we tested to see if DUQ0002I had effects in 5-HT7R knockout animals to determine the potential 
specificity of the behavioral results determined thus far.  If the active compound(s) in DUQ0002I 
was selective for the 5-HT7R, then we would predict that there would be no behavioral changes 
in any of the assays we had previously tested with DUQ0002I using wildtype male mice.  In the 
forced swim test (Figure 16A, unpaired t-test, p=0.2490), DUQ0002I did not cause any change 
on overall time immobile when compared to vehicle injected knockout mice.  Similarly, 
DUQ0002I did not cause animals to spend more time in the open arms (Figure 16B, unpaired t-
test, p=0.7712) or travel a greater percent distance in the open arms (Figure 16C, unpaired t-test, 
p=0.5599) when compared to vehicle-treated knockout animals in the elevated zero maze.  
Finally, in the light dark preference assay, KO animals pretreated with DUQ0002I did not spend 
a greater amount of time in the light side (Figure 16D, unpaired t-test, p=0.1929) when 
compared to KO mice that received vehicle.  These same animals also did not have a greater 
mean visit to the light side when compared to control KO animals (Figure 16E, unpaired t-test, 
*p=0.4342).  Together, these data in the KO animals suggest that the anti-depressive effects 
observed from DUQ0002I are caused by selective antagonism of the 5-HT7R. 
As an additional measure of 5-HT7R specificity and to help determine whether 
DUQ0002I is an agonist or an antagonist, we compared the effects of DUQ0002I with a known 
5-HT7R antagonist.  In a manner similar to DUQ0002I, a five-minute pretreatment of 5 μg of 
SB258719 caused mice to exhibit statistically significant lower levels of immobility in the forced 
swim test when compared to animals that received control vehicle injections (Figure 16F, 
unpaired t-test, *p=0.0275).  This dose of SB-258719 was chosen based on previous published 
data that used this same dose in mice via ICV injection (Zhao et al., 2014).  Since antagonism of 
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the 5-HT7R is known to cause antidepressant-like effects, the similar behavioral effects of 
SB258719 suggested a similar antagonistic mechanism as DUQ0002I. 
Characterization of the Sex-Specific Effects of DUQ0002I 
Due to the known sex differences in depression and anxiety (Kokras and Dalla, 2017), we 
tested DUQ0002I in female animals via ICV injection to see if it induced the same 
antidepression-like and anxiolytic-like effects as we had previously shown in male animals.  
Interestingly, administration of the same dose of DUQ0002I in female mice did not induce any 
changes in immobility time in the forced swim test when compared to control vehicle-injected 
mice (Figure 16G, unpaired t-test, p=0.7675).  To determine if this sex difference was specific 
to our cyanobacteria fraction or was a broader effect of 5-HT7R antagonists, we also tested the 
effects of the commercially available 5-HT7R antagonist, SB258719, in female mice. As with 
DUQ0002I, SB258719 failed to alter immobility time compared to control vehicle-injected 
animals (Figure 16H, unpaired t-test, p=0.5986).  These data suggest there may be an inherent 
difference between males and females in the way they respond to 5-HT7R antagonists or in the 
distribution of 5-HT7R in their brains. 
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Figure 16.  Fraction DUQ0002I shows no effects in 5-HT7R knockout animals or female 
animals via ICV administration. (A) Male homozygote 5-HT7R knockout (KO) mice treated 
with DUQ0002I (n=6) do not show any differences in time immobile compared to vehicle (n=6) 
in the forced swim test.  (B) Male homozygote 5-HT7R KO mice treated with DUQ0002I (n=6) 
do not change the amount of time spent in the open arms of the EOM compared to vehicle (n=6).  
(C) 5-HT7R KO mice treated with DUQ0002I (n=6) also do not change percent of overall 
distance traveled in the open arms of the EOM compared to vehicle (n=6).  (D) 5-HT7R KO mice 
treated with DUQ0002I (n=6) do not change the amount of time spent in the light side of the 
LDP test during the latter half of the test compared to vehicle (n=6).  (E) 5-HT7R KO mice 
treated with DUQ0002I (n=6) do not change the mean visit to the light side of the LDP test 
during the latter half of the test compared to vehicle (n=6). (F) Male wildtype mice treated with 
the 5-HT7R antagonist SB258719 (n=15) show a decrease in time immobile compared to vehicle 
(n=17) in the forced swim test.   (G) Female wildtype mice treated with DUQ0002I (n=8) do not 
show any differences in time immobile compared to vehicle (n=8). (H) Female wildtype mice 
treated with SB258719 (n=8) do not show any differences in time immobile compared to vehicle 
(n=7).  (I) Chemical structure of SB258719.  Un-paired t-tests, *p<0.05. Data shown as mean ± 
SEM.  NL – conducted experiment.  NL, BK – designed experiment. 
 
Characterization of 5-HT7R Knockout Animals 
 In addition to testing the effects of our cyanobacterial extract and how it alters pain, 
depression and anxiety-like behaviors, we also wanted to more fully characterize the 5-HT7R 
knockout strain of mice.  While several studies have previously analyzed this strain of mice, 
many different behaviors remain to be investigated.  In the knockout studies related to 
depression-like behaviors that have been done thus far, the forced swim and tail suspension have 
been conducted (Roberts et al., 2004; Guscott et al., 2005).  In both of these assays, anti-
depression-like effects were found in 5-HT7R KO mice compared to wild type mice.  In terms of 
anxiety-like behavior, the elevated plus maze and the light-dark preference tests have been done, 
with no changes in behavior between wildtype and KO mice (Clemett et al., 1998; Roberts et al., 
2004).  Looking at pain-like behaviors, only one assay, the tail flick test has been done in 5-
HT7R KO animals, with no effects found (Roberts et al., 2004).  Moreover, nearly all of the 
studies that have been done with the 5-HT7R KO animals were done using male mice.  The only 
  90
exception to this is a study that found there was no hypothermic response to 5-HT treatment in 
male or female mice (Hedlund et al., 2003).   Here, we began further characterizing behavior in 
these mice focusing on male mice. Some preliminary results with female 5-HT7R KO animals 
are included, but testing is currently ongoing. 
 To begin our characterization of the KO animals, we began with conducting the tail 
suspension and forced swim tests.  Since these assays had been previously done, these tests 
would function as a positive control to see if our animals showed previously described 
antidepression-like effects.  As expected, the male 5-HT7R KO animals showed a trend in 
decreased overall time immobile in the tail suspension test compared to wild type animals 
(Figure 17A, unpaired t-test, p = 0.1211).  We also found similar results with the forced swim 
test – male 5-HT7R KO animals showed significantly lower immobility time compared to 
wildtype animals (Figure 17B, un-paired t-test, *p = 0.0475).  Of note, no antidepression-like 
effect has been found in female 5-HT7R KO mice with testing completed so far.  These data 
correlate well with the antidepression-like effects of DUQ0002I only being seen in male animals 
and not females.  However, only a small number of both wild-type and knockout females have 
been tested, so these results are only preliminary and final conclusions will not be made until 
similar numbers of animals are included in both males and females. 
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Figure 17.  Antidepression-like effects in male 5-HT7R KO animals. (A) Male homozygote 5-
HT7R knockout (KO) mice (n=6) show a trend in decreased time immobile compared to wildtype 
males (n=8) in the tail suspension test. (B) Male homozygote 5-HT7R knockout (KO) mice (n=6) 
show decreased time immobile compared to wildtype males (n=8) in the forced swim test. Un-
paired t-tests, *p<0.05. Data shown as mean ± SEM.  NL – conducted experiment.  NL, BK – 
designed experiment. 
 We also characterized male 5-HT7R KO animals in a series of anxiety tests.  Previous 
anxiety tests that had been done using this strain showed that there were no effects (elevated plus 
maze and light dark preference tests (Clemett et al., 1998; Roberts et al., 2004)).  Here, we 
decided to screen animals in other anxiety tests that had never been done in this strain before.  
Beginning with the elevated zero maze in males, we found that there was no difference in the 
total time spent in the open arms of the maze between the 5-HT7R KO animals and wildtype 
animals (Figure 18A, unpaired t-test, p = 0.9979).  Similarly, no difference was found in the 
percent distance traveled in the open arms of the maze in males (Figure 18B, un-paired t-test, p 
= 0.8177).  In another previously untested anxiety assay in these animals, the open field test, no 
differences between wild type or 5-HT7R KO animals was seen.  Male wildtype and 5-HT7R KO 
animals spent equal time (Figure 18C, un-paired t-test, p = 0.3269) and traveled a similar 
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percent distance in the center of the open field box (Figure 18D, un-paired t-test, p = 0.6422).  
 
Figure 18. Anxiety testing with male 5-HT7R KO animals shows no differences (A) Male 
homozygote 5-HT7R knockout (KO) mice (n=6) spend equal time in the open arms compared to 
wildtype males (n=8) in the elevated zero maze test.  (B) Male homozygote 5-HT7R knockout 
(KO) mice (n=6) travel an equal overall percent distance in the open arms compared to wildtype 
males (n=8) in the elevated zero maze test. (C) Male homozygote 5-HT7R knockout (KO) mice 
(n=6) spend equal time in the center compared to wildtype males (n=8) in the open field test.  
(D) Male homozygote 5-HT7R knockout (KO) mice (n=6) travel an equal overall percent 
distance in the center compared to wildtype males (n=8) in the open field test. Un-paired t-tests. 
Data shown as mean ± SEM.  NL – conducted experiment.  NL, BK – designed experiment. 
 
 In addition to measuring anxiety-like behaviors, both the elevated zero maze and open 
field tests can measure locomotor behavior to determine if 5-HT7R KO animals show any 
hyperactivity compared to wild type animals.  Looking at this data, we found that male 5-HT7R 
KO and wildtype animals traveled the same overall distance in both the elevated zero maze 
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(Figure 19A, un-paired t-test, p = 0.9061) and the open field test (Figure 19B, un-paired t-test, p 
= 0.9679).  This shows that there was no overall difference in locomotor behavior. 
      
 
Figure 19. Male 5-HT7R KO animals do not show any differences in locomotor behavior 
(A) Male homozygote 5-HT7R knockout (KO) mice (n=6) show no difference in total distance 
traveled compared to wildtype males (n=8) in the elevated zero maze test.  (B) Male homozygote 
5-HT7R knockout (KO) mice (n=6) show no difference in total distance traveled compared to 
wildtype males (n=8) in the open field test. Un-paired t-tests, *p<0.05. Data shown as mean ± 
SEM.  NL – conducted experiment.  NL, BK – designed experiment. 
 
 Next, after the characterization of the 5-HT7R KO animals in the depression and anxiety 
tests, we also wanted to test more pain assays since only one has ever bone done in these animals 
(tail flick assay) (Roberts et al., 2004).  Here, we began with testing animals in reflexive pain 
assays, including the von Frey test, Hargreaves test and formalin test.  We also tested them in an 
operant pain assay, the OPTA. 
 Starting with the mechanical von Frey test, we measured the 50% withdrawal threshold 
on both the right and left paws.  We found that there were no differences in withdrawal threshold 
in the left paw (Figure 20A, un-paired t-test, p = 0.9722) or right paw (Figure 20B, un-paired t-
test, p = 0.6632) between 5-HT7R KO and wildtype male animals.  Next, in the thermal 
Hargreaves test, we measured the withdrawal latencies in both the left and right paws.  Here, we 
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found that, like in the von Frey test, there were no differences in the latencies to withdraw in the 
left paw (Figure 20C, un-paired t-test, p = 0.5849) or right paw (Figure 20D, un-paired t-test, p 
= 0.4667) between 5-HT7R KO and wildtype male mice.   
          
 
Figure 20. Male 5-HT7R KO animals show no differences compared to wildtype animals in 
the von Frey and Hargreaves tests (A) Male homozygote 5-HT7R knockout (KO) mice (n=6) 
show no difference in 50% withdrawal thresholds in the left paw compared to wildtype males 
(n=8) in the von Frey test.  (B) Male homozygote 5-HT7R knockout (KO) mice (n=6) show no 
difference in 50% withdrawal thresholds in the right paw compared to wildtype males (n=8) in 
the von Frey test. (C) Male homozygote 5-HT7R knockout (KO) mice (n=6) show no difference 
in latencies to withdraw in the left paw compared to wildtype males (n=8) in the Hargreaves test.  
(D) Male homozygote 5-HT7R knockout (KO) mice (n=6) show no difference in latencies to 
withdraw in the right paw compared to wildtype males (n=8) in the Hargreaves test. Un-paired t-
tests.  Data shown as mean ± SEM.  NL – conducted experiment.  NL, BK – designed 
experiment. 
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Additionally, the inflammatory model of pain, the formalin test was used to compare the 
strains.  In this assay, we found that 5-HT7R KO male animals showed no differences in time 
pain-like behaviors compared to wildtypes (Figure 21A, 2-way ANOVA, overall effect if 
genotype p = 0.1689, Bonferroni post-hoc tests n.s.).  Finally, in the OPTA, both naïve animals 
and formalin-injected animals were tested.  As described before, animals were trained for two 
days with a sucrose bottle on a 30oC surface before raising it to 45oC on the third day.  On testing 
day, naïve male 5-HT7R KO and wildtype animals spent an equal amount of time around the 
sucrose bottle (Figure 21B, un-paired t-test, p = 0.5471).  Formalin-treated male 5-HT7R KO 
and wildtype animals also spent an equal amount of time around the sucrose bottle (Figure 21C, 
un-paired t-test, p = 0.8328).  Overall, the characterization of the KO animals and the 
preliminary sex differences found compliment the effects seen with DUQ0002I and provide 
evidence that there may be a distinct difference in the 5-HT7R systems between males and 
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females.        
 
 
Figure 21.  No differences between 5-HT7R KO and wild type animals in formalin and 
OPTA tests (A) Male homozygote 5-HT7R knockout (KO) mice (n=6) show no differences in 
time exhibiting pain-like behaviors compared to wildtype males (n=8) in the formalin test. (B) 
Naïve male homozygote 5-HT7R knockout (KO) mice (n=6) show no difference in total amount 
of time spent in the sucrose zone compared to naïve wildtype males (n=8) in OPTA. (C) 
Formalin pre-treated male homozygote 5-HT7R knockout (KO) mice (n=6) show no difference in 
total amount of time spent in the sucrose zone compared to formalin pre-treated wildtype males 
(n=8) in OPTA.  A: 2-way ANOVA, B – C: Un-paired t-tests, **p<0.01. Data shown as mean ± 
SEM.  NL – conducted experiment.  VH, SL – formalin scoring.  NL, BK – designed 
experiment. 
 
Anatomical Characterization of DUQ0002I in Males via Hippocampal Administration   
After characterizing DUQ0002I as having antidepressant and anxiolytic-like effects 
specific to males with ICV injections, we explored which area of the brain was contributing to 
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these behavioral phenotypes.  Previous studies have shown that antagonists of the 5-HT7R 
administered to the CA1 region of the hippocampus induce antidepressant and anxiolytic-like 
effects (Wesolowska et al., 2006).  We delivered DUQ0002I via intrahippocampal injections to 
see if this brain region was sufficient to induce the observed effects of DUQ0002I.  Only male 
animals were used since DUQ0002I was shown to not alter behavior in females (Figure 16).  
Beginning with the forced swim test, we showed that CA1 administration of DUQ0002I caused a 
statistically significant decrease in overall time immobile (Figure 22A, unpaired t-test, 
*p=0.0450); in contrast to ICV delivery, we found that hippocampal-delivered DUQ0002I also 
caused an antidepression-like effect in the tail suspension test (Figure 22B, unpaired t-test, 
**p=0.0046).   
To show overall effects of DUQ0002I in depression-like behavior, we utilized the Z-
score analysis technique (Guilloux et al., 2011).  This method allows for the comparison of 
results across different, but related, sets of data through standardization by comparison to the 
control group.  It enables us to see the overall antidepression-like (or later anti-anxiety-like) 
effects of DUQ0002I by averaging the effects of the depression behavioral tests (time immobile 
in forced swim and tail suspension tests).  Here, the parameter measured for each animal (time 
immobile, X) was given an individual Z-score (Z) to determine how many standard deviations 
(σ) each animal was above or below the mean of the control group (μ) using the following 
formula: Z = (X – μ) / σ.  With this type of analysis, the control group always has an overall Z-
score of zero.  For the experimental groups, positive Z-scores reflect positive emotionality 
changes (i.e. antidepression or antianxiety), whereas negative Z-score reflect negative 
emotionality changes (i.e. depression, anxiety).  Not surprisingly, a Z-score analysis of CA1 
administration showed that DUQ0002I caused a statistically significant antidepression-like effect 
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(Figure 22C, unpaired t-test, **p=0.0045).  These data show that CA1 administration of 
DUQ0002I is sufficient to induce strong antidepression-like effects. 
Next, we tested to see if the anxiolytic-like effects of ICV-delivered DUQ0002I were 
mediated, in part, by 5-HT7R in the CA1 of the hippocampus.  In the EOM test, we showed that 
DUQ0002I did not change the total amount of time spent in the open arms of the maze (Figure 
22D, unpaired t-test, p=0.7875) when compared to control vehicle-injected animals via CA1 
injection.  The fraction also did not change the overall percent distance that the animals traveled 
in the open arms (Figure 22E, unpaired t-test, p=0.7806).  We also tested CA1 administration of 
DUQ0002I in the light-dark preference test and found similar negative results.  DUQ0002I did 
not change the overall amount of time spent in the light side of the light-dark preference test 
(Figure 22F, unpaired t-test, p=0.8695) during the latter half of the test, nor did DUQ0002I 
change the overall mean visit to the light side of the box (Figure 22G, unpaired t-test, 
p=0.5067).  Finally, as was done for the depression tests, an overall anxiety test Z-score was 
calculated for the CA1 administration of DUQ0002I (calculated using the time and percent 
distance traveled in open from the EOM and time and mean visit to the light side).  In contrast to 
what was shown for depression behaviors, the overall emotionality score related to anxiety 
behaviors showed no overall difference between control and DUQ0002I treated animals (Figure 
22H, unpaired t-test, p=0.9127).  Combined, these data show that while DUQ0002I 
administration to the CA1 is sufficient to induce antidepression-like effects, it is not sufficient to 
induce the anxiolytic-like effects.   
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Figure 22.  Administration of fraction DUQ0002I bilaterally to the CA1 region of the 
hippocampus is sufficient to induce antidepression-like effects in male animals. (A) Mice 
treated with DUQ0002I (n=5) decrease time immobile compared to vehicle (n=5) in the forced 
swim test.  (B) Mice treated with DUQ0002I (n=5) decrease time immobile compared to vehicle 
(n=5) in the tail suspension test.  (C) Mice treated with DUQ0002I (n=5) show a positive 
increase in emotionality when looking at the effects of the depression assays (forced swim and 
tail suspension) compared to vehicle (n=5).  (D) Mice treated with DUQ0002I (n=5) show no 
difference in time spent in the open arms of the EOM compared to vehicle (n=5).  (E) Mice 
treated with DUQ0002I (n=5) show no difference in overall percent distance traveled in the open 
arms of the EOM compared to vehicle (n=5).  (F) Mice treated with DUQ0002I (n=5) show no 
  100
difference in time spent in the light side of the LDP box during the latter half of the test 
compared to vehicle (n=5).  (G) Mice treated with DUQ0002I (n=5) show no difference in the 
mean visit to the light side of the LDP box compared to vehicle (n=5).  (H) Mice treated with 
DUQ0002I (n=5) show no changes in emotionality when looking at the effects of the combined 
anxiety assays (elevated zero maze and light-dark preference) compared to vehicle (n=5). Un-
paired t-tests, *p<0.05, **p<0.01. Data shown as mean ± SEM.  NL – conducted experiment.  
NL, BK – designed experiment. 
 
Bioassay-Guided Fractionation of DUQ0002I 
All of the alterations in depression and anxiety-like behavior seen thus far were produced 
using a fraction of cyanobacterial extract (DUQ0002I), which contained a mixture of various 
compounds. In an effort, to move beyond simply testing extracts for behavioral effects and 
identify specific active compounds within this fraction, DUQ0002I was purified into four 
subfractions (named DUQ0002I-1, -2, -3 and -4) using reverse-phase column chromatography.  
Sub-fractions DUQ0002I-2, DUQ0002I-3 and DUQ0002I-4 were all obtained as green pastes. In 
contrast, sub-fraction DUQ0002I-1 was obtained as a yellow paste and, unlike fractions 
DUQ0002I-2, -3 and -4, was shown by NMR to be most chemically similar to DUQ0002I.  Due 
to its chemical similarity to the parent fraction, and the fact that these sub-fractions still 
contained mixtures of compounds, sub-fraction DUQ0002I-1 was further purified using silica gel 
chromatography to yield three more purified sub-fractions, (named DUQ0002I-1A, -B and -C).  
A flowchart illustrating the fractionation of DUQ0002I can be seen in Figure 23. All sub-
fractions and purified sub-fractions describe herein were tested in vivo (see Figure 24) after the 
initial characterization of the parent fraction described below in an attempt to determine if these 
purified fractions contained the active compound(s).  
  101
             
Figure 23. Flowchart of the fractionation of DUQ0002I.   
 
The three subfractions (DUQ0002I-2, -3 and -4) and the three purer subfractions of 
subfraction DUQ0002I-1 (DUQ0002I-1A, -1B and -1C) were tested via CA1 injections in 
separate groups of male animals that underwent either the tail suspension or forced swim tests.  
We predicted that since significant antidepressant-like effects were seen with the parent fraction 
(DUQ0002I) via CA1 injections (see Figure 22), then any subfraction(s) with the active 
compound(s) should have the same, or perhaps stronger behavioral effects. Since subfraction 
DUQ0002I-1 had chemically unique characteristics similar to the parent fraction, we predicted 
that one if its purified subfractions (either DUQ0002I-1A, -1B or -1C) would contain an active 
compound and induce the same antidepression-like effects as the parent fraction.   
Interestingly, none of the subfractions or purified subfractions exhibited any statistically 
significant behavioral effects (DUQ0002I-2 (n=11, vehicle group, n=12) (Figure 24A, unpaired 
t-test, p=0.1810), DUQ0002I-3 (n=6, vehicle group n=5) (Figure 24B, unpaired t-test, p=0.6954) 
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or DUQ0002I-4 (n=6, vehicle group n=6) (Figure 24C, unpaired t-test, p=0.2545; DUQ0002I-
1A (n=6, vehicle group, n=6) (Figure 24D, unpaired t-test, p=0.5780), DUQ0002I-1B (n=6, 
vehicle group, n=5) (Figure 24E, unpaired t-test, p=0.8271), or DUQ0002I-1C (n=7, vehicle 
group, n=7) (Figures 24F, unpaired t-test, p=0.2145)).  Following these negative findings, we 
reconfirmed the activity of the parent DUQ0002I fraction by screening it once again using NMR. 
No changes were observed, such that both the original NMR and this second NMR that 
reconfirmed activity had the same active peaks.  This suggests that the parent nor subfractions 
had degraded. This may suggest that the activity seen in the parent fraction is caused by a 
synergistic effect between two or more unidentified compounds in different subfractions that do 
not have therapeutic activity alone.  For our subsequent SNI studies, we chose to test the parent 
fraction, while structure elucidation efforts continue to identify the individual synergistic 
components that could become lead compounds in drug design.   
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 Figure 24.  Administration of purified subfractions of DUQ0002I bilaterally to the CA1 
region of the hippocampus has no effects in males. (A) Mice treated with DUQ0002I-2 (n=11) 
show no difference in time immobile compared to vehicle (n=12) in the forced swim test.  (B) 
Mice treated with DUQ0002I-3 (n=6) show no difference in time immobile compared to vehicle 
(n=5) in the forced swim test.  (C) Mice treated with DUQ0002I-4 (n=6) show no difference in 
time immobile compared to vehicle (n=6) in the forced swim test.   (D) Mice treated with 
DUQ0002I-1 (n=6) show no difference in time immobile compared to vehicle (n=6) in the tail 
suspension test.  (E) Mice treated with DUQ0002I-1B (n=6) show no difference in time 
immobile compared to vehicle (n=5) in the tail suspension test.  (F) Mice treated with 
DUQ0002I-1C (n=7) show no difference in time immobile compared to vehicle (n=7) in the 
forced swim testUn-paired t-tests.  Data shown as mean ± SEM.  NL – conducted experiment.  
NL, BK – designed experiment. 
 
Utilizing DUQ0002I as a Therapeutic Lead in the Spared Nerve Injury (SNI) Model of Comorbid 
Pain and Depression  
  104
Thus far in our studies, we showed that DUQ0002I causes anxiolytic and antidepression-
like effects that are specific to male animals and likely act through 5-HT7R.  We also showed 
that the antidepression-like effects were likely caused, in part, through targeting the CA1 of the 
hippocampus.  In all of these experiments, the animals that were tested were naïve mice; they did 
not have any underlying manipulation that caused them to be in a heightened state of depression.  
In order to understand more about how targeting the 5-HT7R may be involved in altering 
depression-like behavior, we decided to test DUQ0002I in animals with an underlying 
depression phenotype.  Since there is significant evidence that chronic pain often occurs with 
depression symptoms and that each condition can exacerbate the effects of the other (Von Korff 
et al., 1992; Bair et al., 2003), we decided to use the well characterized spared nerve injury (SNI) 
model (Decosterd and Woolf, 2000) of neuropathic pain with comorbid depression.   
First, we wanted to determine if and when un-injected animals with SNI exhibited 
changes in mechanical sensitivity (i.e. pain-like behavior) and affective behaviors (i.e. 
depression-like behaviors) when compared to control sham animals.  Consistent with the robust 
pain-like phenotype in SNI, we found that at one, three, five, six and ten weeks post-surgery, 
male SNI animals had statistically significantly lower withdrawal thresholds when compared to 
sham animals in the ipsilateral paw (Figure 25A, 2-way ANOVA, overall effect of time 
***p<0.0001, overall effect of surgery ***p<0.0001, Bonferroni post hoc tests, **p<0.01, 
***p<0.001).  We next determined when SNI animals developed depression-like effects in the 
forced swim and tail suspension tests when compared to sham animals.  By the five-week post-
surgery time point, SNI animals showed no differences in overall time immobile in the forced 
swim and in tail suspension tests (data not shown).  However, by the 10 week post-surgery time 
point, SNI animals trended towards showing higher levels of immobility when compared to sham 
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animals in the forced swim test (Figure 25B, unpaired t-test, p=0.0834).  SNI animals also 
showed significantly higher levels of immobility in the tail suspension test when compared to 
control sham animals (Figure 25C, unpaired t-test, **p=0.0037).  Combining the results with a 
Z-score analysis (calculated using the time immobile in the forced swim and tail suspension 
tests) showed that overall, SNI animals showed negative depression emotionality (i.e. greater 
depression-like behavior) compared to sham animals (Figure 25D, unpaired t-test, *p=0.0110). 
Anxiety tests were also conducted at the 10-week post-surgery time point.  Here, both the 
elevated plus maze (EPM) and LDP tests were conducted.  Using the time spent in the open arms 
and overall percent distance traveled in the open arms, the overall Z-score for the elevated plus 
maze test showed SNI animals with a trend towards negative emotionality (i.e., greater anxiety-
like behavior) compared to sham animals (Figure 25E, unpaired t-test, p=0.1335).  For the LDP 
test, using the time in light and number of entries into the light, SNI animals did not show any 
difference in Z-score emotionality compared to sham animals (Figure 25F, unpaired t-test, 
p=0.4617).  Using the Z-scores of the EPM and LDP test, an overall anxiety emotionality score 
was calculated.  SNI animals trended towards showing negative emotionality compared to sham 
animals (Figure 25G, unpaired t-test, p=0.1491).  Finally, using both the depression 
emotionality score and anxiety emotionality score, an overall emotionality score was calculated 
to see the overall effect of all the behaviors in SNI compared to sham animals.  SNI animals 
showed negative emotionality compared to sham animals (Figure 25H, unpaired t-test, 
***p=0.0005). 
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Figure 25.  Spared nerve injury (SNI) induces mechanical hypersensitivity and increases 
depression-like effects 10 weeks post surgery. (A) Mice that receive SNI surgery (n=6) have 
lower withdrawal thresholds for up to 10 weeks post surgery compared to sham (n=6).  (B) Mice 
that receive SNI surgery (n=6) show a trend of increasing time immobile compared to sham 
(n=6) in the forced swim test.  (C) Mice that receive SNI surgery (n=6) increase time immobile 
compared to sham (n=6) in the tail suspension test. (D) Mice that receive SNI surgery (n=6) have 
a negative depression emotionality score when looking at the effects of the combined depression 
assays (tail suspension and forced swim tests) compared to sham (n=6).  (E) Mice that receive 
SNI surgery (n=6) have a trend in negative Z-score when looking at the elevated plus maze 
compared to sham (n=6).  (F) Mice that receive SNI surgery (n=6) show no difference in Z-score 
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when looking at the light dark preference test compared to sham (n=6).  (G) Mice that receive 
SNI surgery (n=6) have a trends towards negative depression emotionality score when looking at 
the effects of the combined anxiety assays (elevated plus maze and light-dark preference tests) 
compared to sham (n=6).  (H) Mice that receive SNI surgery (n=6) have negative overall 
emotionality score (all anxiety and depression measurements) when looking at the effects of the 
combined depression and anxiety assays (tail suspension, forced swim, elevated plus maze, light-
dark preference tests) compared to sham (n=6). A – 2-way ANOVA, main effect of time and 
surgery, Bonferroni post-hoc test *p<0.05, ***p<0.001; B – un-paired t-test, p=0.0834; C – un-
paired t-test, **p<0.01; D – un-paired t-test, *p<0.05; H – un-paired t-test, ***p<0.0001.  Data 
shown as mean ± SEM.  NL – conducted experiment.  NL, BK – designed experiment. 
 
 
Since the SNI model caused both pain-like and depression-like effects 10 weeks after 
surgery, we tested the effects of DUQ0002I at this time point. These data allowed us to 
determine if DUQ0002I would have an overall greater effect on SNI animals when compared to 
sham mice due to the underlying model of comorbidity.  Here, animals underwent either SNI or 
sham surgery 10 weeks prior to the beginning of behavioral testing.  DUQ0002I targeted to the 
CA1 had no behavioral effect on SNI-induced mechanical hypersensitivity (data not shown). 
However, DUQ0002I had an overall effect in reducing immobility in the forced swim test in both 
sham and SNI animals (Figure 26A, 2-way ANOVA, interaction p=0.8487, overall effect of 
compound **p=0.0063, overall effect of surgery p=0.2143, Bonferroni post hoc tests n.s.).  
When looking at each individual group of animals, both sham (Figure 26A, unpaired t-test, 
+p=0.0658) and SNI animals (Figure 26A, unpaired t-test, *p=0.0458) show near or 
significantly lower levels of immobility when DUQ0002I is administered to the CA1 compared 
to vehicle-treated animals.  Similarly, DUQ0002I delivered to the CA1 reduced overall 
immobility in the tail suspension test for both sham and SNI animals (Figure 26B, 2-way 
ANOVA, interaction p=0.0596, overall effect of compound ***p=0.0002, overall effect of 
surgery p=0.4385, Bonferroni post hoc test, **p<0.01).  When looking at each individual group 
of animals, both sham (Figure 26B, unpaired t-test, *p=0.0271) and SNI animals (Figure 26B, 
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unpaired t-test, **p=0.0032) show similar levels of immobility when DUQ0002I is administered 
to the CA1 when compared to vehicle-treated animals.   
To look at the overall effect that DUQ0002I had on both SNI and sham animals, a Z-
score analysis for depression-like behaviors (using time immobile in the forced swim and tail 
suspension tests) was calculated (Figure 26C, 2-way ANOVA, interaction p=0.3991, overall 
effect of compound ***p<0.0001, overall effect of surgery p=0.1728, Bonferroni post hoc tests, 
*p<0.05 – sham, ***p<0.001 – SNI).  This Z-score analysis shows that overall, DUQ0002I 
reduced depression-like behaviors in both SNI and sham animals and that these antidepression-
like effects may be greater in SNI animals when compared to sham animals.  
     
Figure 26. DUQ0002I administration reverses these depression-like effects when 
administered to the CA1 in male animals. (A) SNI mice that receive DUQ0002I (n=12) and 
sham mice that receive DUQ0002I (n=10) both decrease time immobile compared to SNI 
animals that receive vehicle (n=10) and sham animals that receive vehicle (n=12) in the forced 
swim test.  (B) SNI mice that receive DUQ0002I (n=12) and sham mice that receive DUQ0002I 
(n=10) both decrease time immobile compared to SNI animals that receive vehicle (n=10) and 
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sham animals that receive vehicle (n=12) in the tail suspension test.  (C) SNI mice that receive 
DUQ0002I (n=12) and sham mice that receive DUQ0002I (n=10) both show a positive increase 
in emotionality score when looking at the combined effects of the depression assays (forced 
swim and tail suspension) compared to SNI animals that receive vehicle (n=10) and sham 
animals that receive vehicle (n=12).  A – 2-way ANOVA, overall main effect of compound; 
Bonferroni post hoc test n.s. and sham – unpaired t-test, +p=0.0658 and SNI – unpaired t-test, 
*p=0.0458; B – 2-way ANOVA, overall main effect of compound; Bonferroni post-hoc test 
**p<0.01 and sham – unpaired t-test, *p=0.0271 and SNI – unpaired t-test, **p=0.0032; C – 2-
way ANOVA, overall main effect of compound, Bonferroni post-hoc test *p<0.05, ***p<0.001.  
Data shown as mean ± SEM.  NL – conducted experiment.  NL, BK – designed experiment. 
 
DISCUSSION   
Overall, our data show that an extract from a marine cyanobacterium of the genus 
Leptolyngbya induces antidepressant and anxiolytic-like effects that are specific to the 5-HT7R 
and male animals using in vivo models of behavior.  Additionally, we were able to characterize 
male and female (preliminary) 5-HT7R knockout animals in a variety of behavioral tests, show 
that administration of our extract to the CA1 of the hippocampus is sufficient to induce these 
antidepressant-like effects and show that the effects are likely caused by a mixture of compounds 
in the fraction.  Finally, using this fraction, we demonstrated that the active compounds involved 
had similar effects in animals with comorbid pain-like and depression-like behavior. 
The genus from which our extract originated, Leptolyngbya, is one of the major natural 
product-producing genera of marine cyanobacteria (Engene et al., 2013).  The fact that our 
phylogenetic analysis showed that DUQ0002 belonged to Leptolyngbya, a different genus from 
the field identification (Oscillatoria or Moorea), highlights the importance of using 16S rRNA 
gene sequences to obtain more accurate identifications of field collected cyanobacteria.  Recent 
studies using whole-genome and 16S sequencing approaches have changed the traditional 
phylogenetic classification of cyanobacteria (Wilmotte, 1994).  Known compounds extracted 
from Leptolyngbya include palmyrolide A, which has potent sodium channel blocking activity 
  110
without cytotoxicity (Pereira et al., 2010), crossbyanols A – D with antibiotic activity (Choi et 
al., 2010) and honaucins A – C with the ability to inhibit proinflammtory cytokines (Choi et al., 
2012).  Another compound, coibamide A, a potent antiproliferative cyclic depsipeptide, was also 
extracted from a Leptolyngbya species from the Pacific side of Panama but from the other side of 
the Azuero peninsula near Coiba Island (Medina et al., 2008). DUQ0002, however, represents 
the first Leptolyngbya extract with GPCR-specific psychoactive effects. Overall, these data 
suggest that Leptolyngbya species have significant potential in the field of neuropharmacognosy.   
  The observed affinities for cyanobacterial secondary metabolites, including those from 
DUQ0002I for 5-HT1AR and 5-HT7R, are very encouraging from a pharmacological viewpoint 
(Naumenko et al., 2014) and may represent a chemical ecology role for these serotonin receptor 
ligands.  A possible explanation for their presence could be linked to the predator-prey 
relationship between Aplysia sea hares and marine cyanobacteria.  In their natural environment, 
colonial marine cyanobacteria are preyed upon by Aplysia sea hares. This ecological relationship 
could link the biosynthesis of 5-HTR ligands by marine cyanobacteria to these marine mollusks 
due to the simple structure of their nervous system.  In Aplysia, the entire CNS consists of only a 
small number of neurons, which contain 5-HTR and have been shown to be involved in learning 
and memory (Barbas et al., 2003). The compounds from the cyanobacteria could be affecting the 
feeding behavior of the sea hares by targeting their nervous system and provides a possible 
explanation for their presence. 
Like those assays described in the previous chapter, the tests used in this chapter also 
have a long history in the field of drug-discovery testing.   In this chapter, the forced swim test 
was extensively used to demonstrate the antidepression-like effects of DUQ0002I.  This test was 
originally called the Porsolt Test, from the researcher who first developed this assay in the 
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1970’s (Porsolt et al., 1977).  This assay is based off of the principle of learned helplessness or 
behavioral despair where animals are placed in a stressful situation from which they are unable 
to escape.  Here, that stimulus is a beaker of water with high walls (the same principle is used in 
the tail suspension test described in Section 1, Chapter 1, where the stimulus was being 
suspended upside down by the tail).  In early validation experiments, Porsolt found that tricyclic 
antidepressants, monoamine oxidase inhibitors, other atypical antidepressants, all that work in 
humans to reverse the effects of depression, as well as electroconvulsive shock all reduced the 
overall time immobile in mice during the six minute assay (Porsolt et al., 1977).  This test has 
been shown to have very good predictive validity, with the majority of clinically used 
antidepressants decreasing the overall time immobile from acute administration (Castagne et al., 
2010).  With the high degree of predictive validity in this test, the fact that our fraction 
repeatedly decreases immobility following acute administration implies that the active 
compounds could very likely work to treat depression in humans. 
Additionally, two animal models of anxiety were extensively used to characterize the 
effects of our cyanobacterial fractions.  The elevated zero maze (EOM) was developed in 1994 
as an alternative to the well-characterized elevated plus maze (EPM) (Shepherd et al., 1994).  
This variation of the EPM utilizes the same principle of having regions with low walls and 
region with high walls on a raised platform.  However, in the EPM, with the ‘plus’ shape, 
animals would sometimes remain in the corner of one of the high walled arms, and not move 
throughout the rest of the test.  The EOM alleviates this problem by having no corners where the 
animals can hide, but still retaining the high and low walled regions.  It also removes the 
ambiguity of the central region of the plus shape (Shepherd et al., 1994).  This test was validated 
as a good alternative to the EPM, and has been shown to be effective in anxiolytics that work in 
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humans, including the benzodiazepine anxiolytics, diazepam and chlorodiazepoxide (Shepherd et 
al., 1994).  In this same characterization experiment by Shepard, anxiogenic drugs, such as m-
chlorophenyl-piperazine (mCPP), that increase anxiety did the opposite, where animals would 
spend more time in high-walled regions compared to controls.  Since then, other have shown the 
pharmacological validation of the assay (Kumar et al., 2013). Of note however, serotonin 
modulating compounds are known to show discrepancies in both the EPM and EOM in the 
classic measures of time/distance in different zones, and that it may be better to observe these 
classic measures in conjunction with behavioral postures in this assay (such as head dipping and 
risk assessment), when using serotonin modulating compounds (Bourin, 2015).  This is 
something that may be considered for future studies using this assay and should be considered in 
the results we found with DUQ0002I. 
The final anxiety assay, the light-dark preference (LDP) test, was developed in 1980 by 
Crawley and Goodwin (Crawley and Goodwin, 1980).  In contrast to all of the anxiety tests 
described thus far (open field and EOM) that are based on wall-hugging or thigmotaxic 
behaviors, this assay is based on exploratory behavior of a brightly lit chamber from a covered 
dark side (rodents have a natural aversion to brightly lit areas).  This assay was validated by 
Crawley and Goodwin, who found that the classic anxiolytics of benzodiazepines increased 
exploratory activity (time, distance, etc.) in the brightly lit chamber (Crawley and Goodwin, 
1980).  Since these initial validation experiments, other have found that newer anxiolytics such 
as serotonergic drugs and drugs acting on neuropeptide receptors also show positive effects in 
this assay (Bourin and Hascoet, 2003).  One drawback of this assay is that many non-
pharmacological factors, especially odors can alter exploratory behaviors of the light chamber, 
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and prior exposure to other anxiety assays before LDP can alter how animals respond to 
anxiolytics in LDP (Bourin, 2015).   
Using these depression and anxiety assays, our results from the initial screening of 
fraction DUQ0002I with ICV administration correspond well with other studies of the 5-HT7R 
using selective ligands in animal models.  In terms of depression, intraperitoneal administration 
of the selective 5-HT7R antagonist SB269970 decreases depression-like behaviors in the forced 
swim and tail suspension tests in mice (Hedlund et al., 2005; Sarkisyan et al., 2010).  This same 
5-HT7R antagonist also decreases depression-like behaviors in the forced swim and conflict 
drinking tests when administered to the CA1 region of the hippocampus in rats (Wesolowska et 
al., 2006).  Other novel antagonists of the 5-HT7R, such as the recently developed N-
biphenylylmethyl 2-methoxyphenylpiperazinylalkanamides, have shown similar antidepression-
like effects when given intraperintoneally to mice in the forced swim test (Kim et al., 2014). The 
compound vortioxetine, a novel antidepressant has also been found to cause antidepression-like 
effects in the forced swim test when given to mice acutely and chronically for 21 days via oral 
gavage, and the effects were stronger than the classic antidepressant fluoxetine (Guilloux et al., 
2013).   Moreover, male 5-HT7R knockout animals also exhibit a similar phenotype, where mice 
lacking the 5-HT7R show antidepression-like phenotypes in both the forced swim and tail 
suspension tests (Guscott et al., 2005).  This suggests that these changes in behavior are truly 
dependent on the 5-HT7R.  Looking at anxiety-like behavior, studies have shown that the well-
characterized 5-HT7R antagonist SB269970 causes anxiolytic-like effects in the Vogel drinking 
test and elevated plus maze in rats and the four-plate test in mice when administered 
intraperitoneally (Wesolowska et al., 2006).  SB269970 administered intraperitoneally has also 
been shown to cause a reduction in marble burying in mice (Hedlund and Sutcliffe, 2007).  
  114
Moreover, pharmacological blockade of the 5-HT7R with the compound vortioxetine given both 
acutely and chronically for 21 days via oral gavage reduces anxiety-like behavior in the open 
field test in mice (Guilloux et al., 2013).  Combined, these data show that, in general, antagonists 
of the 5-HT7R decrease both depression and anxiety-like behaviors.   
Therefore, since the behavioral phenotype of DUQ0002I mimics the effects of these 
known antagonists, it suggests the active compound(s) in DUQ0002I is most likely acting as an 
antagonist of the 5-HT7R.  Of note, one possible mechanism of action with multiple receptor 
subtypes could involve an interaction between DUQ0002I and the 5-HT7R and 5-HT1AR.  5-
HT7R is a part of the Gs GPCR family and stimulates the production of adenylyl cyclase and 5-
HT1AR is a part of the Gi GPCR family and inhibits the production of adenylyl cyclase (Hannon 
and Hoyer, 2008).  Because of this, DUQ0002I could act as an antagonist to the 5-HT7R and 
agonist to 5-HT1AR to induce the same downstream effect.  However, our data support an overall 
anti-depressant and anti-anxiety role of inhibiting 5-HT7R since we were able to induce the same 
behavioral effect with ICV injections of a known 5-HT7R antagonist SB258719, which has 100-
fold greater selectivity for the 5-HT7R compared to the other 5-HTRs  (Forbes et al., 1998).  
Moreover, the fact that DUQ0002I failed to induce antidepressant and anxiolytic-like effects in 
5-HT7R knockout animals shows the selectivity of the active compounds in DUQ0002I and 
provides evidence that the active compounds are likely not acting on any other serotonin 
receptors.  This includes the 5-HT1AR, which is known to play a role in both depression and 
anxiety (Albert et al., 2014), and ligands to this receptor are known to cause antidepression-like 
effects in tests like the forced swim test (Jastrzebska-Wiesek et al., 2018).   However, due to the 
fact that DUQ0002I does show affinity for other receptors (5-HT1AR, mGluR5, etc.), the 
possibility exists that DUQ0002I acts on a combination of these receptors, and not just 5-HT7R.  
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If this were the case, the 5-HT7\R knockout animals, lacking the 5-HT7R, would be missing one 
of the essential receptors to induce the phenotype, meaning that the effects are not solely 
dependent on the 5-HT7R. Future testing could look into testing other knockouts (mGluR5, 5-
HT1AR) with DUQ0002I to determine if an antidepression-like effect is present with DUQ0002I 
administration in these other knockouts to rule out this possibility.   
In addition to the effects that were seen in both depression and anxiety tests with 
DUQ0002I via ICV administration, the series of pain tests that were conducted using this same 
administration route yielded no changes in pain-like behavior (see Figure 14).  These tests 
included the experimenter induced pain models, consisting of the inflammatory pain model of 
the formalin test, the thermal pain models of the tail flick and Hargreaves test and the mechanical 
pain test of von Frey testing.  All of these assays are well-characterized in the pain field (Gregory 
et al., 2013).  The history of the formalin test is described in the previous chapter.  The thermal 
assays, starting with the tail flick test was developed in 1970 (Dewey et al., 1970).  While 
effective, this assay is not commonly used since it is based on a spinal reflex response and the 
thermal stimulus cannot be applied to a specific area.  To circumvent this, the Hargreaves 
thermal test was developed by Hargreaves in the late 1980’s to have a localized target with a 
radiant beam of light to the paw (Hargreaves et al., 1988).  The cognitive pain assay of the 
OPTA test was also used, but this is a brand new test that was just developed last year and 
characterized by our colleague at the University of Cincinnati (Sammohi et al., 2017).   
While the 5-HT7R activation in the parafascicular nucleus of the medial thalamus has 
been shown to cause analgesic-like behaviors (Harte et al., 2005), these results are not surprising 
due to the fact most of the literature that shows changes in pain-like behavior with modulating 
the 5-HT7R does not occur centrally.  This is especially true with formalin behavior, where 
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intrathecal administration of 5-HT7R antagonists increase pain-like behaviors in this test with 
male rodents (Liu et al., 2013), whereas intrathecal 5-HT7R agonists increased pain-like 
behaviors (Rocha-Gonzalez et al., 2005) and antagonists decreased pain-like behaviors in female 
rats (Godinez-Chaparro et al., 2011).  This is also true for mechanical pain tests, where 5-HT7R 
antagonists administered IP increase mechanical hypersensitivity in the capsaicin test with male 
mice (Brenchat et al., 2009), but 5-HT7R antagonists reverse the hypersensitivity in female rats 
with SNL injury (Amaya-Castellanos et al., 2011).  Local administration of 5-HT7R modulating 
compounds has also been found to alter pain-like behaviors, where antagonists administered to 
the ipsilateral paw block formalin-induced hypersensitivity (Rocha-Gonzalez et al., 2005; 
Godinez-Chaparro et al., 2011).  Together, these data suggest that the reason DUQ0002I did not 
induce any changes in pain-like behaviors is because via ICV injection, the active compounds in 
the fraction do not reach the 5-HT7R in the spinal cord or periphery at a high enough dose to 
induce effects.  Future testing could involve intrathecal administration of DUQ0002I in pain 
testing and possible peripheral administration with pain testing if larger amounts of compound 
could be synthesized or collected.   
Despite the lack of effects in the pain assays with DUQ0002I, we were still able to show 
how broad administration of known 5-HT7R antagonists can induce analgesic-like effects in 
animals with SNI surgery (see Figure 15).  Here, we showed that the known 5-HT7R antagonist 
SB269970 injected IP blocks SNI-induced hypersensitivity for up to four hours post injection 
while not affecting sham animals.  Interestingly though, in a cognitive pain assay, the CPP test, 
SB269970 did not cause SNI or sham animals to develop preference for the compound (see 
Figure 15).  Tests like this with IP administration are not possible with the cyanobacteria 
compounds due to the large amount of compounds needed for experiments like this.  In the 
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future, if we discover that it is possible to obtain large amounts of compound or synthesize active 
compounds in fractions, then it will be possible to test in other administration routes such as this.  
With the known 5-HT7R antagonist data though, we are still able to draw conclusions that 
suggest that while blocking the 5-HT7R clearly has effects in experimenter-induced pain assays 
like the von Frey test, it does not have effects in spontaneous pain models such as the CPP test. 
Our data show a potentially interesting and uncharacterized sex difference in terms of 
response to inhibition of the 5-HT7R in depression and anxiety-like behaviors.  All of our initial 
antidepressant and anxiolytic-like DUQ0002I effects were found in male animals and were not 
replicated in female mice.  Likewise, female mice did not show any behavioral changes with 
administration of the 5-HT7R antagonist SB258719.  Despite the known sex differences in 
depression and anxiety (Kokras and Dalla, 2017), all of the depression studies (Hedlund et al., 
2005; Wesolowska et al., 2006; Sarkisyan et al., 2010; Mnie-Filali et al., 2011; Kim et al., 2014) 
and anxiety studies (Wesolowska et al., 2006; Hedlund and Sutcliffe, 2007; Guilloux et al., 
2013) that have looked into the behavioral effects of 5-HT7R antagonists were done using only 
male animals.  This is also true for the knockout studies where only male mice have been tested 
in cognitive assays (Roberts et al., 2004; Guscott et al., 2005).  The only exception is a study that 
found there no hypothermic response to intraperitoneally administered 5-HT in male or female 5-
HT7R knockout mice (both male and female wildtype mice showed the same significant 4oC 
drop in body temperature after 5-HT administration) (Hedlund et al., 2003).  It is known that 
estrogens can interfere with the effects of antidepressants (Keers and Aitchison, 2010) and that 
females can exhibit higher levels of serotonin and synthesize it more slowly (Nishizawa et al., 
1997).  Additional work is needed to determine the mechanism behind the observed sex 
differences. In the pain literature, as discussed earlier, several studies have found that 5-HT7R 
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antagonists increase pain-like behaviors in males (Brenchat et al., 2009; Liu et al., 2013), 
whereas antagonists decrease pain-like behaviors in females (Amaya-Castellanos et al., 2011; 
Godinez-Chaparro et al., 2011).  Our failure to see an effect of DUQ0002I in SNI-induced 
hypersensitivity may have been caused by a floor effect in the assay where male SNI-treated 
mice could not show additional pain behavior.  Future studies with DUQ0002I will explore 
potential effects in the context of other models of acute and chronic pain.  
Our work with testing for potential effects of DUQ0002I in 5-HT7R knockout animals 
also lead us to more fully characterize these animals compared to wild-types.  Based on the 
differences found with our pharmacological data, we also used this strain of animals to begin 
looking at potential fundamental differences between male and females.  As stated earlier, of all 
the knockout studies done with this strain, only one study looking at hypothermic responses has 
included both males and females (Hedlund et al., 2003).  The 5-HT7R knockout strain has been 
well-studied for its effects in depression assays, where it has repeatedly been found that 5-HT7R 
knockout males exhibit an anti-depression-like phenotype compared to wildtype counterparts 
(Guscott et al., 2005; Hedlund et al., 2005).   We were able to replicate these findings with our 
male animals in these same assays.  Based on the data from our pharmacological findings, where 
DUQ0002I only induced antidepression and anxiolytic effects in male animals, it was 
hypothesized that this sex difference could exist in the genetically altered animals as well.  With 
the preliminary number of animals tested to date, this seems to be the case: female 5-HT7R 
knockouts do not show an antidepression phenotype compared to wildtypes.  This suggests that 
there may be a fundamental difference in the way that the 5-HT7R affects behaviors related to 
depression, but definitive conclusions cannot be made until the same numbers of animals are in 
both the male and female groups.   
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Studies related to anxiety-like behavior in this strain, however, are limited.  The EPM and 
the LDP test have been done, but researchers found no differences between 5-HT7R knockout 
and wild type mice (Roberts et al., 2004; Guscott et al., 2005).  Similar to these previous studies, 
we found no differences between the genotypes in males the open field test.  Similar to the 
anxiety results, no differences were found with locomotor behavior in either the elevated zero 
maze or the open field tests.  No studies have ever looked into locomotor differences in this 
strain of animals, and to our knowledge, there have not any pharmacological studies 
investigating the role of the 5-HT7R in locomotion.   
The final set of characterization studies done with the 5-HT7R knockout animals 
expanded the testing of this strain of animals in several pain assays.  The only known pain assay 
previously conducted in these animals was the tail flick test, which found no differences between 
the genotypes (Roberts et al., 2004).  Our data expanded the understanding of 5-HT7R 
significantly by conducting tests in mechanical, thermal and cognitive pain tests.  However, in 
the von Frey, Hargreaves test, formalin and OPTA tests, no differences were found between the 
genotypes in males.  Further testing is still required to draw definitive conclusions about the 
phenotype of the knockout animals, and a complete set of data for the characterization of these 
animals will include the female data as well.  
The results from our anatomical studies have provided insight into where the compounds 
present in DUQ0002I may be acting to induce the effects observed.  The initial characterization 
experiments with ICV injections allowed us to broadly target the 5-HT7R in the CNS.  The lack 
of anatomical specificity with the ICV injections is most likely the reason behind the wide range 
of effects we saw in the behavioral assays.  5-HT7R is known to be expressed in a variety of 
regions including the cortex, hippocampus, amygdala, hypothalamus and thalamus (Bonaventure 
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et al., 2004; Gellynck et al., 2013b). The hippocampus is part of the limbic circuitry of the brain 
and serotonin in this region is involved in emotional states (Hensler, 2006) and may play a role 
in the action of antidepressants (Nestler et al., 2002; Vythilingam et al., 2004).  Previous studies 
have shown that blocking 5-HT7R in the CA1 region of the hippocampus decreases depression-
like behaviors in rodents (Wesolowska et al., 2006), and our results obtained in the forced swim 
and tail suspension tests show the same effect with administration of DUQ0002I.  Of note, we 
saw antidepressant-like effects in both FST and TST with CA1 administration of DUQ0002I; 
with ICV injection, effects were only seen in FST.  This TST difference could be a result of an 
insufficient dose of the active compounds in DUQ0002I reaching the area of activation with the 
ICV injections.  We also completed a Z-score analysis (Guilloux et al., 2011) of “depression” 
behaviors.  The Z-score analysis is a powerful that allows for the comparison of results across 
similar assays and has been used in studies that use multiple measures of behavior (de Sa-
Calcada et al., 2015; Sargin et al., 2016; Maluach et al., 2017; Mendez-David et al., 2017).  The 
Z-score analysis highlights the robust anti-depressant effect that DUQ0002I had when 
administered to the CA1. 
The strong anti-depressant effect was in contrast to our failure to observe anxiety-like 
behaviors with CA1 administration of DUQ0002I.  We showed that there were no effects in 
either the EOM or LDP tests.  The contrast between the Z-score analyses of the depression 
behaviors and anxiety behaviors highlights this difference very clearly.  The fact that anxiolytic-
like effects were not seen via CA1 administration but were seen with ICV administration also 
tells us that DUQ0002I has the potential to act at multiple CNS sites.  Notably, the amygdala is 
one of the central brain regions known to be involved with anxiety and fear (Adhikari et al., 
2015).  The fact that 5-HT7R are expressed in the amygdala (Bonaventure et al., 2004) and that it 
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is close to the cerebrospinal fluid system targeted with ICV injections means that it could 
possibly be the site of action for the anxiety-like effects of DUQ0002I.  
 Interestingly, in our attempt to find the active compound in DUQ0002I responsible for 
inducing the behavioral effects shown, we found that none of the subfractions DUQ0002I-1A, B 
and C and 2, 3 and 4 induced any antidepressant-like effects with CA1 administration. This 
suggests that a mixture of one or more compounds found in the original parent fraction itself 
(DUQ0002I) is responsible for the changes in behavior.  This type of synergistic effect from 
natural products is not uncommon.  Isoflavone and curcumin, two natural products, inhibit the 
growth of pancreatic cancer cells and alter gene expression in vitro, but only in combination 
(Wang et al., 2008).  Other examples include the wide variety of plant extracts, such as 
terpenoids, glycosteroids, flavonoids and polyphenols, that all have weak little to no antibiotic 
activity on their own, but have strong synergistic antibiotic effects on a wide range of microbes 
(Hemaiswarya et al., 2008).  One well-characterized example of this is the combined action of 
berberine and 5’-methoxyhydnocarpin produced by the berberry plant (Stermitz et al., 2000).  
Berberine strongly intercalates DNA and can kill bacteria but is readily pumped out of bacterial 
cells via pathogen-encoded multidrug resistance (MDR) pumps.  Berberine is only effective 
because the berberry plant also produces 5’-methoxyhydnocarpin that effectively blocks MDR 
pumps.  A similar type of synergistic effect is possibly occurring with the mixture of compounds 
found in DUQ0002I. 
 Finally, our work indicates how natural products can be used for more than simply drug 
discovery.  Natural product research can be used to develop tools to understand biological 
systems.  In this case, we chose to use DUQ0002I in the context of the spared nerve injury (SNI), 
a well-established model of neuropathic pain with comorbid depression (Suzuki et al., 2007; 
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Norman et al., 2010), to learn more about the role of the 5-HT7R in the development of this 
condition.  Rates of major depressive disorder (MDD) and depression symptoms are very high 
(13 – 82%) in chronic pain patients depending on the type of pain studied (Bair et al., 2003).  In 
contrast, MDD only exists at a rate of 6.7% in isolation in U.S. adults (Kessler et al., 2005) and 
rates of chronic pain conditions, such as facial pain (4%) and fibromyalgia (2.5%) are also fairly 
low in isolation (NCHS, 2006).  Our results indicate that SNI induces robust hypersensitivity 
from the first week of surgery up through ten weeks after surgery.  Similar to previous findings 
(Suzuki et al., 2007), SNI mice did not develop significant depression-like symptoms until ten-
weeks post-surgery, suggesting that the development of “depression” is slow to develop and is 
secondary to the primary hypersensitivity.  Other studies have also demonstrated that chronic 
stress exacerbates the depression-inducing effects of SNI (Norman et al., 2010).  The Z-score of 
depression-like behaviors in SNI when compared to sham animals highlight the behavioral 
changes that occur in SNI animals.  With this model established, we showed that not only does 
DUQ0002I decrease depression-like behaviors in the forced swim and tail suspension tests in 
sham animals, but it also has a significant effect in SNI animals. This is similar to results that 
were found in another model of depression, the olfactory bulbectomy paradigm in rats, where 
blockade of the 5-HT7R with the selective antagonist SB269970 was found to counteract the 
model’s depression-inducing effects (Mnie-Filali et al., 2011).  Future studies will have to 
investigate what other changes occur with 5-HT7R in the context of comorbidity.   
 Overall, our study demonstrates the power of utilizing natural products derived from 
marine cyanobacteria in CNS drug discovery.  Here, we were able to show that a synergistic 
mixture of compounds from a species of Leptolyngbya could induce robust antidepressant and 
anxiolytic-effects in animal models of behavior.  Beyond drug discovery, this extract shed light 
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onto the anatomical specificity of the depression-like effects of blocking the 5-HT7R, helped us 
to discover a possible fundamental difference between males and females in the way the 5-HT7R 
serotonin system works to induce these effects, and provided evidence that the 5-HT7R may play 
a role in comorbid pain and depression.  These discoveries illustrate the impact that these 
microbial secondary metabolites could have in the future treatment of CNS disorders related to 
GPCR malfunction.   
  
MATERIALS AND METHODS 
Field Sampling: A dark green/black cyanobacterial biomass was collected by snorkeling 
on January 28, 2013 while at a depth of 1 m off the coast of Mogo Mogo (GPS coordinates: 
8°34’50.2” N, 79°01’10.6” W) in the Las Perlas Archipelago, Panama. The sample was fully 
suspended in ethanol:seawater (50:50) mixture to preserve the sample until it could be stored in a 
light-tight lab at -20 °C prior to extraction. A voucher specimen (PLP-28Jan13-2) is deposited in 
the Department of Medicinal Chemistry, Graduate School of Pharmacy, Duquesne University. 
 
Extraction: The cyanobacterial biomass (75 g, dry wt) was extracted with 2:1 CH2Cl2-
MeOH to afford 3.3 g of crude extract. This crude extract was fractionated over normal phase 
silica gel with a stepwise gradient solvent system of increasing polarity starting from 100% 
hexanes to 100% MeOH, to yield nine fractions (A–I). The fraction eluting with 100% methanol 
(fraction I (DUQ0002I), 292 mg) was chromatographed on hypersep C18 reversed phase (2000 
mg/15 mL) column using methanol:water, gradient 50–100% to yield four sub-fractions, 
DUQ0002I-1-4 corresponding to 224.9, 5.7, 7.9 and 13.9 mg, respectively. The fraction most 
similar to the crude fraction, sub-fraction DUQ0002I-1 (167.5 mg), was further purified over 
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silica gel (90.6 g) using methanol:dicloromethane, gradients 5, 8 and 10% to yield sub-fractions, 
DUQ0002I-1A (3.2 mg), DUQ0002I-1B (4.0 mg) and DUQ0002I-1C (7.9 mg). 
 
General Experimental Procedures: NMR spectra were recorded with methanol as 
internal standard (δC 49.9, δH 3.34), on a Bruker 500 MHz spectrometer operating at 499.7 MHz 
for 1H and 125.7 MHz for 13C equipped with a 5 mm PATXI 1HD/D-13C/15N Z-GRD Probe. 
Column chromatography was performed using Sorbent Technologies silica gel (230-400 mesh). 
Solvents were evaporated on a Heidolph rotary evaporator.  
Psychoactive Drug Screening Program Binding Assays: All binding data for fractions 
DUQ0002A-I were performed and generously provided by the National Institute of Mental 
Health's Psychoactive Drug Screening Program (NIMH PDSP) utilizing a radioligand 
competition-binding assay.  Experimental details are available online at 
http://pdsp.med.unc.edu/.  Binding assays performed by the NIMH PDSP employ stably or 
transiently transfected cell lines expressing human recombinant receptors, monoamine 
transporters, or ion channels for targets of interest.  Receptors screened for cyanobacterial 
fraction DUQ0002I were the same as those from 2064H and DUQ0008, which included 5-
HT1AR, 5-HT1BR, 5-HT1DR, 5-HT1ER, 5-HT2AR, 5-HT2BR, 5-HT2CR, 5-HT3R, 5-HT4R, 5-
HT5AR, 5-HT6R, 5-HT7R, Alpha1A, Alpha1B, Alpha1D, Alpha2A, Alpha2B, Alpha2C, Beta1, 
Beta2, Beta3, CB1, CB2, D1, D2, D3, D4, D5, DAT, DOR, GABAA, H1, H2, H3, KOR, M1, 
M2, M3, M4, M5, MOR, NET, PBR, SERT, Sigma 1, Sigma 2 and the addition of the mGluR5 
and H4 receptors not screened previously.  For primary binding experiments, fractions were 
tested at a single concentration (10 μM) and in quadruplicate in 96-well plates.  For primary 
binding results, non-specific binding in the presence of 10 μM of a reference compound is set as 
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100% inhibition; total binding in the absence of fraction or reference compound is set as 0% 
inhibition. Plates are incubated with compounds and fractions at room temperature and in the 
dark for 90 minutes.  Reactions are stopped by vacuum filtration onto 0.3% polyethyleneimine 
(PEI) soaked 96-well filter mats using a 96-well Filtermate harvester, followed by three washes 
with cold wash buffers. Scintillation cocktail is then melted onto the microwave-dried filters on a 
hot plate and radioactivity is counted in a Microbeta counter.  Compounds showing a minimum 
of 50% inhibition at 10 μM are tagged for secondary radioligand binding assays to determine 
equilibrium binding affinity at specific targets. In secondary binding assays, fractions are tested 
at 11 concentrations (0.1, 0.3, 1, 3, 10, 30, 100, 300 nM, 1, 3, 10 μM) and in triplicate (3 sets of 
96-well plates).  Radioactivity is counted in the same way as the primary assay.  The following 
radio-labeled and reference compounds were used for the receptors that underwent secondary 
screening: 5-HT1AR, [3H]-Way100635 and OH-DPAT; 5-HT7R, [3H]-LSD and clozapine; 
mGlurR5, [3H]-MPEP and fenobam; SERT, [3H]-citalopram and amitriptyline; NET, [3H]-
nesoxitine and desipramine.  Total binding and nonspecific binding are determined in the 
absence and presence of 10 μM of each reference compound and IC50 is the concentration at 
which 50% observed binding was inhibited. Ki values are calculated from best-fit IC50 values 
using the Cheng-Prusoff equation. 
 Microscopy: Samples of DUQ0002 used for microscopy were prepared using a piece of 
the sample stored in RNAlater solution.  Filaments were spread out onto a slide with distilled 
H2O and imaged at 20X on a (Nikon 1AR-HD) using the FITC (487 nm), TRITC (560nm) and 
Cy5 (637 nm) channels. 
 16S rRNA Gene Sequencing and Phylogenetic Analysis: Genomic DNA was extracted 
from DUQ0002 that was preserved in RNAlater® solution (Thermo Fisher) after collection 
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(GenBank Number: MH357345).  Lysis buffer (10 mM Tris, 0.1 M EDTA, 0.5% (w/v) SDS, 20 
μg/mL RNase, pH 8.0) was added to the cyanobacteria mass at 10X the biomass of the cells (i.e. 
100 mg cells = 1000 μL lysis buffer).  This was followed by 100 μL of lysozyme solution (10 
mg/mL, Sigma) for 30 minutes with an incubation at 37°C.  0.01X the volume of Proteinase K 
(10 mg/mL, Gene Link) was then added and incubated for 1 hr at 50°C.  Following this, the 
mixture was centrifuged at 13,000 rpm for 3 minutes and the remaining pellet was used with the 
Wizard Genomic DNA Purification Kit (Promega).  Extracted genomic DNA then underwent 
PCR to amplify the 16S rRNA gene with primers (CYA106F and CYA1509R) previously 
utilized (Nubel et al., 1997; Engene et al., 2010).  Successful PCR amplifications (~1370 bp) 
underwent PCR purification using the Min Elute PCR Purification Kit (Qiagen) and purified 
PCR products were used for TOPO cloning.  One Shot E. coli cells along with the pCR® 4-
TOPO vector with kanamycin resistance from the TOPO TA Cloning ® Kit (Invitrogen) were 
used and cells were plated overnight at 37°C on LB KAN plates.  Successful transformants were 
selected and used in colony PCR with the M13F and M13R primers to confirm the presence of 
the 16S rRNA sequence now in the TOPO vector (~1535 bp).  Purified PCR product for correct 
samples was sent to Beckman Coulter (now GENEWIZ) to undergo forward and reverse Sanger 
sequencing with the M13F and M13R primers.  Our sequence for DUQ0002, along with 16S 
rRNA gene sequences that were obtained with sequence data available at the National Center for 
Biotechnology (NCBI) webpage (http://www.ncbi.nlm.nih.gov) were then used for phylogenetic 
analysis.  Gene sequences were aligned using the Muscle algorithm and phylogeny 
reconstruction was done using maximum likelihood method with 500 bootstrap replicates using 
the MEGA (version 5.1) program (Hall, 2013). 
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 Animals: All animal procedures were reviewed and carried out in accordance with the 
National Institutes of Health Guide for the Care and Use of Animals and the Institutional Animal 
Care and Use Committee at Duquesne University.  Experiments were performed on either male 
or female C57Bl/6J mice that were 8–10 weeks old. For experiments using the SNI/sham model, 
animals were 8-10 weeks old when SNI/sham surgeries were completed, and all behavioral 
testing began 10 weeks after surgery.  For 5-HT7R knockout experiments, 8-10 week-old 5-
HT7R -/- (homozygote) mice and 5-HT7R +/+ (wildtype) sibling controls were used (Jackson 
Laboratories (Cat: 019453)).  Mice were previously backcrossed onto a C57Bl/6J line and were 
re-derived in C57 female mice.  The generation of this knockout strain has been described 
previously (Hedlund et al., 2003).  Briefly, the 5-HT7R gene was isolated from a library made 
from genomic DNA from strain 129/SvJ.  The neomycin expression cassette was inserted into 
exon II, at the 3’ end coding for a transmembrane domain.  A thymidine kinase expression 
cassette was attached to the 5’ end of the knockout construct so that non-homologous integrants 
could be selected against. Non-functional truncated 5-HT77R protein was verified.  The construct 
was transfected into 129Sv/Ev embryonic stem cells and cells in which one copy of the gene was 
inactivated by homologous recombination was isolated.  These cells were used to produce mice 
that gave germ-line transmission of the modified gene.  These animals were then bred with the 
C57Bl/6J strain and homozygotes were found to be viable and fertile.  Animals were individually 
housed and maintained on a 12h light/dark cycle (lights on between 7:00AM and 7:00PM) with 
ad libitum access to food and water.  All procedures were done during the light cycle.  All 
behaviors performed were recorded and analyzed by a male or female experimenter blinded to 
experimental treatments. 
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 Surgical Procedures: For cannulation surgeries, animals were anesthetized with 3% 
isoflurane/0.6% oxygen.  Intracerebroventricular (ICV) surgeries were done as described 
previously (Glascock et al., 2011) and CA1 bilateral cannulations were performed as 
subsequently described.  Briefly, mice were placed in a stereotaxic frame and steel cannulas (one 
8.00 mm for ICV and two 5.60 mm for CA1) were placed into the right lateral ventricle (ICV) or 
bilaterally into the CA1 region of the left and right hippocampus.  The following anatomical 
coordinates were used: ICV – 0.5 mm anterior to bregma, 1.0 mm lateral to midline and 2.0 mm 
ventral to the skull; CA1 – 1.6 mm anterior to bregma, 1.0 mm lateral to midline and 1.6 mm 
ventral to the skull.  A dental cement skullcap secured with two bone screws was used to hold 
cannulas in place.  Mice were allowed to recover on heating pads, housed in individual cages and 
were given one week of recovery prior to the beginning of behavioral testing.  Following all 
behavioral tests, cannula placement was verified with necropsy. For spared nerve injury (SNI), 
animals were anesthetized with 10:1 ketamine/xylazine mixture injected intraperitoneally into 
the mice (10 μL/g) and surgery was performed as described previously (Decosterd and Woolf, 
2000; Richner et al., 2011).  Briefly, a suture thread was tied around tibial and common peroneal 
branches of the sciatic nerve, both of which were ligated 2 mm distal to the suture. The sural 
branch of the sciatic nerve was not manipulated.  Sham surgeries followed the same procedure, 
without manipulation of the sciatic nerve. Mice recovered on heating pads and were group 
housed until cannulation surgeries were performed 9 weeks after SNI/sham. Mice were group 
housed after SNI surgery, but individually housed after cannulation surgeries to decrease the 
chance that skull-caps are lost. 
 Compound Preparation and Administration:  Cyanobacterial extracts were prepared as 
described previously (Lax et al., 2016).  Briefly, samples from collection DUQ0002, fraction I 
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(DUQ0002I), the known 5-HT7R antagonists SB258719 (SB258719 hydrochloride, Tocris) and 
SB269970 (SB269970 hydrochloride, Tocris) and subfractions isolated from the parent fraction 
(DUQ0002I-1A-C, 2-4) were dissolved in a mixture of 50% DMSO and 50% artificial 
cerebrospinal fluid (aCSF) containing the following (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 
25 NaHCO3, 2.0 CaCl2, 1.0 MgCl2 and 25 D-glucose, bubbled with 95% O2/5% CO2 for 20 
minutes. prior to use.  Previous analysis has shown no behavioral effect of this vehicle in mice 
compared to 100% aCSF (Lax et al., 2016).  Microinjections were performed using a 32-gauge 
injector that extended 0.5 mm beyond the tip of the ICV or CA1 cannulas.  The injector was 
attached to flexible tubing and a 1.0 μL syringe (Hamilton) that was used to deliver a total 
volume of 0.5 μL over a 2 minute period (two syringes, injectors and sets of tubing were used for 
bilateral CA1 injections; 0.5 μL per CA1).  The injectors were kept in place for one minute after 
the injections were complete to allow for complete compound infusion and all behaviors were 
conducted 5 minutes after compound administration. For all injections, fraction DUQ0002I and 
subfractions DUQ0002I-1A-C, DUQ0002-2-4 were administered at a dose of 40 μg per cannula 
and SB258719 was administered at a dose of 5 μg based on previously literature (Zhao et al., 
2014).  50%/50% aCSF/DMSO was used as a vehicle control in all experiments. 
Behavioral Testing:  For all behavioral tests, mice were habituated for 1-2 hours in the 
Bayer Hall Animal Care Facility room 103G, with 60 dB of white noise to block any ambient 
background noise.  Experimenters waited an additional 30 minutes after entering the room to 
begin behavioral testing due to the known effects of human pheromones on rodent behavior 
(Sorge et al., 2014).  For experiments with compounds, all animals received 
fraction/subfractions/drug (DUQ0002I, DUQ0002I-1A-C, DUQ0002-2-4, SB258719, SB26970) 
or vehicle 5 minutes prior to the beginning of testing unless otherwise indicated.  All compound 
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delivery was done blinded to fraction/drug versus vehicle delivered, surgery type (e.g. SNI vs 
sham, where applicable) and genotype (e.g. wild-type vs homozygous KO).  All behavioral 
testing and analysis of behavior was done blinded to treatment and/or surgery type and genotype.  
Forced Swim Test: The forced swim test was performed as described previously (Porsolt 
et al., 1977).  After mice were injected with compound or fraction via cannula, animals were 
returned to their home cages for five minutes.  After the five minutes, mice were placed in a 
beaker of water (~750 mL in a 1.0 L beaker, temperature 26 – 30°C – with temperature recorded 
at the beginning and end of test, while monitoring throughout), with all but their heads 
submerged.  Dirty water was replaced with clean water of the same temperature half way through 
the test.  Beakers with water were place on a raised platform.  The animals’ movements were 
recorded with a Logitech Pro 9000 webcam for scoring offline in one-minute long bins for a total 
of 6 minutes.  Two beakers were used so two animals could be tested at the same time.  
Immobility was defined as time when the mouse did not exhibit any outward movements or 
when it only exhibited only movements necessary to maintain buoyancy (i.e., one paw gently 
moving in water).   
Tail Suspension Test: The tail suspension test was performed as described in detail in 
Section 1, Chapter 1.  Briefly, mice were suspended by the distal ends of their tail in a Plexiglas 
enclosure (35 × 25 × 25 cm) with white sides. The animals’ movements were recorded with 
webcam for scoring offline in one-minute long bins for a total of 6 minutes.  Immobility was 
defined as time when the mouse did not exhibit any outward movement of its limbs or body.   
Elevated Zero Maze (EOM): The elevated zero maze was performed as described 
previously (Shepherd et al., 1994).  The test was performed in a dimly lit room (no overhead 
lights on, three desk lamps facing the corners of the room) with an IR light above the apparatus 
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in order to more easily track the animals in the low light.  After mice were injected with 
compound or fraction via cannula, animals were returned to their home cages for five minutes.  
After the five minutes, mice were placed on an elevated circular platform (50 cm off ground, 4.5 
cm wide platform, 63.5 cm diameter) with two ‘arms’ that are open, and two ‘arms’ that contain 
a high wall (walls are 16 cm high) enclosing the platform.  Animals were recorded with an over-
head videocamera (Logitech Pro 9000) and locomotion was tracked with ANY-maze software 
(Stoelting Co., version 4.98, Wood Dale, IL).  Time spent and distance traveled in the open and 
closed arm were recorded for the 10-minute long test.  Arms were removed and the maze was 
cleaned with Quatricide between animals. 
Light-Dark Preference (LDP) Test: The light-dark preference was performed as 
described previously (Crawley and Goodwin, 1980).  The test was performed in a dimly lit room 
(no overhead lights on, two desk lamps facing the corners of the room, one over the “light” side 
of the box).  After mice were injected with compound or fraction via cannula, animals were 
returned to their home cages for five minutes.  In this assay, a box (46 cm L x 27 cm W x 31 cm 
H) with a ‘dark’ and ‘light’ side that take up 1/3 and 2/3 of the box space respectively is used. A 
door (5 cm x 6 cm) separates the two regions.  After the five minutes in their home cage, first, 
mice are placed in the dark side with the lid on and door to the light side closed for one minute.  
After the one minute, the door is opened and animals were recorded with an over-head camera 
(Logitech Pro) and tracked with ANY-maze software (Stoelting Co., version 4.98, Wood Dale, 
IL).  Time spent and mean visit time to the light side was recorded for the 10-minute long test.  
The apparatus was cleaned with Quatricide between animals.  
Formalin Testing: Spontaneous pain-like behaviors were measured using the formalin 
test as described in detail in Section 1, Chapter 1 methods.  Briefly, mice were habituated in 
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clear, ventilated Plexiglas boxes (12 × 12 × 20 cm) for 2 h.  Five minutes after compound or 
vehicle injection, the animal received a 10 μL intradermal injection of 4% formalin into the right 
paw and was videotaped for 1 h followed by offline scoring.  The mice were analyzed for 
nocifensive behaviors (lifting, biting, lifting and flinching of the injected paw) in 5 minute bins. 
Tail-Flick Test: Thermal pain-like behaviors were measured via the tail-flick assay as 
described previously (Dewey et al., 1970).  After mice were injected with compound or fraction 
via cannula, animals were returned to their home cages for five minutes.  After the five-minute 
pretreatment, animals were placed in a conical tube with their tails exposed.  The distal third of 
the tail was inserted into a water bath heated to 45oC and the time to flick the tail was recorded.  
A cutoff time of 20 seconds was used to avoid burns.  
Hargreaves Test: Thermal pain-like behaviors were measured using the Hargreaves test 
as described previously (Hargreaves et al., 1988).  Mice were habituated in clear, ventilated 
Plexiglas boxes (12 × 12 × 20 cm) for 1 h on the glass surface of the Hargreaves apparatus, with 
opaque dividers between animals so they could not see each other.  A maximum of eight animals 
could be tested at once on the apparatus.  After mice were injected with compound or fraction via 
cannula, animals were returned to their enclosure for five minutes.  Five minutes after compound 
or vehicle injection, the animal’s latency to withdraw its paw (targeting the center of the foot 
pads on the planter surface) from the radiant light source generated by the Hargreaves machine 
was recorded.  Three trials were performed on each paw to generate an average withdraw 
latency.   
Mechanical Sensitivity Test: Mechanical sensitivity was measured with von Frey 
filaments (Touch Test) ranging from 0.02 – 2.56 g to determine the 50% withdrawal thresholds 
using the up/down method (Dixon, 1980; Chaplan et al., 1994). Animals were placed in Plexiglas 
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boxes, with opaque dividers between them, on a wire mesh surface for two hours prior to testing.  
A maximum of 12 animals could be tested at once.  Paw withdrawal was defined as a full lifting 
of the foot off of the wire-mesh surface when a filament was applied to the lateral edge of the 
paw (area innervated by the intact sural branch of sciatic nerve).  After two days of baseline 
testing before any treatments, where two up/measurements were taken per paw, animals were 
either given a 5-minute pretreatment with DUQ0002I or vehicle and additional measurements 
were taken at 5 minutes and two hours post injection or mice underwent SNI/sham surgery.  For 
testing with SB269970, animals were tested 14 weeks after surgery.  For the tests with 
DUQ0002I, one week after the surgery, mice were subjected to von Frey testing again to observe 
withdrawal thresholds.  Additional testing was done at two, three, five, six and ten weeks after 
surgery. 
Operant Plantar Thermal Assay (OPTA): Pain tolerance in order to receive a sucrose 
reward was measured using the operant plantar thermal assay (OPTA).  This novel cognitive 
pain assay was developed by Steve Davidson at the University of Cincinnati (Sammohi et al., 
2017).  Our OPTA apparatus and behavioral paradigm was developed based on his schematics.  
In this three-day assay, mice are placed on a two-plate thermal platform, where the temperature 
of each plate can be changed.  Plexiglass wall surround the platform and there is an open “door” 
separating the two thermal plates.  Each thermal plate also has a water bottle associated with it.  
On days one and two of the assay, both thermal plates are set to 30oC and one water bottle is left 
empty and the other is filled with 5% sucrose solution.  Mice are placed, one at a time, in the 
apparatus for 20 minutes where they learn the location of the sucrose water bottle.  On day three, 
mice are again placed in the apparatus, but now the sucrose bottle side is set to 45oC while the 
empty bottle side remains at 30oC.  Each day, the time spent in the zone around each bottle was 
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recorded with an over-head camera (Logitech Pro) and tracked with ANY-maze software 
(Stoelting Co., version 4.98, Wood Dale, IL).  Total time spent in the sucrose bottle zone is 
compared between groups to measure how much heat the animals are willing to tolerate to 
receive the learned sucrose reward. 
Conditioned Place Preference:  For spontaneous pain-like behavior, the analgesic 
conditioned place preference (aCPP) assay was used as previously described (Lax et al., 2014).  
Mice first underwent SNI surgery.  One week after the surgery, mice were subjected to the 5-day 
aCPP assay, with the addition of a pretreatment that allowed for the testing of long-lasting 
analgesic compounds.  In the aCPP assay, positive reinforcement is used to detect non-evoked 
spontaneous pain where animals learn to associate a visual cue with the positive effects of a drug 
(Tzschentke, 1998).  A detailed description of room setup and details can be found in Section 2, 
Chapter 1 methods, where this assay was used more extensively.  The assay uses a box with 
three different chambers: two outer chambers that differ only in the visual patterns on the wall 
(horizontal versus vertical black and white stripes) and a small neutral chamber connecting the 
two outer chambers.  On the first day of the aCPP experiment (known as Day One or “pre-
conditioning”), the mice are placed in the neutral chamber and allowed to roam free between all 
three chambers for 30 minutes. No drugs are given to the mice during this time. The total time 
that the animals spend in each chamber is recorded with an overhead camera.  On the next three 
days of the experiment (Days 2 – 4 or conditioning days), the mice receive a control vehicle 
injection (20 uL of saline) in the morning and are restricted to one of the outer chambers for 30 
minutes. In the afternoon, the mice then receive an injection of the short-term analgesic drug (20 
uL of 10 mg/kg SB269970) and are placed in the opposite outer chamber for 30 minutes.  
Finally, on the last day of the experiment (Day 5 or post-conditioning), the mice are placed with 
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no injection in the neutral chamber and allowed to roam free across the entire apparatus for 30 
minutes, this exposure being a repeat of the testing from Day One. The total time spent in each 
chamber is recorded using two overhead web-cameras (Logitech Webcam Pro 9000 and Canon 
ZR420) and AnyMaze software. Total times recorded on Day One are compared to those of Day 
5 to measure if a preference for the chambers developed. All behavioral testing was done blinded 
to treatment and surgery. 
 
Z-score analysis:  Z-scores were calculated for each animal in each behavior tested based 
on the published method (Guilloux et al., 2011) where applicable.  This method of analysis only 
works if each animal receives the same treatment across each behavioral experiment (this was 
not done during the initial screening with ICV injections and therefore this analysis was not done 
for those data).  From each parameter measured (X - time immobile for FST and TST, open arm 
time and percent distance traveled in open for EOM and time in light side and mean visit to light 
side for LDP), an individual Z-score (Z) was calculated to determine how many standard 
deviations (σ) each animal was above or below the mean of the control group (μ) using the 
following formula: Z = (X – μ) / σ.  Z-scores for individual parameters were then averaged to 
generate “depression” and “anxiety” emotionality scores.  With this type of analysis, the control 
group always has an overall Z-score of zero.  For the experimental groups, positive Z-scores 
reflect positive emotionality changes (i.e. antidepression or antianxiety), whereas negative Z-
scores reflect negative emotionality changes (i.e. depression, anxiety).  
Statistics: Graph Pad Prism version 5 for Mac OS X was used for all statistical analysis.  
All data are presented as mean ± SEM. Statistical significance was determined between groups 
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using un-paired t-tests or 2-ANOVAs followed by a Bonferroni post hoc test.  Statistical 
significance was established at a 95% confidence interval (p<0.05).  
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SUMMARY 
 
Marine cyanobacterial natural products provide a robust source in the search for new 
pharmacological agents. Due to the similarity of marine cyanobacterial secondary metabolites to 
endogenous GPCR ligands (Tan, 2007), these organisms are ideal candidates for screening at 
CNS targets for ligand discovery. In contrast to previous screenings that looked only at 
cannabinoid receptor ligands from cyanobacteria (Sitachitta and Gerwick, 1998; Han et al., 2003; 
Gutierrez et al., 2011; Montaser et al., 2012), our studies are the first to broadly screen 
cyanobacteria for GPCR ligands and other CNS targets. We were able to show that several 
fractions, including 2064H with affinity for the 5-HT2CR and a purified HPLC peak isolated 
from this fraction, 2064H3, and DUQ00021 with affinity for the 5-HT7R induced a series of 
behavioral effects in mice.  For 2064H, these effects included antidepressant-like effects in the 
tail suspension test, anxiolytic-like effects in the open field test, and an increase in pain-like 
behaviors in the formalin test.  Further characterization of this potentially interesting fraction, 
with attempting to block its effects with the known 5-HT2CR agonist CP809101, was not possible 
due to its degradation. 
For DUQ0002I, due to its stability in storage, a more thorough characterization was 
possible.  This fraction showed that broad CNS administration caused antidepressant-like effects 
in the forced swim test and anxiolytic-like effects in the elevated zero maze and light-dark-
preference tests.  With DUQ0002I, we also showed that the anti-depressant and anxiolytic-like 
effects were specific to male animals and that the extract was unable to induce these behaviors in 
5-HT7R knockout animals.  Along with these specificity studies, the characterization of the 5-
HT7R knockout animals compared to wildtype was initiated to show potentially interesting and 
previously un-described sex differences in depression, anxiety and pain assays.  Administration 
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of DUQ0002I to the CA1 of the hippocampus was found to be sufficient for inducing the anti-
depressant-like effects.  Our studies also suggest that DUQ0002I acts as a synergistic mixture of 
compounds responsible for inducing the behaviors that were found.  Finally, we showed how 
cyanobacterial natural products can be used for more than simply drug discovery.  After testing 
the SNI model of comorbid pain and depression, we showed that DUQ0002I is just as effective 
in reversing the depression-like effects in these animals as naïve animals.  Our results highlight 
the potential of cyanobacterial-derived compounds in CNS drug discovery and therapeutic leads 
in probing biological systems. 
 
FUTURE DIRECTIONS 
The results of the work conducted with cyanobacterial extracts related to serotonergic 
receptors has generated many future directions, both related to potential drug discovery leads and 
fundamental questions about serotonin biology discovered with these extracts.  With regard to 
the 5-HT2CR data, while fraction 2064H was a potentially interesting finding, due to its lack of 
stability and its degradation, further pursuits with this fraction are impossible without 
recollection.  While it may be possible to return to Panama based on the GPS coordinates and 
description of the collection, due to changing environments over the years since the original 
collection in 2011, it may be difficult to find the sample since it may not be growing in the same 
area any longer. The finding that certain compounds are unstable, however, could lead to 
changes in storage or collection techniques to ensure the compounds last as long as possible, or 
structure elucidation occurs prior to degradation.  Changes may include freezing samples instead 
of storing them at 4oC after compound extraction and taking voucher HPLCs monthly on each 
fraction to monitor for any potential issues.  Despite the dead end with 2064H, our pursuits with 
  140
other 5-HT2CR active fractions have led to other leads that merit further testing.  DUQ0008C 
could be further tested in other assays related to pain, depression and anxiety based on the trends 
in the open field data that were found during the initial characterization. This could lead to an 
entire series of experiments, similar to what was done with DUQ0002I, in order to learn more 
about 5-HT2CR biology related to pain, depression and anxiety.  Other insightful pieces of 
information were also learned about negative results that could be used in further studies.  
Mainly, discoveries of 5-HT2CR active fractions from the PDSP screening do not guarantee 
effects in behavioral assays.  This was true with DUQ000G and its subfractions, due to the 
different active compounds, with potentially very different structures found in each collection.  
Even though there are hits at the same receptor that indicates the compounds are ligands, they 
might induce very different responses at the receptor (some may be antagonists, some may be 
agonists).  In the future, it may be best to initially screen a large number of fractions that show 
activity at the 5-HT2CR (or any receptor of interest) and then pursue further studies with the 
fractions with the strongest effects. 
An even greater number of future experiments are possible based on the extensive 
characterization of the 5-HT7R that occurred with fraction DUQ0002I.  One of the biggest 
questions that remain about this fraction is the active compounds that are causing the behavioral 
effects.  Based on our testing of the four subfractions of DUQ0002I, we showed that none of 
these subfractions induces behavioral effects in isolation.  This suggests that a mixture of two or 
more active compounds are working together in the parent fraction to alter the behavior of the 
animals.  This sort of polypharmacology has been shown in other natural products, including the 
way that Texas coral snake toxin uses a heteromeric complex of Kunitz- and phospholipase-A2-
like proteins that act as a potent agonist for acid sensing ion channels (Bohlen et al., 2011)  
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Future studies could possibly test the four subfractions in combination to determine which 
combinations induce effects.  This information could be used to then find what the compounds 
are, and possibly isolate the individual compounds that are working together. 
Further testing of DUQ0002I in different areas are also a possible future lead to look for 
more anatomical characterization of the fraction.  While the antidepression-like effects were 
shown to be caused by injection into the CA1 of the hippocampus, it is still unknown what areas 
of the brain are causing the anxiolytic-like effects that were found with males.  Injections of 
DUQ0002I into the amygdala could be an area to be targeted since its one of the regions known 
to be involved with anxiety and fear (Adhikari et al., 2015) and 5-HT7R are expressed there 
(Bonaventure et al., 2004).   Another area to target would be the spinal cord, with intrathecal 
injections.  This is the administration route where we would most likely see changes in pain-like 
behaviors since many studies have shown that targeting the 5-HT7R in the spinal cord changes 
pain-like behaviors (Rocha-Gonzalez et al., 2005; Godinez-Chaparro et al., 2011; Liu et al., 
2013).  Future testing via these different administration routes could provide more into where 
and how DUQ0002I is working to alter behavior.   Moreover, additional chronic behavioral tests 
could be conducted since thus far only acute tests have been used for characterization.  Those 
types of assays might be an important addition for future screening of DUQ0002I as well as 
other fractions. 
Our data also have shown that there is a possible fundamental difference in the way that 
the 5-HT7R works in depression and pain in males compared to females. Together, the lack of 
antidepression-like effects with DUQ0002I in females and the preliminary differences between 
the sexes found in the knockout studies warrant further investigation. One aspect of this 
difference could be the influence of gonadal hormones on sex differences. Hormones can have 
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both organizational (i.e. developmental) and activational (i.e. transcriptional or rapid cell-
signaling effects in adulthood) influences. Bilateral gonadectomies (or sham surgeries) in both 
male and female mice (orchidectomy/castration in male; oophorectomy/ovariectomy in females) 
could be conducted to evaluate the efficacy of DUQ0002I in the depression and anxiety assays.  
Here, we would predict that the effects of DUQ0002I in baseline sham surgery mice will be the 
same as the existing data set from naïve mice (i.e. effects in male mice with no effects in female 
mice).  The results of DUQ0002I in the gonadectomized males and females will allow us to 
determine if androgens or estrogens either activate or inhibit the anti-depression/anxiolytic 
effects of DUQ0002I.  We would predict that since estrogens are known to interfere with the 
effects of antidepressants (Keers and Aitchison, 2010), gonadectomized females would show the 
same antidepression-like effects as the males with DUQ0002I administration.  In addition, with 
the knockout animals, some interesting trends were found between genotypes and males and 
females.  With the low number of animals per group, especially with the females, additional 
animals need to be tested in the same assays, in the same order, to determine if any of these 
trends are real effects and to make more definitive conclusions.   
Further molecular testing could provide some interesting insights to compliment the 
behavioral data.  One thing that is unknown about the 5-HT7R is whether or not there is a change 
in 5-HT7R expression in the SNI model or whether or not there are differences in expression 
between males and females.  Future testing could involve performing SNI and sham surgeries 
and measuring how 5-HT7R expression changes up to the 10-week post-surgery time point 
(when significant depression-like behavioral effects were found in SNI animals compared to 
sham) using a 5-HT7R antibody and a Western blot.  Similar expression studies using Western 
blot analysis could also be done between naïve male and female animals.  One last 
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complimentary piece of data that could potentially be helpful would be 5-HT7R expression 
studies using immunohistochemistry in wild-type and knockout animals to see the receptor 
expression in areas like the hippocampus (the region where DUQ0002I was injected to induce 
anti-depression-like effects). 
Finally, the results of our phylogenetic analyses could lead to future studies focusing on 
collecting species of cyanobacteria from either the Leptolynbya or Okeania genera.  Initial 
collections of cyanobacteria in both Panama and Curacao (data not shown) simply collected all 
cyanobacteria where enough biomass for extraction was likely.  Future collections could be more 
guided, focusing on areas where these genera are found or looking into environments similar to 
the conditions where DUQ0002 or 2064 were collected.  A similar environment could lead 
convergent evolution, which may cause the production of similar compounds (or compounds 
with similar effects) if the same herbivores and other ecological threats are present.  Our results 
show the vast potential of marine cyanobacteria in the field of marine pharmacognosy. 
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Section 2 
Chapter 1 
The role of the mGluR5 antagonist fenobam in ongoing spontaneous 
chronic pain 
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The majority of the text contained within this chapter is adapted from the following publication: 
Lax NC, George DC, Ignatz CM, Kolber BJ. 2014. The mGluR5 antagonist fenobam induces 
analgesic conditioned place preference in mice with spared nerve injury. PLoS ONE 9(7): 
e103524. 
 
David George performed experiments in Figures 30 and 32 and completed initial pilot 
experiments for setting up the conditioned place preference and fenobam testing in the 
conditioned place preference assay. 
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ABSTRACT 
 
Antagonists of metabotropic glutamate receptors (mGluRs) have the potential to act as 
analgesic drugs that may help alleviate chronic pain.  This study was done to look at the possible 
rewarding properties of the mGluR5 antagonist, fenobam, in a cognitive assay.  Analgesic 
conditioned place preference (aCPP) was used to examine the effects of the repurposed drug, 
fenobam (30 mg/kg) and the prototypical mGluR5 antagonist, MPEP, and these effects were 
compared to those of a drug with known analgesic properties, morphine (10 mg/kg).  In each 
experiment, one group of mice received spared nerve injury (SNI) surgery to model chronic pain; 
the other group received a control sham surgery.  Both fenobam and MPEP induced preference 
in the SNI mice, such that SNI mice spent significantly more time in the mGluR5 antagonist-
paired chamber compared to a vehicle-paired chamber.  No such preference developed for sham 
mice.  Morphine induced preference in male and female mice in both the SNI and sham groups.  
The results showed that fenobam and MPEP likely reduced on-going distress in the SNI mice, 
causing them to prefer the chamber paired with the drug compared to the vehicle-paired 
chamber.  Since sham animals did not prefer the drug-paired chamber, these data demonstrate 
that mGluR5 antagonism is non-rewarding in the absence of pain-like injury. 
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INTRODUCTION 
Over 100 million people in the United States suffer from chronic pain at some point in 
their lifetimes, making this one of the most widespread of medical conditions (Butler et al., 
2011a).  Despite the prevalence of chronic pain, options are limited for patients seeking 
treatment.  Non-steroidal anti-inflammatory drugs (NSAIDs) and opioid drugs, such as 
morphine, remain the most commonly prescribed medications for chronic pain sufferers (Ingham 
and Portenoy, 1993).  These drugs, which can have deleterious side effects, often do not work for 
patients (Fries et al., 2006; Benyamin et al., 2008; Ng and Chan, 2010).  Recently, metabotropic 
glutamate receptor 5 (mGluR5) has emerged as a potential new target in the treatment of chronic 
pain.   
mGluR5 is a G-protein coupled receptor localized to regions of the periphery, spinal cord 
and brain involved with the processing of pain (Shigemoto R, 1993; Valerio et al., 1997; 
Neugebauer et al., 2004).  Activation of mGluR5 receptors in the spinal cord and amygdala, 
using (R,S)-3,5-dihydroxyphenylglycine (DHPG), causes pain-like behaviors in mice, while 
inhibition with the prototypical antagonist, 2-methyl-6-(phenylethynyl)pyridine hydrochloride 
(MPEP), decreases these responses (Fisher and Coderre, 1996; Kolber et al., 2010a).  However, 
non-specific effects of MPEP have led to the search for more specific mGluR5 agents, such as 
fenobam [N-(3-chlorophenyl)-N’-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea] 
(Montana et al., 2009).  Fenobam was first developed in the 1970s as an anxiolytic drug 
(LaPierre and Oyewumi, 1982), but was later found to be a specific noncompetitive antagonist of 
mGluR5 (Porter et al., 2005).  Fenobam, when compared to MPEP, is more selective for 
mGluR5, where fenobam does not induce any analgesic-like effects in mGluR5 knockout 
animals, but MPEP does (Montana et al., 2009).  Using models of inflammatory pain, such as the 
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Complete Freund’s Adjuvant (CFA) and formalin tests, fenobam acts as an effective analgesic-
like agent at 30 mg/kg (Montana et al., 2009).  In animals, fenobam has a good safety profile and 
there is no evidence for the development of long-term tolerance in mice (Montana et al., 2011).  
The action of fenobam has only been demonstrated in classic acute reactive pain tests in which 
nocifensive responses are directly induced by an experimenter.  It remains unclear if fenobam 
relieves on-going spontaneous chronic pain or affects naïve animals.  Additionally, only male 
mice have been studied in the context of fenobam treatment.   It is important to consider the 
effects of fenobam in both sexes since more women are reported to suffer from chronic pain than 
men (Mogil, 2012) and since there are sex differences in degrees of pain and analgesia (Craft et 
al., 2004; Paller et al., 2009).  
Given the clinical potential of fenobam, we tested if fenobam would induce place 
preference in the context of neuropathic injury, a chronic pain pathology.  We also determined if 
the effects of fenobam were coupled with the rewarding properties in the absence of any 
discomfort. This is an unwanted side-effect of some commonly used pain-relieving families such 
as agonists of the mu opioid receptor.  Spared Nerve Injury (SNI), a model of spontaneous 
chronic neuropathic pain (Richner et al., 2011), was used in conjunction with the analgesic 
Conditioned Place Preference (aCPP) assay, similar to the CPP assay described above in Section 
1 of this dissertation.  SNI has been shown repeatedly to induce mechanical hypersensitivity in 
the affected limb for up to nine weeks post-surgery (Decosterd and Woolf, 2000; Bourquin et al., 
2006; Richner et al., 2011).  Conditioned place preference has been widely used to test the 
rewarding and addictive potentials of numerous drugs (Tzschentke, 1998).  A new variant of this 
assay, aCPP, utilizes positive reinforcement to detect and treat non-evoked spontaneous pain.  In 
the aCPP assay, animals learn to associate a physical visual cue with the effects of a particular 
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drug.  Using this assay, rats and mice with Spared Nerve Ligation (SNL) or Complete Freund’s 
Adjuvant (CFA) injury developed a preference for clonidine (mice and rats) (King et al., 2009), 
omega conotoxin (rats) (King et al., 2009), or lidocaine (mice) (He et al., 2012), drugs known to 
alleviate pain in humans (Tryba and Gehling, 2002; Xia et al., 2006).  In these studies, animals 
with sham injuries (and therefore no hypersensitivity) showed no place preference.  We 
hypothesized that fenobam, based on its molecular target and known effects, could produce 
aCPP in mice with SNI.  Subsequently, we wanted to compare the fenobam results to results 
obtained with morphine, which induces analgesia, but which also induces euphoria and addiction 
in uninjured humans (Corbett et al., 2006).  
 
RESULTS 
Balancing of the aCPP Apparatus 
  
 Using custom aCPP boxes, we first determined what the best room setup and physical 
context of the two pairing chambers of the aCPP box were for the area where behavioral testing 
would be conducted. CPP boxes include two main testing chambers separated by a small hallway 
(“neutral” chamber).  There are five days total of testing – one day of baseline testing where 
animals have access to all three chambers, three days of conditioning, with vehicle 
administration in one of the outer chamber and drug administration in the opposite outer chamber 
(neutral chamber closed) and a final day of testing where animals have access to all three 
chambers again (see picture of apparatus and timeline in Figure 27).  
  151
   Figure 27. Diagram of CPP box and timeline of typical experiment. CPP apparatus image 
comes from Stoelting Co. 
 
During conditioning, animals learn to associate a treatment (e.g. delivery of a drug) with 
the physical characteristics of the two chambers. In the field, different types of cues are used to 
help mice (or rats) distinguish between physical spaces. These can include visual cues like we 
use with the patterns of the walls, or tactile cue from the flooring material or olfactory cues from 
smells placed in the different chambers. We chose to use a standard bedding in both chambers 
and used different patterns on the walls of the chambers without any smells.  In order to make 
our patterns distinguishable yet similar, we first chose to use stripes of different orientations.  
Starting with horizontal stripes in one chamber, and diagonal stripes in the other, male naïve 
mice (n=8) were placed in the aCPP boxes with access to all three chambers for 30 minutes.  The 
total amount of time that animals spent in each chamber was analyzed to determine if there was 
any pre-conditioning bias.  We found that animals spent significantly more time in the side with 
diagonal stripes compared to horizontal stripes (Diagonal Stripes Time = 747.5 ± 33.17 sec, 
Horizontal Stripes Time = 611.6 ± 26.38 sec, paired t-test, *p=0.0378).  This is bad because we 
would be unable to measure an animal’s development of preference for a drug or compound if it 
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already has a bias before drug administration.   Modifying the patterns, we then tested another 
group of naïve male mice with vertical stripes compared to diagonal stripes in the aCPP 
chamber.  We found no preconditioning bias with these patterns (Diagonal Stripes Time = 698.3 
± 40.08 sec, Vertical Stripes Time = 776.9 ± 42.92 sec, paired t-test, p=0.3708).  Based on these 
results, the vertical and diagonal striped designs were used for all behavioral testing with the 
aCPP box. 
 
aCPP with Fenobam in Male Mice 
Using the aCPP assay, we first evaluated the analgesic effect of fenobam (Figure 28A) at 
30mg/kg in male mice with SNI surgery (n=15) compared to male mice with a control sham 
surgery (n=15).  Baseline data for the time and distance traveled during 30 minute trials in the 
aCPP apparatus was collected on preconditioning day 1. SNI injury is associated with behavioral 
hypersensitivity (Richner et al., 2011) and impaired movement due to loss of sensory and motor 
neurons, respectively.  Thus, we compared the total distance traveled by sham and SNI animals 
on pre-conditioning day 1 in an attempt to see if either group showed a reduction in locomotor 
output.  Comparing the overall distance traveled in both of the large outer chambers, we failed to 
find a statistically significant difference between SNI and sham operated mice (Figure 28B; un-
paired t-test, p=0.9246).   
Following day 1, vehicle (100% DMSO) and fenobam were paired with their own 
respective chambers on conditioning days 2-4.  During this time, the mice were conditioned to 
associate the effects of the vehicle control with one of the outer chambers and the effects of 
fenobam with the other outer chamber.  On each of the conditioning days, the total distance 
traveled in the vehicle-paired chamber was recorded in the morning, and the total distance 
traveled in the fenobam-paired chamber was recorded in the afternoon.  We found that both SNI 
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and sham groups traveled significantly more after administration of the fenobam compared to 
administration of the vehicle on day 2 (Figure 28C; 2-way ANOVA, significant main effect of 
treatment, Bonferroni post-hoc test, p<0.01) and day 3 (Figure 28D; 2-way ANOVA, significant 
main effect of treatment, Bonferroni post-hoc test, p<0.001).  However, no statistically 
significant hypermobility was found on day 4 in either group of mice (Figure 28E; 2-way 
ANOVA, no significant main effect of treatment, p>0.05).  
 
Figure 28. Male SNI and sham mice travel similar distances and show tolerance to 
locomotor side-effects. (A) Chemical structure of fenobam.  (B) SNI (n=15) and sham (n=15) 
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mice travel a similar distance in both outer chambers of the aCPP apparatus on preconditioning 
day 1.  (C) On conditioning day 2 and (D) conditioning day 3, both SNI and sham mice are 
hyperactive when treated with fenobam.  Mice were restricted to only one of the outer chambers 
when these measurements were taken. (E) However, by day 4, neither group of mice show 
increased distance traveled in the fenobam chamber compared to the vehicle-paired chamber.  
Two-way ANOVA followed by Bonferroni post hoc test, **p<0.01, ***p<0.001.  Chemical 
structure derived from Sigma-Aldrich.  NL – conducted experiment.  NL, BK – designed 
experiment. 
 
On post-conditioning day 5, mice were exposed again to the entire apparatus (i.e. all three 
chambers) for 30 minutes.    By comparing the times spent in each chamber on day 5 to day 1, it 
was possible to see if preferences for the chambers changed after the three days of pairing.  We 
used two methods of analysis to look for preference for the fenobam chamber in SNI or sham 
mice.  First, we directly compared the time spent in the fenobam-paired chamber on day 5 to the 
time spent in the DMSO-paired chamber on day 5.  Indicative of a preference for fenobam, SNI 
mice spent more time in the fenobam-paired chamber compared to the DMSO-paired chamber 
on day 5 (Figure 29A; paired t-test, p=0.0084).  In contrast, sham mice did not show an increase 
in time spent in the fenobam chamber compared to the DMSO-paired chamber on day 5 (Figure 
29B; paired t-test, p=0.409).  Second, we accounted for small individual baseline biases by 
calculating the difference in time spent in each chamber (e.g. fenobam-paired chamber, vehicle-
paired chamber) on day 1 compared to day 5.  We found that SNI mice spent more time in the 
fenobam-paired chamber (day 5 minus day 1) than the DMSO-paired chamber (day 5 minus day 
1) (Figure 29C, paired t-test, p=0.033).  In contrast, sham-operated mice did not show a 
significant difference between the time spent in the fenobam-paired chamber, compared to the 
DMSO-paired chamber (Figure 29D; paired t-test, p=0.097).  
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       Figure 29. Fenobam induces place preference in male SNI mice only. (A) SNI mice (n=15) 
spent significantly more total time in the fenobam-paired chamber compared to vehicle-paired 
chamber on post-conditioning day 5.  (B) Sham mice (n=15) show no difference in the total 
amount of time spent in fenobam and vehicle-paired chamber on post-conditioning day 5.  (C) 
SNI mice increase the amount of time they spent in the fenobam-paired chamber on day 5 (post-
conditioning) compared to baseline (day 1 pre-conditioning) while (D) sham mice show no such 
difference. Paired t-test, *p<0.05, **p<0.01.  NL – conducted experiment.  NL, BK – designed 
experiment. 
 
aCPP with Fenobam in Female Mice 
Since there are significant reported gender differences in chronic pain conditions and 
treatment (Craft et al., 2004; Paller et al., 2009; Mogil, 2012), we next tested if fenobam would 
induce similar conditioning in female SNI mice.  We found no difference between SNI and sham 
mice in the total distance traveled on day 1 (Sham mice = 79.60 ± 6.617m, SNI mice = 69.52 ± 
7.135m, un-paired t-test, p=0.312).  Analysis of preference data on day 5 showed similar results 
to those seen in male mice; female SNI mice (n=10) spent more time in the fenobam-paired 
chamber than the DMSO-paired chamber on day 5 (Figure 30A; paired t-test, ***p=0.006).  For 
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the sham-treated female mice (n=11), there was no preference for the fenobam-paired chamber 
over the DMSO-paired chamber on day 5 (Figure 30B; paired t-test, p=0.409).  When day 5 data 
was compared to day 1, we saw that SNI mice spent more time (day 5 minus day 1) in the 
fenobam-paired chamber than the DMSO-paired chamber (Figure 30C; paired t-test, *p=0.012).  
Conversely, sham treated mice showed no significant increase in the time spent in the fenobam-
paired chamber when compared to the DMSO-paired chamber (Figure 30D; paired t-test, 
p=0.656).   
          
Figure 30. Fenobam induces place preference in female SNI mice only. (A) SNI mice (n=10) 
spent significantly more total time in the fenobam-paired chamber compared to vehicle-paired 
chamber on post-conditioning day 5. (B) Sham mice (n=11) show no difference in the total 
amount of time spent in fenobam and vehicle-paired chamber on post-conditioning day 5. (C) 
SNI mice increase the amount of time they spend in the fenobam-paired chamber on day 5 (post-
conditioning) compared to baseline (day 1 pre-conditioning) while (D) sham mice show no such 
difference.  Paired t-test, *p<0.05, **p<0.01. DG – conducted experiment.  NL, DG, BK – 
designed experiment. 
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aCPP with MPEP in Male Mice 
In order to confirm that the preference induced by fenobam in the SNI mice was due to 
antagonism of mGluR5 and not a confound of using DMSO as the vehicle, an additional set of 
aCPP trials were performed using the prototypical mGluR5 antagonist MPEP with a saline 
vehicle.  We hypothesized that the same preference would be induced in the SNI mice, while not 
affecting the sham control mice.  In this experiment, the same aCPP assay was used, but MPEP 
(30 mg/kg) and saline (0.9%) were substituted for fenobam and DMSO respectively on days 2-4 
of testing.  Analysis of the preference data on day 5 replicated the aCPP results that were 
obtained with fenobam; male SNI mice (n=8) spent more time in the MPEP-paired chamber than 
the saline-paired chamber on day 5 (Figure 31A; paired t-test, p=0.0372).   For the sham mice 
(n=8), no preference developed for the MPEP-paired chamber over the saline-paired chamber on 
day 5 (Figure 31B; paired t-test, p=0.2344).  In the same manner that was seen with the fenobam 
data, when day 5 data was compared to day 1, we saw that SNI mice spent more time (day 5 
minus day 1) in the MPEP-paired chamber than the saline-paired chamber (Figure 31C; paired t-
test, p=0.0065).  Sham mice did not increase the time that they spent in the MPEP-paired 
chamber when compared to the saline-paired chamber (Figure 31D, paired t-test, p=0.8092). 
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Figure 31.  MPEP induces place preference in male SNI mice only. (A) SNI mice (n=8) spent 
significantly more total time in the MPEP-paired chamber compared to vehicle-paired chamber 
on post-conditioning day 5. (B) Sham mice (n=8) show no difference in the total amount of time 
spent in MPEP and vehicle-paired chamber on post-conditioning day 5. (C) SNI mice increase 
the amount of time they spend in the MPEP-paired chamber on day 5 (post-conditioning) 
compared to baseline (day 1 pre-conditioning) while (D) sham mice show no such difference.  
Paired t-test, *p<0.05, **p<0.01. NL – conducted experiment.  NL, BK – designed experiment. 
 
aCPP with Morphine in Male Mice 
Having demonstrated that fenobam induced preference in male and female mice with SNI 
but not in sham-operated mice, we next examined the effect of morphine in the aCPP assay, 
hypothesizing that all mice, regardless of surgery type, would show conditioned place preference 
for the drug.  This experiment is essentially a positive control for the self-reinforcing and 
unwanted side-effect properties of morphine treatment. The same aCPP assay was used, but 
morphine (10 mg/kg) and saline (0.9%) were substituted for fenobam and DMSO respectively on 
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days 2-4 of testing.  Different vehicle solvents were needed to dissolve morphine compared to 
fenobam.  
         
Figure 32. Morphine induces place preference in all male mice. (A) SNI mice (n=9) spend 
significantly more total time in the morphine-paired chamber compared to vehicle-paired 
chamber on post-conditioning day 5. (B) Sham mice (n=15) showed a similar significant 
preference. (C) SNI mice increase the amount of time they spent in the morphine-paired chamber 
on day 5 (post-conditioning) compared to baseline (day 1 pre-conditioning) while (D) sham mice 
showed a similar significant preference.  Paired t-test, *p<0.05, **p<0.01.  DG – conducted 
experiment.  NL, DG, BK – designed experiment. 
 
 We tested the effects of morphine in the aCPP assay in SNI and sham-operated mice.  We 
looked at the total time spent in both the vehicle-paired chamber and the morphine-paired 
chamber on day 5, following three days of drug-pairing.  Both SNI mice (n=9) (Figure 32A; 
paired t-test, **p=0.002) and sham mice (n=15) (Figure 32B; paired t-test, **p=0.009) spent 
more total time in the morphine-paired chamber than the vehicle-paired chamber on day 5.  Next, 
we compared the time spent in each of the chambers on day 5 and day 1.  Both SNI and sham 
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mice spent more time in the morphine-paired chamber on day 5 (compared to day 1), while 
simultaneously decreasing the time spent in the saline-paired chamber (SNI Figure 32C, paired 
t-test, **p=0.002; sham Figure 32D, paired t-test, *p=0.011).  Overall, when using morphine, 
preference was induced in both SNI and sham male mice.   
        Figure 33.  Morphine induces place preference in all female mice. (A) SNI mice (n=5) spend 
significantly more total time in the morphine-paired chamber compared to vehicle-paired 
chamber on post-conditioning day 5. (B) Sham mice (n=6) show a similar significant preference. 
(C) SNI mice increase the amount of time they spent in the morphine-paired chamber on day 5 
(post-conditioning) compared to baseline (day 1 pre-conditioning). (D) Sham mice show a 
similar significant preference.  Paired t-test, *p<0.05, **p<0.01, ***p<0.001.  NL – conducted 
experiment.  NL, BK – designed experiment. 
 
aCPP with Morphine in Female Mice 
Having demonstrated that morphine can induce conditioned place preference in male 
mice following three days of drug pairing, regardless of surgery treatment, next we tested the 
effect of morphine in female SNI and sham-operated mice.  Both SNI (n=5) (Figure 33A; paired 
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t-test, **p=0.001) and sham (n=6) (Figure 33B; paired t-test, *p=0.014) mice spent more total 
time in the morphine-paired chamber compared to the vehicle-paired chamber on day 5.  We also 
compared the total amount of time spent in each chamber on day 5 compared to day 1 for both 
groups of mice.  Again, similar to male mice, both SNI and sham female mice exhibited an 
increase in the time spent in the morphine-paired chamber on day 5 compared to day 1, along 
with a significant decrease in the time spent in the vehicle-paired chamber (SNI Figure 33C, 
paired t-test, **p=0.001; sham Figure 33D, paired t-test, **p=0.001).  Overall, these data 
mirrored the results seen in males, with all mice spending more time in the side of the aCPP 
apparatus paired with morphine, regardless of surgery treatment.  
 
DISCUSSION 
mGluR5 has recently emerged as a potentially important target in pre-clinical reflexive 
and experimenter-induced pain assays and also may be a target for the development of new 
analgesic drugs.  This is the first study that has looked at the benefit of fenobam or any other 
mGluR5 antagonist in models of on-going chronic pain-like behavior, but since then, others have 
replicated our results (Vincent et al., 2016).  Here, for the first time, we show that mGluR5 
inhibition induces conditioned preference in animals with a chronic neuropathic injury.  
Furthermore, we show that fenobam and MPEP do not induce preference in sham mice.  These 
data indicate that in the absence of pain-like injury, inhibition of mGluR5 is unlikely to have 
reinforcing properties on its own, a desirable quality for potential therapeutics.  The injury-
specific effects of fenobam and MPEP are in contrast to the non-specific effects of morphine 
seen in our studies. Morphine induces CPP in all mice regardless of injury status.  
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 Fenobam was first developed as an anxiolytic drug by McNeil Laboratories (Porter et al., 
2005).  Initially, it was shown to be effective in animal models of anxiety (Pecknold et al., 1982).  
In human clinical trials, it was nearly as effective as the anxiolytic diazepam (Pecknold et al., 
1982).  Fenobam eventually entered Phase II outpatient trials, but additional development ceased 
due to psychostimulant side-effects present at high doses (300 to 600 mg per patient) of the drug 
(Friedmann et al., 1980).  More recently, fenobam was found to act as an antagonist of mGluR5 
(Porter et al., 2005).  With regards to specificity, fenobam is more selective for the mGluR5 
receptor compared to MPEP since it has been shown that MPEP still has analgesic-like effects in 
the formalin test when mGluR5 knock-out mice are used (Montana et al., 2009).  Regardless, 
data from the last 20 years suggests that mGluR5 plays an important role in the regulation of 
pain (Chiechio and Nicoletti, 2012). Expression and activity of the receptor is implicated at 
numerous levels of the pain neuroaxis (Zhu et al., 2005), including the periphery (Bhave et al., 
2001), the spinal cord (Jia et al., 1999) and the amygdala (Li and Neugebauer, 2004; Crock et al., 
2012a).  Following the administration of intraperitoneally-delivered fenobam, the drug rapidly 
moves into the brain and is metabolized within one hour in mice (Montana et al., 2009).  While 
the rapid break down of fenobam is not ideal from a pharmacokinetic perspective, modification 
to its chemical structure could potentially lead to slower metabolism and extended effects.  
Recently, it was shown that the mGluR5 antagonist (AZD9272) did not reduce pain in healthy 
male controls (Kalliomaki et al., 2013).  While this result is not supportive of mGluR5 in the 
modulation of control models of human pain, it does not necessarily indicate that all mGluR5 
antagonists would be ineffective. AZD9272 is known to act centrally (Kalliomaki et al., 2013); 
in our studies, fenobam may be acting both in the periphery and in the central nervous system, 
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but this is unknown at this time.  Future studies with peripherally restricted antagonists would be 
of interest to limit any potential for central side-effects.   
In a number of classic pain assays, both fenobam and MPEP have proven to reduce pain-
like behaviors (Osikowicz et al., 2008; Montana et al., 2009). However, classic inflammatory 
reflexive or experimenter-evoked (e.g. mechanical von Frey) models of persistent or acute pain 
to test novel analgesic compounds may be problematic.  In particular, the predictive nature of 
these assays for efficacy in human clinical trials has been called into question (Blackburn-
Munro, 2004).  Recently, a number of groups have validated a modified version of the 
conditioned place preference, aCPP, in the post hoc analysis of known human analgesic agents 
(King et al., 2009; He et al., 2012; Woller et al., 2012).  aCPP is an important new variation on 
the classic conditioned place preference that has been used for over 30 years to study drugs of 
abuse (Tzschentke, 1998).  In the aCPP model, animals receive a nociceptive injury prior to 
testing.  Next, pairing with known or unknown analgesic agents occurs.  Animals develop a 
preference for the drug-paired chamber only if they receive relief from on-going or spontaneous 
nociception or other negative stimulation (e.g. anxiety).  Other groups have shown that both 
mGluR1 antagonism via intra-VTA microinjections of the mGluR1 antagonist JNJ16259685 and 
protein synthesis inhibitor cycloheximide significantly attenuated or blocked the acquisition of 
cocaine-induced conditioned place preference (CPP) in rats (Yu et al., 2013a).  Similarly, others 
have found that mGluR5 antagonism with MPEP blocks morphine CPP in mice (Popik and 
Wrobel, 2002) and meth-CPP in rats (Herrold et al., 2013).  Here, we show for the first time that 
systemic mGluR5 inhibition with fenobam or MPEP induces aCPP only in the context of a 
neuropathic injury, SNI.  Both male and female SNI-operated mice developed a preference for 
the chamber paired with the mGluR5 antagonist.  SNI mice spend a greater amount of time in the 
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mGluR5 antagonist-paired chamber, compared to the vehicle chamber on day 5.  In addition to 
this, there is also a significant increase in the time spent in the mGluR5 antagonist chamber on 
day 5 (post-conditioning) compared to the baseline day 1 (pre-conditioning).  In contrast, male 
and female sham-operated mice show no statistically significant differences in the amount of 
time spent in the mGluR5 antagonist-paired chamber, when compared to the vehicle-paired 
chamber.  These data suggest that mGluR5 antagonism is rewarding only in the context of SNI 
and that the rewarding effect may be caused by analgesia.  The failure of both fenobam and 
MPEP to induce statistically significant preference in sham animals indicates that these drugs 
have a low potential for rewarding or deleterious effects in the absence of injury.  In addition, 
this also highlights the value of aCPP as a screening paradigm.  Avoiding agents that induce 
preference in naïve or sham-operated mice may reduce the chance of addiction in humans. 
One additional aspect addressed in our studies is the fact that fenobam was able to 
produce preference in both male and female mice.  This is important because there are many 
differences in pain condition prevalence between men and women (Munce and Stewart, 2007).  
For example, fibromyalgia (Wolfe et al., 1995) and interstitial cystitis (Clemens et al., 2005) 
have been found to be much more prevalent in women compared to men.  Despite this, many 
basic science studies only test male animals, neglecting the potential differences that could be 
found with females (Beery and Zucker, 2011).  It is important to include both groups in studies 
in order to determine if the effects can be replicated in both men and women.  Here, we failed to 
find any sex differences with either fenobam or morphine aCPP.  This suggests that mGluR5 
antagonism with fenobam may be an effective strategy to broadly treat pain in both sexes. 
 Although the aCPP model represents an important step forward as a pain assay, it does 
not distinguish between analgesic effects of a drug versus affective effects.  For example, chronic 
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pain is associated with comorbid depression and anxiety (Bair et al., 2003) and treatment with 
psychotherapy (pharmacological or non-pharmacological) can be beneficial to some patients.  
Mice (Fisher and Coderre, 1996; Mutso et al., 2012) and rats (Blackburn-Munro, 2004; 
Gonçalves et al., 2008) exhibit some comorbid depression/anxiety-like behavior with SNI.  Thus, 
from the aCPP assay, it is not entirely clear whether fenobam induces place preference because it 
is reducing on-going pain or anxiety associated with SNI.  Notably, mGluR5 antagonists like 
fenobam are known to have anxiolytic-like effects in the Vogel conflict test, Geller-Seifter test, 
conditioned emotional response, EOM and context freezing tests at the same dose tested in our 
study (Porter et al., 2005; Jacob et al., 2009; Montana et al., 2011).  Although we cannot 
differentiate between these two hypotheses, from a clinical standpoint, it may be sufficient to get 
relief from any negative stimulation, whether that stimulus is primarily nociceptive or primarily 
anxiogenic stimulation. 
As described above, human clinical trials for fenobam were stopped in part because of 
observed psychostimulant effects at a dose that is much higher (300 – 600 mg per patient per 
day) than what we used in the present study.  In addition, mice exhibit hyperlocomotion to acute 
treatment of 30 mg/kg fenobam (Montana et al., 2011).   These data suggest that fenobam, and 
mGluR5 antagonists in general, may have unwanted stimulant effects that may or may not be 
related to analgesic efficacy.  In the present study, we find that the stimulatory and rewarding 
effects of fenobam can be disassociated and that the stimulatory effects may be short term.  In 
the first two days of pairing, SNI and sham mice injected with fenobam traveled more than 
animals injected with vehicle.  These data show that all mice, irrespective of neuropathic injury, 
respond to the stimulatory effects of fenobam.  This is particularly interesting because on post-
conditioning day 5, the SNI mice only prefer to spend significantly more time in the fenobam-
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paired chamber.  This time preference in SNI mice demonstrates that the rewarding effects of the 
drug in the context of injury are separate from its locomotor effects.  Of note, the locomotor 
effects of fenobam are not seen on the last day of pairing, day 4.  It is unclear whether this lack 
of an effect is indicative of habituation to fenobam-induced hyperactivity and/or a phenomenon 
associated with repeated testing habituation to the environment.   
DMSO was chosen as the vehicle for fenobam because of fenobam’s limited solubility in 
other solvents and the established use of DMSO in studies showing the analgesic effects of 
fenobam (Montana et al., 2009; Montana et al., 2011; Crock et al., 2012b).  The 
pharmacokinetics of fenobam, which are important for demonstrating aCPP, were established in 
mice with a DMSO vehicle (Montana et al., 2011).  DMSO is known to have some analgesic 
properties of its own and chronic administration of DMSO for 14 days has not been shown to 
cause any liver or metabolic abnormalities nor any changes in sensory/motor behavior in mice 
(Montana et al., 2011).  The analgesic effects of fenobam are maintained with chronic pre-dosing 
with fenobam or DMSO, suggesting that in this context DMSO is not masking or altering the 
behavioral effects of fenobam.  Nonetheless, due to the potential for side-effects of DMSO as a 
vehicle, future studies may explore alternative vehicle options.  Of note, fenobam does show 
good oral bioavailability in powdered form for human studies (Kalliomaki et al., 2013).  It is 
possible that some element of the behavioral effects that we saw from fenobam were due to the 
analgesic effects of DMSO, where animals received some type of on-going relief from SNI 
injury from the vehicle.  However, if this were the case, the effects were minimal and the relief 
was not as rewarding as that induced by fenobam/MPEP.  Otherwise, we would predict that the 
animals would not develop preference for either chamber if both produced equally rewarding 
effects. 
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 Finally, our results with the morphine aCPP show the benefit of aCPP as a screening tool 
for addictive potential of analgesic compounds, allowing the researcher to separate euphoria-
inducing drugs (e.g. morphine) from non-euphoric drugs (e.g. fenobam).  Morphine preference 
has been demonstrated in naïve rats and mice, as well as in mice with spinal cord injury (SCI) 
(Reid et al., 1989; Vindenes et al., 2006; Woller et al., 2012).  As far as we know, this is the first 
report of the behavioral effects of morphine in SNI mice.  Not surprisingly, all male and female 
animals, regardless of injury, show preference for morphine.  It is likely that there is an 
interaction between the analgesic and euphoric effects of morphine.  Our dose of morphine (10 
mg/kg) has been shown to be analgesic (Mohammed et al., 2013b) and has also been shown to 
induce preference in naïve mice in the classic conditioned place preference assay (Mattioli et al., 
2012; Ruiu et al., 2013).  This preference is likely developing in the sham animals through a 
euphoria-like mechanism and in the SNI mice through both analgesic and euphoria-induced 
positive reinforcement.  Overall, data from our morphine experiments help demonstrate the 
significant contrast of mGluR5 antagonists compared to mu opioid receptor agonists like 
morphine.   We show that mGluR5 inhibition with fenobam does not induce preference in sham 
animals at a dose that is analgesic (Montana et al., 2009) in injured mice.      
  Overall, mice with induced neuropathic injury develop a preference for fenobam or 
MPEP after three days of pairing in the aCPP assay. Mice without SNI show no such preference.  
Since fenobam and MPEP do not show any deleterious effects in these sham mice, these data 
suggest that these drugs have no positive reinforcing effect in the absence of pain and induce 
preference only when a chronic injury is present. Finally, the locomotor side effects of fenobam 
are distinct from the analgesic effects of the drug.  Our results demonstrate that fenobam and 
more broadly mGluR5 antagonists may have a promising future in the treatment of chronic pain. 
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MATERIALS AND METHODS 
Animals 
All mouse procedures were reviewed and approved in accordance with National Institutes 
of Health Guide for the Care and Use of Animals and the Institutional Animal Care and Use 
Committee at Duquesne University (Protocol Number: 1201-02).  All behavior experiments were 
performed using C57Bl/6J male or female mice. Mice were individually housed and maintained 
on a 12-hour light/dark cycle (lights on 7:00 AM – 7:00 PM) with ad libitum access to food and 
water.  Mice were between 6.5 and 8 weeks old when behavioral experimentation took place.  
All procedures were carried out during the light cycle.  The mouse’s surgery type was blinded to 
the experimenter prior to all behavioral testing.  
Surgical Procedures 
A 10:1 ketamine/xylazine mixture was injected intraperitoneally into the mice for 
anesthesia (10 µL/g). Spared nerve injury (SNI) to the sciatic nerve was performed as described 
previously (Decosterd and Woolf, 2000).  M. biceps femoris muscle was found after cutting the 
skin parallel to the femur bone.  After the sciatic nerve was located underneath the muscle, a 
suture thread was tied around tibial and common peroneal branches of the sciatic nerve, both of 
which were ligated 2 cm distal to the suture.  The sural branch of the sciatic nerve was not 
manipulated.  Sham surgeries followed the same procedure, without manipulation of any 
branches of the sciatic nerve and without cutting the overlying muscle (only a skin incision).  
Mice recovered on heating pads and were housed in individual cages for one week prior to aCPP 
testing.  Following all behavioral procedures, sham and SNI surgeries were verified post-hoc 
with necropsy. 
Drugs 
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Fenobam ([N-(3-chlorophenyl)-N’-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-
yl)urea], Abcam Biochemicals, Fenobam, Cambridge UK) was dissolved in 100% dimethyl 
sulfoxide (DMSO) on the first day of drug-pairing (day 2 of 5-day aCPP experiment) at a dose of 
30 mg/kg (volume = 20 L) and stored in the dark at room temperature between tests.  Dosage 
was determined from published dose response curves (Montana et al., 2009) and our own 
preliminary data showing significant analgesic effects of fenobam in the spontaneous formalin 
test (data not shown).  DSMO was chosen as the vehicle due to its use with fenobam in other 
pain and pharmacological studies (Montana et al., 2009; Montana et al., 2011; Crock et al., 
2012b) and fenobam’s lack of solubility in other solvents. MPEP ([2-Methyl-6-
(phenylethynyl)pyridine], Enzo Life Sciences, MPEP hydrochloride, New York USA) was 
dissolved in 0.9% saline on the first day of drug-pairing (day 2 of 5-day aCPP experiment) at a 
dose of 30 mg/kg (volume = 20 μL) and stored in the dark at room temperature between tests.  
Dosage was determined from published dose response curves (Montana et al., 2009).  Unlike 
fenobam, MPEP can be dissolved in saline solution.  Morphine (Sigma, morphine sulfate, USA) 
was dissolved in 0.9 % saline solution on the first day of drug pairing (day 2 of the 5-day aCPP 
experiment) at a dose of 10 mg/kg (volume = 100 μL) and stored in the dark at room temperature 
between tests.  The dose for morphine was determined from previous studies showing CPP for 
morphine in naïve mice (Mattioli et al., 2012; Ruiu et al., 2013).  
Drug Administration 
Fenobam solution was administered intraperitoneally (30 mg/kg) in a volume of 20 μL, 5 
minutes prior to behavioral testing, when fenobam concentration in the brain is maximal 
(Montana et al., 2009).  The vehicle control for fenobam trials was 100 % DMSO (volume = 20 
L).  MPEP solution was administered intraperitoneally (30 mg/kg) in a volume of 20 μL, 5 
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minutes prior to behavioral testing as well.  The vehicle control for MPEP trials was 0.9 % saline 
solution (volume = 20 μL).  Morphine was administered to mice subcutaneously (10 mg/kg) in a 
volume of 100 μL, 5 minutes prior to behavioral testing.  The vehicle control for the morphine 
trials was 0.9 % saline (volume = 100 L). In separate trials of 5-day aCPP tests (see below), 
fenobam or morphine was given to mice once daily for three consecutive days (on days 2, 3, and 
4 of aCPP). 
Analgesic Conditioned Place Preference (aCPP) 
The aCPP apparatus consisted of a three-compartment box made from Plexiglas.  The 
box consisted of two large outer chambers (26.75 cm x 27.5 cm) and one smaller middle 
chamber (“neutral” chamber – 9 cm x 5 cm) that connected the two outer chambers. The two 
large outer chambers differed only in the patterns on the wall (vertical, horizontal or diagonal 
black and white stripes, all 2.675 cm thick), while the rest of the parameters remained identical 
between chambers (white noise 60 dB, non-enrichment bedding). The neutral chamber in the 
middle of the apparatus consisted of white walls with no bedding.  Room B103G in the Bayer 
Animal Care Facility was used for all aCPP experiments.  Four aCPP boxes were used at the 
same time, allowing testing of four animals at once.  The four aCPP boxes were arranged with 
each outer chamber alternating the patterning of the box next to it (to balance patterns vs side of 
room and to limit preconditioning biases).  The boxes were oriented parallel with the door so 
there was not one outer chamber close to the door where experimenters entered and exited.  A 
blue curtain was also placed around the room to limit any preconditioning biases from things in 
the behavior room.  Non-enrichment bedding was placed in both of the outer boxes of the CPP 
boxes, but not in the neutral chamber. 
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On day 1 of aCPP testing, seven days following SNI/sham surgeries, the male or female 
mice were placed in the neutral chamber and allowed to move freely between the three chambers 
for 30 minutes.  Mice were tracked by two overhead cameras (Logitec Webcam Pro 9000 and 
Canon ZR420) using ANY-maze software (Stoelting Co., version 4.98).  This program recorded 
the time spent and distance traveled by each mouse in all three chambers on days 1 and 5 of 
aCPP testing.  Additionally, the distance traveled on days 2-4 for male mice treated with 
fenobam was recorded.  Day 1 established baseline results upon which the balancing of the 
apparatus was assessed.  In order to avoid preconditioning biases, we made the a priori decision 
to exclude any mouse that had a difference of greater than 400 seconds in either of the two outer 
chambers (vertical vs horizontal/diagonal) on day 1 (pre-conditioning) of aCPP testing.  For 
remaining animals that passed the exclusion test, on days 2, 3, and 4, drug or vehicle was 
administered in two separate 30-minute sessions (one session in the morning and one in the 
afternoon).  During these trials, the neutral chamber was sectioned off and the mice only had 
access to one of the large outer chambers (either horizontal or vertical/diagonal).  In the morning 
session, mice were injected with the vehicle control and placed in the vehicle-paired outer 
chamber. Three hours later, in the afternoon trial, the same mice were injected with the 
experimental drug (i.e. fenobam or morphine in vehicle) and placed in the drug-paired outer 
chamber, opposite to the chamber used in the morning session.  The chamber paired with the 
drug was randomly assigned to mice such that some mice received the drug in a horizontal 
chamber and others in a vertical/diagonal chamber.  On day 5 (post-conditioning), mice were 
again allowed to roam free between all three chambers for 30 minutes.  These new times were 
then compared to day 1 (pre-conditioning) testing times to see if and how the mouse’s preference 
changed after three days of drug-pairing. 
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Statistical Analysis 
Graph Pad Prism version 5 for Mac OS X was used for all statistical analysis.  All data 
are presented as mean ± SEM.  Raw data can be obtained by contacting the corresponding 
author.  Statistical significance was determined between groups using t-tests or ANOVA 
followed by a post hoc test.  The combined total distances were analyzed with an un-paired t-test 
and days 2-4 distance data were analyzed with a two-way ANOVA followed by a Bonferroni 
post-hoc test.  When analyzing total time per chamber on day 5, a paired t-test was utilized.  Day 
5 – Day 1 time difference data was analyzed using a paired t-test.  Statistical significance was 
established at a 95% confidence interval (p<0.05). 
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Section 2 
Chapter 2 
Characterization of a novel mu opioid drug formulation, 
PolyMorphine, in several models of chronic pain 
	
	
	
	
	
	
	
	
	
 
  174
 
 
 
 
 
 
The majority of the text contained within this chapter is adapted from the following publication: 
Lax NC, Chen RX, Leep SR, Uhlrich KE, Kolber BJ. 2017. PolyMorphine provides extended 
analgesic-like effects in mice with spared nerve injury. Molecular Pain. DOI: 
10.1177/1744806917743479. 
 
PolyMorphine was prepared and provided by Renxun Chen (Rutgers University) and Kathryn 
Uhlrich (Rutgers University).  Figures 34 and 35 were prepared by Renxun Chen to show the 
synthesis process of PolyMorphine.  All behavioral testing was completed at Duquesne 
University by Neil Lax with Sarah Leep assisting with formalin testing and scoring in Figure 37. 
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ABSTRACT 
 
Morphine is a well-characterized and effective analgesic commonly used to provide pain 
relief to patients suffering from both acute and chronic pain conditions.  Despite its widespread 
use and effectiveness, one of the major drawbacks of morphine is its relatively short half-life of 
approximately four hours. This short half-life often necessitates multiple administrations of the 
drug each day, which may contribute to both dependence and tolerance to morphine. Here, we 
tested the analgesic properties of a new polymer form of morphine known as PolyMorphine. 
This polymer has monomeric units of morphine incorporated into a poly(anhydride-ester) 
backbone that has been shown to hydrolyze into free morphine in vitro. Using an animal model 
of chronic pain, the spared nerve injury surgery (SNI), we showed that PolyMorphine is able to 
block SNI-induced hypersensitivity in mice for up to 24 hours post administration. Free 
morphine was shown to only block SNI-induced hypersensitivity for up to two hours post 
injection. PolyMorphine was also shown to act through the mu opioid receptor due to the ability 
of naloxone (a mu opioid receptor antagonist) to block PolyMorphine-induced analgesia in SNI 
animals pretreated with PolyMorphine.  Additionally, we observed that PolyMorphine causes 
similar locomotor and constipation side effects as free morphine. Finally, we investigated if 
PolyMorphine had any effects in a non-evoked pain assay, conditioned place preference (CPP).  
Pretreatment of SNI mice with PolyMorphine blocked the development of CPP for MPEP, a 
short-lasting mGluR5 antagonist with analgesic-like properties. Free morphine does not block 
the development of preference for MPEP, suggesting that PolyMorphine has longer lasting 
analgesic effects compared to free morphine. Together, these data show that PolyMorphine has 
the potential to provide analgesia for significantly longer than free morphine while likely 
working through the same receptor. 
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INTRODUCTION 
 
Morphine is one of the most commonly used and most well-known analgesics in both 
humans and animals (Mohammed et al., 2013a).  Morphine is an agonist of the mu opioid 
receptor (MOR) and binds to this receptor 3.4 and 10 times stronger than the other opioid 
receptor subtypes, the kappa and delta opioid receptors, respectively (Kilpatrick and Smith, 
2005).  With activation of the MOR, morphine inhibits neurotransmitter release by decreasing 
calcium entry at presynaptic nerve endings and induces hyperpolarization in the post-synaptic 
cell at a number of CNS sites and on primary afferent neurons (Chahl, 1996).  These mechanisms 
are believed to cause the analgesic effects of morphine. Yet, despite its success in blocking pain, 
a major drawback to morphine use is its relatively short half-life of approximately four hours 
(Sverrisdottir et al., 2015).  In vivo, morphine is quickly distributed (Spector and Vesell, 1971) 
and subsequently metabolized, mainly in the liver, into inactive morphine-3-glucaronide (M3G) 
and the analgesic morphine-6-glucaronide (M6G) (Christrup, 1997).  These metabolites are then 
excreted via the kidneys (Yeh, 1975).  This fast metabolism leads to the need for repeated 
administration of morphine, can result in low compliance, and can contribute to the development 
of tolerance and dependence over time (Akbarali et al., 2014).  While several capsule forms 
(King and Khabazian, 2003; Hagen et al., 2005; Ross and Hahn, 2008) have been developed to 
circumvent some of these problems, these tablets often lead to abuse because they can be crushed 
into a powder.  Crushing these tablets causes a large amount of morphine to be available at once, 
rather than slowly releasing the drug over time, leading to greater psychotropic effects and risk 
for abuse.  This is particularly concerning due to the ongoing opioid crisis in the United States. 
Furthermore, these extended release tablets only modestly extend the analgesic effects of 
morphine (Butler et al., 2011b; Katz et al., 2011; Setnik et al., 2013). 
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Recently, our colleagues at Rutgers University developed a new formulation of 
morphine, called PolyMorphine, that could circumvent these issues (Rosario-Melendez et al., 
2012).  PolyMorphine is efficiently synthesized by chemically incorporating morphine in each 
repeat unit through a poly(anhydride ester) backbone in a 3-step reaction (Rosario-Melendez et 
al., 2012).  PolyMorphine was shown to be analgesic for three days in naïve mice using the tail-
flick assay, which is 20 times longer than free morphine (Rosario-Melendez et al., 2012).  What 
remained unclear is the extent to which PolyMorphine works as an analgesic in chronic pain 
models, how long its effects may last in these other models, if it acts on the MOR in a manner 
similar to free morphine, and what side effects may be associated with PolyMorphine treatment.  
In this study, PolyMorphine was evaluated for prolonged analgesia potential in the spared nerve 
injury (SNI) model of chronic pain (Decosterd and Woolf, 2000).  The SNI model has been 
shown to induce long-lasting hypersensitivity in the ipsilateral (injured) paw for up to nine weeks 
post-surgery (Bourquin et al., 2006; Richner et al., 2011).  Herein, this chronic pain model was 
combined with several measures of pain-like behaviors including von Frey mechanosensory 
testing and the conditioned place preference (CPP) assay.   
Based on the previously shown extended analgesic effects of PolyMorphine, we 
hypothesized that this polymer could block SNI-induced hypersensitivity as measured by von 
Frey mechanosensory testing for up to three days post administration.  We also hypothesized 
that, if PolyMorphine works through activation of the MOR, then pretreatment with naloxone, a 
MOR antagonist, would block the analgesic-like effects of PolyMorphine. Since the effects of 
PolyMorphine are ultimately due to the release of free morphine monomers, we also predicted 
that PolyMorphine would cause side effects similar to free morphine such as hyperactivity (Koek 
et al., 2012; Koek, 2014) and constipation (Raehal et al., 2005). Finally, we hypothesized that the 
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long-lasting analgesic effects of PolyMorphine would have the ability to block the development 
of preference for a short-lasting analgesic in the analgesic CPP assay (Tzschentke, 1998; He et 
al., 2012; Lax et al., 2014). 
 
RESULTS 
PolyMorphine Synthesis and Degradation into Free Morphine 
Morphine diacid was synthesized via ring-opening reaction between glutaric anhydride 
and morphine, followed by acetylation of the diacid and polymerization of the monomer by melt-
condensation (Figure 34).  PolyMorphine was shown to hydrolytically degrade in vitro at 
physiological conditions (37 C and pH 7.4) to free morphine in the following stages: hydrolytic 
cleavage of the anhydride bonds to morphine-diacid 3, followed by hydrolysis of the ester bonds 
to yield free morphine (Figure 35). 
   
Figure 34. Synthesis of PolyMorphine (5). PolyMorphine 5 was synthesized from the reaction 
of morphine 1 and glutaric anhydride 2 via ring-opening followed by acetylation of the diacid 3 
and polymerization of the monomer 4 by melt-condensation. RC – conducted synthesis.  RC, 
KU, BK – designed experiment. 
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Figure 35. Hydrolytic degradation of PolyMorphine 5.  The anhydride linkages of polymer 5 
are hydrolyzed first to generate diacid intermediates (3), which are then further hydrolyzed to the 
final products, morphine (1) and adipic acid (7).   RC – conducted synthesis.  RC, KU, BK – 
designed experiment. 
 
 
PolyMorphine Blocks SNI-Induced Hypersensitivity  
 
The ability of PolyMorphine to block SNI-induced mechanical hypersensitivity was 
measured.  Using von Frey testing to determine 50% withdrawal thresholds, a pretreatment of 
PolyMorphine (n=8) reversed SNI-induced hypersensitivity for up to 24 hours post-injection 
compared to vehicle-treated SNI animals (n=8).  The reversal of SNI-induced hypersensitivity in 
mice treated with regular morphine (n=8) was gone after 2 hours (Figure 36).  These data 
demonstrate a significant increase in PolyMorphine analgesia over time compared to free 
morphine. 
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Figure 36. PolyMorphine blocks SNI-induced hypersensitivity longer than free morphine. 
SNI mice treated with 200 mg/kg of PolyMorphine (n=8) show reduced hypersensitivity 
compared to control SNI mice (n=8) for up to 24 hours after administration.  SNI mice treated 
with 10 mg/kg of free morphine (n=8) show reduced hypersensitivity compared to control SNI 
mice for only 2 hours after administration. 2-way ANOVA, overall main effect of treatment *P = 
0.0153, overall main effect of time ***P < 0.0001, Bonferroni post-hoc tests compared to saline, 
* P < 0.05, *** P < 0.0001. NL – conducted experiment.  NL, BK – designed experiment. 
 
Naloxone Blocks the Analgesic-like Effects of PolyMorphine 
To determine if PolyMorphine works through the same molecular mechanism as free 
morphine, a mu opioid receptor antagonist (naloxone) was used to potentially inhibit the 
analgesic effects of PolyMorphine.  First, we determined a dose of naloxone sufficient to block 
free morphine effects using the spontaneous formalin test.  Animals received a pretreatment of 
either vehicle or morphine (10 mg/kg) IP and vehicle or naloxone (1 or 10 mg/kg) prior to 
formalin injection. Using this assay, a dose of 10 mg/kg of naloxone was found to be effective in 
fully blocking the analgesic effects of free morphine (Figure 37A).  Once this dosage was 
determined, the ability of this dose of naloxone to block the analgesic effects of PolyMorphine 
was measured.  Using von Frey testing to determine 50% withdrawal thresholds, pretreatments 
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of naloxone prior to each experimental time point blocked the analgesic effects of PolyMorphine 
in SNI animals with PolyMorphine (Figure 37B).  Animals that received pretreatments of 
vehicle showed the normal reversal of SNI-induced hypersensitivity of up to 24 hours post 
PolyMorphine injection (Figure 37B).  These data show that PolyMorphine likely works through 
the mu opioid receptor. 
 
Figure 37. Naloxone blocks both free morphine and PolyMorphine-induced analgesia. (A) 
Mice treated with 10 mg/kg of free morphine and 10 mg/kg of naloxone (n=6) show equal 
amounts of pain-like behaviors compared to control mice (n=12).  Mice treated with only 10 
mg/kg of morphine (n=5) show significantly less pain-like behaviors compared to the control and 
morphine/naloxone (10 mg/kg) groups.  1 mg/kg of naloxone (n=6) was not a sufficient dose to 
block the analgesic effects of morphine.  (B) SNI mice treated with 200 mg/kg of PolyMorphine 
and 10 mg/kg of naloxone (n=6) prior to each post injection time point remained hypersensitivity 
compared to control SNI mice (n=6) that received PolyMorphine with vehicle injections. 
Formalin test - One-way ANOVA, overall main effect ***P = 0.0007, Bonferroni post-hoc tests, 
* P < 0.05, *** P < 0.0001. von Frey test - 2-way ANOVA, overall main effect of treatment *P = 
0.0211, overall main effect of time ***P < 0.0001, Bonferroni post-hoc tests, * P < 0.05, *** P < 
0.0001.  NL – conducted experiment.  SL – formalin scoring.  NL, BK – designed experiment. 
 
PolyMorphine Causes Constipation and Increased Motor Activity 
Next, the side effects of free morphine and PolyMorphine were compared.  Animals were 
pretreated with free morphine, PolyMorphine or vehicle and motor deficiencies, constipation, 
hyperactivity, body weight, body temperature, and food/water consumed for up to three days 
post-injection were measured.  No differences were found between the groups in terms of body 
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weight, body temperature, or food/water consumed at any of the time points measured (Table 7).   
 Saline 
Side 
Effect 
Body Weight Body Temp Food Water 
3 hr 23.50 ± 0.74 g 34.2 ± 0.70 oC 1.35 ± 0.38 g 1.30 ± 0.14 g 
1 Day 22.08 ± 0.51 g 33.8 ± 0.57 oC 1.97 ± 0.74 g 1.68 ± 0.36 g 
2 Day 21.98 ± 0.45 g 34.0 ± 0.43 oC 0.65 ± 0.15 g 0.87 ± 0.11 g 
3 Day 22.07 ± 0.37 g 34.0 ± 0.14 oC 0.62 ± 0.16 g 0.97 ± 0.20 g 
 Morphine 
Side 
Effect 
Body Weight Body Temp Food Water 
3 hr 23.57 ± 0.69 g 34.4 ± 0.46 oC 1.18 ± 0.41 g 1.42 ± 0.33 g 
1 Day 21.65 ± 0.76 g 34.4 ± 0.31 oC 1.67 ± 0.65 g 2.00 ± 0.51 g 
2 Day 21.77 ± 0.72 g 33.5 ± 0.46 oC 0.92 ± 0.38 g 0.62 ± 0.18 g 
3 Day 21.88 ± 0.63 g 34.6 ± 0.43 oC 0.53 ± 0.30 g 1.07 ± 0.12 g 
 PolyMorphine 
Side 
Effect 
Body Weight Body Temp Food Water 
3 hr 24.83 ± 0.45 g 33.9 ± 0.73 oC 1.13 ± 0.37 g 1.12 ± 0.10 g 
1 Day 23.10 ± 0.26 g 33.0 ± 0.54 oC 1.43 ± 0.56 g 1.70 ± 0.26 g 
2 Day 22.53 ± 0.31 g 33.9 ± 0.53 oC 0.45 ± 0.12 g 0.80 ± 0.16 g 
3 Day 22.78 ± 0.26 g 34.4 ± 0.37 oC 0.45 ± 0.19 g 1.35 ± 0.35 g 
 
Table 7. Average body weight, body temperature, food and water consumption in animals 
treated with morphine or PolyMorphine.  No differences were found between any groups (n = 
6 per group) in terms of body weight changes (Body weight, 2-Way ANOVA, overall effect of 
drug. p = 0.2732; Body temp, 2-Way ANOVA, overall effect of drug, p = 0.4573; Food 
consumed, 2-Way ANOVA, p =0.7213; Water consumed, 2-Way ANOVA, overall effect of 
drug, p = 0.9594). Data shown as mean ± SEM.  NL – conducted experiment.  NL, BK – 
designed experiment. 
 
For constipation, animals treated with both free morphine and PolyMorphine showed 
constipation for the first three hours post injection (Figure 38A).  This effect was not seen on 
days 1-3 post-injection.  Finally, hyperactivity was measured using the open field test.  Animals 
treated with free morphine showed hyperactivity at three hours post-injection, while no 
hyperactivity was observed with PolyMorphine at this time point (Figure 38B).  However, by 
one day post-injection, PolyMorphine pretreated animals now showed hyperactivity whereas free 
morphine pretreated animals did not.  Overall, these data show that PolyMorphine has some of 
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the same side effects as free morphine with subtle but potentially important differences. 
 
 
Figure 38. PolyMorphine and free morphine induce constipation and hyperactivity. (A) 
Mice treated with 200 mg/kg of PolyMorphine (n=6) or 10 mg/kg of free morphine (n=8) show 
constipation effects at three hours post injection compared to control animals (n=6), with no 
effects one to three days post injection. (B) Mice treated with 200 mg/kg of PolyMorphine (n=6) 
show hyperactivity at one day post injection with no effects 3 hours or 2-3 days post injection 
compared to vehicle treated animals (n=6).  Mice treated with 10 mg/kg of free morphine (n=8) 
show hyperactivity at 3 hours post injection with no effects 1-3 days post injection compared to 
vehicle treated animals. Constipation - 2-way ANOVA, overall main effect of treatment *P = 
0.0385, overall main effect of time ***P < 0.0001, Bonferroni post-hoc tests compared to 
vehicle, ** P < 0.01. Hyperactivity - 2-way ANOVA, overall main effect of treatment P = 
0.1275, overall main effect of time ***P < 0.0001, Bonferroni post-hoc tests compared to 
vehicle, * P < 0.05, *** P < 0.0001.  NL – conducted experiment.  NL, BK – designed 
experiment. 
 
PolyMorphine Blocks the Development of Preference for MPEP in the Analgesic CPP Assay 
For spontaneous pain-like behaviors, the analgesic CPP assay was used.  As described 
above in Section 2 Chapter 1, typically in the analgesic CPP assay, a short-lasting analgesic (e.g. 
fenobam) is repeatedly paired with a physical space to induce a conditioned preference response 
in a mouse with on-going spontaneous pain (Tzschentke, 1998; Lax et al., 2014).  If a drug lasts 
longer than ~30 minutes then this assay cannot be used in the traditional manner since the effects 
of the drug will last outside of the 30 minute pairing in the chamber. As PolyMorphine is 
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hypothesized to have an analgesic effect lasting multiple days, PolyMorphine could not be used 
as the normal pairing drug during the pairing days.  Instead, animals were given a pretreatment 
of the PolyMorphine to determine if pretreatment blocked the preference-inducing effect of a 
short-lasting analgesic, the mGluR5 antagonist MPEP. As described above in Section 2 Chapter 
2, short lasting MPEP pairing induces preference in SNI-treated mice but sham mice (Figure 
31). The theory is that an animal that is already receiving analgesia from a long-lasting drug like 
PolyMorphine will not receive any additional benefit from a short-lasting analgesic like MPEP. 
Thus, PolyMorphine pre-treatment is predicted to block MPEP-induced CPP.  Pretreatment 
(given the evening of Day 1 of CPP testing, after baseline) with PolyMorphine was compared to 
pretreatment with free morphine or vehicle (saline).  Unlike PolyMorphine, neither free 
morphine nor vehicle pretreatment were hypothesized to block MPEP CPP in SNI mice.  As 
predicted, pretreatments with saline caused SNI mice to develop normal MPEP-induced CPP 
(Figure 39A); SNI mice pretreated with regular morphine also developed MPEP-induced CPP 
(Figure 39B).  In contrast, pretreatment with PolyMorphine blocked MPEP-induced CPP in SNI 
mice (Figure 39C). Overall, these results support the hypothesis that PolyMorphine causes 
analgesic-like behavioral effects in both reflexive and spontaneous pain-like behavior assays.  
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Figure 39. PolyMorphine blocks MPEP-induced CPP in male SNI mice. (A) SNI Mice 
pretreated with vehicle (n=8) develop normal preference for the MPEP-paired chamber.  (B) SNI 
mice pretreated with 10 mg/kg of free morphine (n=8) also develop preference for the MPEP-
paired chamber. (C) SNI mice pretreated with PolyMorphine (n=8) do not develop preference for 
the MPEP-paired chamber. Paired t-tests,* P < 0.05.  NL – conducted experiment.  NL, BK – 
designed experiment. 
 
DISCUSSION 
 
Morphine and other mu opioid agonists have a long history in being used to treat both 
acute and chronic pain conditions. There is an active push in the United States to prepare 
compounds that could avoid the negative side effects and short half-lives of most opioids.  A 
majority of the newer treatments using morphine have specifically focused on trying to 
circumvent the problem of rapid metabolism of the compound by focusing on extended-release 
formulations of the drug (Nicholson, 2008).  Here, for the first time, we show the extended 
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analgesic-like effects of a polymer form of morphine, PolyMorphine, in a preclinical model of 
chronic pain combined with behavioral testing in mice.  Using von Frey mechanosensory testing, 
PolyMorphine was able to block SNI-induced hypersensitivity for up to 24 hours post 
administration.  This effect is in contrast to the short-lived one of free morphine, wherein the 
SNI-induced hypersensitivity is suppressed by morphine for only two hours post administration.  
Mechanistically, naloxone antagonism of MOR receptor blocked the analgesic-like effects of 
PolyMorphine in SNI animals.  Additionally, PolyMorphine caused comparable side effects of 
free morphine, such as constipation and hyperactivity.  Finally, in a non-evoked behavioral pain 
test, the analgesic conditioned place preference (aCPP) assay, PolyMorphine blocked the effects 
of the short-term analgesic MPEP.  This is again in contrast to free morphine wherein normal 
MPEP-induced CPP developed with free morphine pretreatment. 
 The use of opioids to treat pain has substantially increased over the past few years, 
especially in the treatment of non-cancer pain (Chou et al., 2009). This increase in use has 
coincided with the development of extended release forms of morphine that allow patients to be 
administered the compounds less frequently.  Some of the more commonly used formulations 
that are available are Embeda®, which contains pellets of morphine sulfate with sequestered 
naltrexone (Badalamenti et al., 2012) and Kadian®, which contains polymer coated morphine 
sulfate pellets (Nicholson, 2008).  Morphine has also been incorporated into nanogels 
(Hassanzadeh et al., 2016) and liposomes (Smith et al., 2003) in order to increase the duration of 
its analgesic effects.  The main difference between these formulations and PolyMorphine is that 
in these compounds, free morphine is sequestered in a polymer coating whereas in 
PolyMorphine, free morphine is directly incorporated into a polymer form.  Despite these 
differences in design, Embeda®, Kadian®, and Polymorphine have all been found to release free 
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morphine over time (Johnson et al., 2011). Other approaches have also been taken that attempt to 
limit abuse liability by slowing the rate at which compounds cross the blood-brain barrier (BBB) 
instead of extending the release of drugs over time.  One notable example is NKTR-181, a 
compound that contains a five-ring morphine-like scaffold bonded to a short-chain poly(ethylene 
glycol) (Gonçalves et al.; Miyazaki et al., 2017). This functional group has previously been 
shown to reduce oral bioavailability and transmission rate across the BBB (Corsetti and Tack, 
2015; Bui et al., 2016). Through this mechanism, NKTR-181 provides analgesia in humans and 
is currently in Phase III clinical trials.  However, this type of formulation only circumvents 
potential abuse problems and does not extend the analgesic effects of the compound for longer 
than free opioids.  Other attempts, such as polymer formulations to extend analgesia and prevent 
abuse, have tried using a polyurethane backbone, but these formulations are problematic because 
they lead to poor bioavailability due to their inability to degrade in vivo (Mahkam and Sharifi-
Sanjani, 2003).  The poly(anhydride-ester) backbone used in PolyMorphine can circumvent 
many of the problems associated with other extended release morphine formulations and has 
already been used to make polymer formulations of NSAIDs (Schmeltzer et al., 2013), 
antiseptics (Schmeltzer and Uhrich, 2006) and antioxidants (Anastasiou and Uhrich, 2003).  This 
specific polymer-type formulation may be the key behind extending analgesia without the worry 
of abuse. 
 Additionally, our results show that PolyMorphine has the potential to be effective in 
providing extended analgesia in animal models.  Original testing with PolyMorphine using the 
tail-flick assay showed that the drug provided extended analgesic relief in mice, for up to three 
days (20 times longer than free morphine) (Rosario-Melendez et al., 2012).  While these results 
were promising, the tests were only done in naïve mice and only in one “experimenter-induced” 
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pain assay.  Our results expand upon these data, showing that PolyMorphine is effective in a 
classic model of chronic neuropathic pain, SNI, providing similar reduction in mechanical 
hypersensitivity compared to free morphine initially along with extended relief up to 24 hours 
after delivery. These extended analgesic results are similar to those obtained in other rodent 
studies that looked at liposome-encapsulated morphine in vivo.  Liposome-encapsulated 
morphine was shown to block the hypersensitivity associated with male rats that had spinal nerve 
ligation (SNL) in thermal sensory testing (Smith et al., 2003) and extend analgesic-like effects in 
naïve animals using the tail-flick test (Grant et al., 1994).  Other extended release formulas of 
morphine, however, such as those produced using nanogels, only resulted in the extension of 
analgesic effects for approximately one hour longer than that of free morphine when tested using 
the hot-plate test in naïve mice (Hassanzadeh et al., 2016).  Similarly, NKTR-181, the five-ring 
morphine-like scaffold bonded to a short-chain PEG produced analgesic-like effects for only up 
to four hours post administration in the hot-plate test in mice, this being similar to the effects of 
free opioids (Miyazaki et al., 2017).  
In addition to this 24-hour block in hypersensitivity with PolyMorphine administration, 
we also showed that PolyMorphine is effective in altering spontaneous pain-like behaviors.  In 
the classic aCPP assay, animals receive a pain-inducing injury prior to testing.  Following injury, 
animals are conditioned to learn the effects of a short-lasting analgesic agent.  If animals receive 
relief from their ongoing nociception, they will develop a preference for the drug-paired 
chamber.  We had previously shown that three days of pairing with MPEP, an mGluR5 
antagonist, alone induces preference in SNI but not sham-operated mice (Lax et al., 2014).  In 
our experiments here, we used a pretreatment injection to determine if the extended analgesic 
effects of PolyMorphine could block the short-lasting analgesic effects of MPEP, such that 
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animals do not develop preference for the MPEP-paired chamber.  The MPEP results from 
vehicle-pretreated mice were consistent with our previous data with MPEP in SNI mice(Lax et 
al., 2014), wherein MPEP induced CPP.  In a similar matter, pretreatment with free morphine 
also resulted in mice developing a preference for MPEP.  This is because the short-term effects 
of the morphine wear off before the pairing with MPEP occurs (e.g. approximately 20 hours after 
morphine administration).  Conversely, animals pre-treated with PolyMorphine did not develop 
any preference for the MPEP-paired chamber.  This suggests that unlike free morphine, 
PolyMorphine provided relief from the animal’s ongoing nociception, such that when MPEP was 
administered, the animals did not receive any additional relief during the three days of pairing.  
These aCPP results, which suggest PolyMorphine induces analgesic-like effects over a three-day 
time period are in slight contrast to our von Frey data that show the effects of PolyMorphine 
wearing off by the 2-day time point. One possible reason for this difference could be the 
fundamentally different types of pain that are being measured in each assay (i.e. experimenter-
induced pain measured with von Frey testing compared to spontaneous non-evoked pain 
measured with aCPP).  Our data suggest that PolyMorphine is able to provide continuous 
ongoing relief to injured animals with spontaneous non-evoked pain for a significantly longer 
period of time.  The lack of preference for MPEP in the PolyMorphine pretreatment group also 
shows that there is no additive effect of the two drugs. This observation is in contrast to studies 
that have shown that coadministration of mGluR5 antagonists and acute MOR agonists can 
generate enhanced effects (Kozela et al., 2003; Smeester et al., 2014). If there had been some 
type of additive effects where animals received greater relief from the combined effects of MPEP 
and PolyMorphine, we would have predicted preference to still develop after PolyMorphine pre-
treatment.   
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Our results with both the experimenter-induced and spontaneous pain-like behavior 
assays suggest that PolyMorphine has the potential to work significantly better than other slow-
release morphine formulations.  This compound could be very useful for the treatment of chronic 
pain conditions that require frequent administration of analgesics.  It could also be considered for 
those who need an effective analgesic for post-operative pain, while reducing the number of 
administrations.  Further investigation with PolyMorphine is required to determine if its 
extended analgesic-like effects are observed when using female animals since all of the testing 
done thus far has focused on males.  However, since female animals are known to respond to 
morphine similar to males (Lax et al., 2014), we expect PolyMorphine to work in females as 
well.  Additional work investigating the potential addictive nature of PolyMorphine will also 
need to be completed.  To our knowledge, no studies have investigated the self-administration 
rates of polymers of opioids.  However, since the morphine is sequestered into a polymer that 
slowly releases free morphine, animals would not be predicted to self-administer. In humans, 
there is some abuse potential as the polymer could be used to derive free morphine in the black 
market.  The requirement for the drug to be injected in a clinical setting would make it much 
more difficult for the drug to be abused compared to many current opioids distributed in pill 
form.  
Mechanistically, we demonstrated that PolyMorphine most likely works through the 
same pathway as free morphine.  Since PolyMorphine was previously shown to generate free 
morphine in vivo (Rosario-Melendez et al., 2012), it was expected that the free morphine 
generated would also work through MOR activation.  We were able to reverse PolyMorphine-
induced analgesia with a pre-treatment of the drug naloxone.  Naloxone is a relatively selective 
antagonist of the mu opioid receptor and has been extremely valuable for investigating the opioid 
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actions of compounds preclinically.  Naloxone has nine times greater affinity for mu compared 
to the kappa opioid receptor and 60 times greater affinity for mu compared to the delta opioid 
receptor (Codd et al., 1995).  Unlike other selective antagonists (such as β-FNA and norBNI) 
whose actions can last for weeks after the elimination of the drug, naloxone acts as a simple 
competitive antagonist, whose effects are much shorter and reversible (Pasternak and Pan, 2013). 
Thus, our results show that PolyMorphine, just like free morphine, likely works through MOR 
activation.  
Finally, PolyMorphine was shown to have a comparable side effect profile to free 
morphine.  With the doses of PolyMorphine (200 mg/kg) and free morphine (10 mg/kg) used, no 
motor deficiencies, ataxia or hypothermia were observed.  This result is not surprising however, 
since this dose of morphine may be too low to observe these particular effects (Koek et al., 
2012).  It also suggests that when PolyMorphine is metabolized into free morphine in vivo, the 
amount of free morphine in the animal’s bloodstream remains at or below the amount when free 
morphine is administered at the rate of 10 mg/kg.  However, further testing of blood 
concentrations of free morphine in animals treated with PolyMorphine would be needed to 
confirm this hypothesis.  Other side effects of morphine and related compounds include opioid-
induced constipation (Wheeler et al., 2002; Raehal et al., 2005) due to the presence of the MOR 
in the colon.  Both PolyMorphine and free morphine treated animals develop this acute side 
effect three hours after administration.  Similarly, opioids are known to stimulate motor activity 
(Koek et al., 2012; Koek, 2014).  Hyperactivity was seen at different times post administration 
between free morphine (3 hrs) and PolyMorphine (24 hrs).  This lack of increase in the 
magnitude of side effects, with an extension in analgesic-like properties has been shown in other 
animal models with liposome deliveries of morphine (Kim et al., 1996; Yaksh et al., 1999).  
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While these side effects of hyperactivity and constipation would be a downside to the use of 
PolyMorphine, these are not outside the normal scope of expected effects, and the fact that it 
could reduce the frequency of administration outweigh these drawbacks. 
The varying times at which each of the different side effects are seen may provide some 
insight into how PolyMorphine is distributed and metabolized after injection.  Our data suggest 
that when PolyMorphine is first administered, some of the first free morphine generated in the 
bloodstream from polymer breakdown remains in the periphery and immediately binds with the 
MORs in the GI tract (Pappagallo, 2001) causing constipation.  The delay in locomotor 
hyperactivity with PolyMorphine shows that there may not be enough free morphine present in 
the CNS until 24 hours after injection to stimulate the dopaminergic locomotor system (Johnson 
and North, 1992).  This could be a drawback of this drug if it were to be used clinically since it 
would partially be needed in the CNS to induce its effects.  However, on the other hand, 
PolyMorphine induces both acute (2 and 4 hour) and extended (24 hour) analgesic effects.  This 
data suggests that enough free morphine is cleaved off the polymer quickly and for an extended 
period of time, where it can act at analgesic targets in the periphery and CNS.  With regular 
morphine, since no breakdown of a polymer is needed to generate free morphine, sufficient drug 
is immediately available to induce analgesia and all of the side effects immediately after 
administration, and none of the effects persist longer than three hours after injection.  These data 
suggest the potential for slightly altered release kinetics of PolyMorphine after injection on side-
effect profiles. 
Overall, mice that receive an injection of PolyMorphine have a reversal of SNI-induced 
hypersensitivity for up to 24 hours post administration and this effect is blocked by naloxone.  
PolyMorphine also has a similar side effect profile to free opioids.  Lastly, SNI animals do not 
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develop preference for the short-term analgesic MPEP when given a PolyMorphine pretreatment, 
presumably because of PolyMorphine’s long-lasting effects.  These effects are in contrast to 
those of free morphine, whose effects are no longer observed after a couple of hours.  Our results 
demonstrate that the poly(anhydride-ester) backbone in the synthesis of an extended-release 
morphine may have a promising future in the treatment of chronic pain conditions.  A valuable 
goal is to find an opioid that can be administered in the clinic and last for weeks or longer to treat 
persistent acute pain (e.g., following major trauma), thus preventing the need for distribution and 
potential abuse. While PolyMorphine does not yet achieve this level of efficacy, future 
formulations may represent a step in the right direction for battling the current opioid epidemic. 
 
MATERIALS AND METHODS  
PolyMorphine:  The polymer was prepared according to previously published procedures 
(Rosario-Melendez et al., 2012).  Briefly, Morphine (1 in Figure 33, 1.00 g, 1 eq) was dissolved 
in anhydrous pyridine under argon and stirred for 5 minutes. Glutaric anhydride (2, 3.97 g, 10 
eq) was slowly added manually. The reaction mixture was heated to 60 C and stirred overnight. 
Pyridine was azeotropically removed using toluene. The brown paste obtained was washed 10 x 
50 mL with DCM to remove the excess glutaric acid. The final product was dried under vacuum 
at room temperature. Morphine-based diacid (3, 0.18 g) was acetylated by reacting with an 
excess of acetic anhydride (36 mL, Fisher, Fair Lawn, NJ). The reaction mixture was stirred 
overnight at room temperature. The excess acetic anhydride was removed under reduced 
pressure. Yield: 0.16 g (89 %), orange paste. Morphine-based monomer (4, 1.00 g) was 
polymerized by melt-condensation polymerization at 170 C, under constant vacuum (< 2 
mmHg), and constant stirring (100 rpm) using an overhead mechanical stirrer (T-line laboratory 
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stirrer, Talboys Engineering Corp., Montrose, PA). Polymerization continued until the mixture 
solidified (~ 30 minutes). The product was cooled to room temperature and dissolved in DCM (2 
mL). The polymer was precipitated dropwise over excess diethyl ether (50 mL) and isolated by 
vacuum filtration. The product was dried under vacuum at room temperature overnight. Yield: 
0.70 g (70 %), tan solid. 
Animals: All mouse protocols were in accordance with National Institutes of Health 
guidelines and approved by the Animal Care and Use Committee of Duquesne University 
(Pittsburgh, PA). All behavioral experiments were performed on male C57Bl/6J mice.  All mice 
were 8 – 10 weeks old when surgery and behavioral experimentation took place.  Animals were 
individually housed after SNI surgery and kept on a 12-hour light/dark cycle from 7:00AM – 
7:00PM with ad libitum access to both food and water.  Experiments were conducted during the 
light cycle and performed by an experimenter who was blinded to treatment and surgery type.  
Surgery: Spared nerve injury (SNI) was performed as previously described (Decosterd 
and Woolf, 2000).  Mice were anesthetized with a 10:1 mixture of ketamine/xylazine at a dose of 
10  L/g. The hair overlying the sciatic nerve was shaved and a 1 cm incision was made parallel 
to the nerve. The sciatic nerve of the left hind paw was exposed and two of the three branches 
(tibial and common peroneal) were ligated.  The third branch of the sciatic nerve, the sural 
branch, was not manipulated.  Mice were allowed to recover on heating pads following surgery 
and a 2% lidocaine cream was placed over the suture on the skin for acute pain relief.   
Drugs: Free morphine (Morphine sulfate, Sigma) and PolyMorphine were separately 
dissolved in a 5 % Cremophor EL saline solution at a dose of 10 mg/kg and 200 mg/kg, 
respectively.  Dosages of these compounds were determined based on previously published 
results (Rosario-Melendez et al., 2012; Lax et al., 2014).  Naloxone (Naloxone hydrochloride 
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dihydrate, Sigma) was dissolved in 0.9% saline at a dose of 1 or 10 mg/kg. These doses were 
based on previous publications (Cendan et al., 2005; Gupta et al., 2013). 2-Methyl-6-
(phenylethynyl)pyridine hydrochloride (MPEP hydrochloride, Enzo Life Sciences) was 
dissolved in 0.9 % saline on the first day of drug pairing (day 2 of CPP) at a dosage rate of 30 
mg/kg. The dose of MPEP was determined using previously published CPP results with MPEP 
in the SNI model (see Section 2 Chapter 1 above) (Lax et al., 2014). 
Drug Administration: Morphine and PolyMorphine were both administered 
intraperitoneally (10 mg/kg and 200 mg/kg, respectively) in a volume of 100 L.  The vehicle 
control for both morphine and PolyMorphine was 5% Cremophor EL saline in a volume of 100 
L.  In the naloxone experiments, naloxone (1 or 10 mg/kg) was administered subcutaneously in 
a volume of 10  L/g.  The vehicle control for naloxone was 0.9% saline in a volume of 10 L/g. 
In the CPP experiments, MPEP (30 mg/kg) was administered intraperitoneally in a volume of 20 
L 5 minutes prior to behavioral testing.  The vehicle control for MPEP was 0.9% saline in a 
volume of 20 L.  In von Frey testing, morphine, PolyMorphine, or vehicle was injected once 
following von Frey testing completed one week after surgery.  In the naloxone von Frey 
experiment, PolyMorphine was injected once following von Frey testing one-week post-SNI and 
naloxone was administered two hours prior to the beginning of each time point measured.  In the 
formalin test, naloxone (or saline) and morphine (10 mg/kg or saline) were administered 20 
minutes before the injection of formalin (4% in a volume of 10 L). Spontaneous behavior 
(described below) was then analyzed for 60 minutes.  For the side effect experiments, morphine, 
PolyMorphine, or vehicle was injected once immediately prior to starting testing.  In the CPP 
test, morphine, PolyMorphine or vehicle was injected in the evening on day one of CPP (several 
hours after baseline Day One times were measured).  MPEP and vehicle were given to mice once 
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a day for three consecutive days (on days 2, 3 and 4 of CPP, see below). 
Behavioral Testing: For mechanosensory studies with von Frey filaments, mice 
underwent baseline testing to determine 50% withdrawal thresholds using the up/down method 
(Dixon, 1980; Chaplan et al., 1994).  Animals were placed in Plexiglas boxes on a wire mesh 
surface for two hours prior to testing.  Withdrawals were defined as a full lifting of the foot off of 
the wire-mesh surface when a filament was applied to the lateral edge of the paw (area 
innervated by the sural branch of sciatic nerve).  Filaments ranging from 0.20 mN – 25.1 mN 
(0.02 – 2.56 g) were used to determine the 50% withdrawal thresholds.  After baseline testing, 
mice underwent SNI.  One week after the surgery, mice were subjected to von Frey testing again 
to observe withdrawal thresholds.  All animals were then given an injection of PolyMorphine 
(200 mg/kg), free morphine (10 mg/kg) or vehicle.  von Frey testing was performed at 2 and 4 
hours, as well as 1, 2, 3, 4 and 7 days after injection (corresponding to days 7, 8, 9, 10, and 14 
days after surgery).  This same procedure was repeated for the mechanosensory testing with 
PolyMorphine (200 mg/kg) and naloxone (10 mg/kg) studies, with naloxone or vehicle injections 
occurring two hours before each von Frey time point. 
For spontaneous formalin behavior, animals were placed in Plexiglas boxes on a clear 
Plexiglas surface for two hours prior to testing.  A detailed description of this assay can be found 
in Section 1, Chapter 1.  After drug and formalin administration (see above), spontaneous pain-
like behaviors were recorded with a web-camera from beneath the animals for 60 minutes and 
scored offline.  Pain-like behaviors were defined as the animal lifting, flinching or biting the 
injected paw. 
For side effect behaviors, animals were injected with PolyMorphine (200 mg/kg), free 
morphine (10 mg/kg) or vehicle and individually housed for three hours post-injection.  During 
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the three-hour time period, animals were subjected to sensory motor battery tests (platform test, 
ledge test, pole test and 60/90/inverted screen tests (Kolber et al., 2010b) at 30 minutes and two 
hours post-injection. Also at the two hour time point, animals were placed in an open field box to 
measure total distance traveled in a 10 minute time period. Activity was monitored with an 
overhead web-camera (Logitec Webcam Pro 9000) using AnyMaze software (Stoelting Co., 
version 4.98). Total food and water consumed after injection, at the end of the three hour time 
point were also measured.  Finally, body temperature (rectal) and total fecal boli deposited over 
the three hour time period were also measured. On days one to three post-injection, mice 
underwent sensory motor battery and open field again; food and water consumed and body 
temperature/fecal boli were also measured over these days as described for the injection day. 
For spontaneous pain-like behavior, the analgesic conditioned place preference (aCPP) 
assay was used as previously described (De Felice et al., 2013; Lax et al., 2014).  A more 
detailed description of this assay and room setup can be found in Section 2, Chapter 1.  Mice first 
underwent SNI surgery.  One week after the surgery, mice were subjected to the 5-day aCPP 
assay, with the addition of a pretreatment that allowed for the testing of long-lasting analgesic 
compounds.  In the aCPP assay, positive reinforcement is used to detect non-evoked spontaneous 
pain where animals learn to associate a visual cue with the positive effects of a drug (Tzschentke, 
1998). The assay uses a box with three different chambers: two outer chambers that differ only in 
the visual patterns on the wall (horizontal versus vertical black and white stripes) and a small 
neutral chamber connecting the two outer chambers.  On the first day of the aCPP experiment 
(known as Day One or “pre-conditioning”), the mice are placed in the neutral chamber and 
allowed to roam free between all three chambers for 30 minutes. No drugs are given to the mice 
during this time. The total time that the animals spend in each chamber is recorded with an 
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overhead camera. Six hours following baseline testing on day one animals are given a 
pretreatment injection (100  L) of PolyMorphine (200 mg/kg), free morphine (10 mg/kg) or 
vehicle. On the next three days of the experiment (Days 2 – 4 or conditioning days), the mice 
receive a control vehicle injection (20  L of saline) in the morning and are restricted to one of 
the outer chambers for 30 minutes. In the afternoon, the mice then receive an injection of the 
short-term analgesic drug (20  L of 30 mg/kg MPEP) and are placed in the opposite outer 
chamber for 30 minutes.  Finally, on the last day of the experiment (Day 5 or post-conditioning), 
the mice are placed with no injection in the neutral chamber and allowed to roam free across the 
entire apparatus for 30 minutes, this exposure being a repeat of the testing from Day One. The 
total time spent in each chamber is recorded using two overhead web-cameras (Logitec Webcam 
Pro 9000 and Canon ZR420) and AnyMaze software. Total times recorded on Day One are 
compared to those of Day 5 to measure if a preference for the chambers developed. All 
behavioral testing was done blinded to treatment and surgery. 
Statistical Analysis: Prism (version 6.0, GraphPad) was used for all behavioral analysis.  
All data are shown as mean ± SEM.  Statistical significance was determined using t-tests or 2-
way ANOVA followed by a post-hoc test.  When analyzing von Frey, open field and 
constipation data, withdrawal thresholds, distance traveled and total fecal boli deposited were 
analyzed using a 2-way ANOVA followed by Bonferroni post-hoc tests, respectively.  When 
analyzing formalin data, total amount of time exhibiting pain-like behaviors was analyzed using 
a one-way ANOVA followed by a Bonferroni post-hoc test.  When analyzing time difference 
data from the CPP assay, a paired t-test was used.  Statistical significance was determined with a 
95% confidence interval (p < 0.05). 
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CONCLUSION 
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This dissertation examined the role of both serotonergic and non-serotonergic GPCRs in 
depression, pain and anxiety.  Specifically, novel ligands derived from marine cyanobacteria and 
novel/repurposed drugs provided sources of ligands for targeting GPCRs of interest.  Screening 
techniques were used to show that compounds produced by organisms in their natural 
environment could selectively target both the 5-HT2CR and 5-HT7Rs.  Additionally, these 
extracts were successfully used to alter behaviors related to pain, depression, and anxiety.  In 
some cases, these changes seen with the extracts were therapeutically relevant, since decreases in 
depression and anxiety were found following extract administration.  Through on-going structure 
elucidation efforts, we hope to soon find what the specific compounds are that are inducing these 
effects.  Once they are identified, someday they could be used to treat MDD in humans or 
alleviate anxiety.  Moreover, even if these identified compounds are never used to treat humans, 
they could still be valuable tools to probe further into the basic biology behind the receptors, as 
was shown by looking into how they worked in animal models involving induced comorbid pain 
and depression.   
Furthermore, this dissertation also showed how drugs like fenobam could be repurposed 
from their original use.  Originally made for treating anxiety, fenobam was later discovered to be 
a selective ligand for the GPCR mGluR5 and was used here to show the critical role that 
mGluR5 plays in spontaneous pain-like behavior using the CPP paradigm.  This drug was never 
pursued further for treating anxiety since it did not work any better than other anxiolytics 
available at that time.  Now, with the discovery of its role in treating chronic pain with no 
addictive effect in animals without injury, it could become a viable treatment for chronic pain 
conditions in humans such as fibromyalgia, diabetic neuropathy, arthritis and low back pain 
among others, without the worry for abuse.  Finally, the work with PolyMorphine demonstrated 
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how a century’s old drug could be transformed into a novel drug for targeting a well-known 
GPCR related to pain.  This polymer form of morphine was shown to be an effective drug, with 
longer lasting analgesic-like effects in both experimenter-evoked and spontaneous pain models 
compared to traditional morphine, without the possible abuse associated with other slow-release 
opioids.  This polymer could be used to treat pain conditions in humans and could be a viable 
alternative to many of the opioids that are used to treat post-operative pain or pain in terminal 
conditions like cancer, decreasing the need for constant injections and with a decrease in the 
possible abuse of the drug.  This is very relevant in the age of the current on-going opioid 
epidemic. 
 Overall, this work highlighted the importance of utilizing natural and novel sources of 
ligands in drug discovery and biology.  Hopefully this dissertation will provide a basis for future 
studies that will ultimately lead to the development of novel therapeutics for those suffering from  
pain, depression and anxiety. 
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